Last updated: May 05, 2020 - 02:00 BST
| MG-COVID: Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients |
Coronavirus disease 19 infection |
standard of care alone, Plaquenil plus azithromycin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-05-02 |
2020-09-02 |
2020-001702-35, APHP200447, MG-COVID, NCT04371406 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
2770 |
Alix PENEL, Julie CHASTANG, Dr, Sarra POCHON |
2020-05-04 |
| Trifluoperazine Effectiveness in Treatment of Coronavirus |
Coronavirus disease 19 infection |
standard care alone, trifluoperazine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rasht University of Medical Sciences |
|
Iran |
2020-05-04 |
2020-05-27 |
IR.GUMS.REC.1399.021, IRCT20200329046892N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
|
70 |
Nematollah Ahangar, Seyed Ali Alavi |
2020-05-04 |
| Genetics of COVID-19 Susceptibility and Manifestations |
Coronavirus disease 19 infection |
SNP chip assay alone, genome sequencing alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
National Human Genome Research Institute |
National Institutes of Health Clinical Center |
US |
2020-05-07 |
2025-06-01 |
20-HG-0090, 200090, NCT04371432 |
Phase Not Applicable |
Recruiting |
0 |
60 Months |
2500 |
Julie Sapp, Leslie G Biesecker, M.D. |
2020-05-04 |
| CATCH COVID-19: Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection |
Coronavirus disease 19 infection |
Serology test alone, Viral RNA test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Texas Cardiac Arrhythmia |
|
US |
2020-05-31 |
2021-06-30 |
CATCH COVID-19, NCT04372004, TCAI_CATCH COVID-19 |
Phase Not Applicable |
Not yet recruiting |
0 |
13 Months |
100 |
Andrea Natale, Executive Medical Director, Deb Cardinal, RN MBA, MITRA Mohanty, MD |
2020-05-04 |
| Direct evidence of rectal cancer patient infected with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zhangnan Hospital |
|
China |
2020-05-06 |
2020-05-16 |
ChiCTR2000032514 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
13 |
Jiang Congqing |
2020-05-04 |
| Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity: a NutriQuebec Sub-study |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universite Laval |
|
Canada |
2020-04-16 |
2020-05-07 |
2018-042PHASE IIA6/09-04-2020, NCT04371848 |
Phase Not Applicable |
No longer recruiting |
1 |
|
2465 |
Benoît Lamarche |
2020-05-04 |
| Nursing Perspective on Burnout and Medical Errors in the Intensive Care Unit During Covid-19 Pandemic |
Coronavirus disease 19 infection, Depression |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Malaya |
|
Malaysia |
2020-05-01 |
2020-06-30 |
54843, NCT04371302 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
145 |
Samuel E H Tsan, Samuel EH Tsan, MD, BMedSc |
2020-05-04 |
| A randomized, double-blind, placebo-controlled, Phase II/III trial to determine the safety and efficacy of DSTAT in COVID-19 patients with acute lung injury (ALI) |
Acute lung injury, Coronavirus disease 19 infection |
dociparstat (iv, AML/acute lung injury/COVID-19), Chimerix alone |
CXCR4 chemokine modulator, Cathepsin G inhibitor, Complement cascade inhibitor, Elastase inhibitor, Heparin agonist, High mobility group protein B1 inhibitor, L selectin antagonist, P selectin antagonist, Platelet factor 4 ligand inhibitor, Stromal cell-derived factor 1 ligand modulator |
|
Chimerix Inc |
|
|
2020-04-29 |
|
|
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
|
524 |
|
2020-05-04 |
| Effect of Formoterol in treatment of covid19 |
Coronavirus disease 19 infection |
formoterol(Medochemie Company) alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
National Research Institute of Tuberculosis and Lung Diseases |
|
Iran |
2020-04-18 |
|
IR.SBMU.NRITLD.REC.1398.003, IRCT20170210032478N3 |
Phase 3 Clinical |
Recruiting |
1 |
|
50 |
Dr. Parisa Farnia, Fariba Ghorbani, Giti Pourdoulat, Guitti Pourdowlat |
2020-05-04 |
| Study on data management and diagnosis-treatment mode of TCM intervention for novel coronavirus pneumonia (COVID-19) convalescence |
Coronavirus disease 19 infection, Viral pneumonia |
TCM intervention alone |
|
|
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, National Science and Technology Support Plan of the People's Republic of China |
|
China |
2020-04-29 |
2021-04-22 |
2020YFC0845000, ChiCTR2000032480, ChiMCTR2000003257 |
Phase Not Applicable |
Not yet recruiting |
5 |
11 Months |
1000 |
Liu Baoyan, Liu Jia |
2020-05-04 |
| Effect of interactive psycho-educational interventions on patients infected with COVID-19 |
Coronavirus disease 19 infection |
psycho-educational interventions alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shiraz University of Medical Sciences |
|
Iran |
2020-05-14 |
|
IR.SUMS.REC.1399.012, IRCT20130616013690N7 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
50 |
Maryam Shaygan, Younes Ghasemi |
2020-05-04 |
| Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings |
Coronavirus disease 19 infection |
hydroxychloroquine plus melatonin |
|
|
Gonabad University of Medical Sciences |
|
Iran |
2020-04-14 |
|
IR.GMU.REC.1399.016, IRCT20200408046988N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Najmeh Davoodian, Najmeh Davoudian, Shayla khosravan |
2020-05-04 |
| FORCE: Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
avdoralimab (IPH5401) alone |
CXCR1 chemokine antagonist, Complement C5a receptor antagonist, IL-8 receptor antagonist, Monocyte chemotactic protein 1 ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux De Marseille |
Innate Pharma SA |
France |
2020-04-27 |
2020-10-27 |
2020-21, FORCE, NCT04371367 |
Phase 2 Clinical |
Recruiting |
0 |
6 Months |
108 |
Emilie Garrido-Pradalie, Julien CARVELLI, Julien CARVELLI, MD, Nicolas, SCHLEINITZ, MD |
2020-05-04 |
| KILLER: Povidone-iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19 |
Coronavirus disease 19 infection |
povidone-iodine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation |
|
France |
2020-05-01 |
2020-08-01 |
KILLER, KILLER, NCT04371965 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
24 |
Olivier MIMOZ, Professor, Sabrina SEGUIN, CRA |
2020-05-04 |
| Evaluation of the effect of Iranian medicine product, Algro, on patients with Coronavirus 19 |
Coronavirus disease 19 infection |
Algro alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bagheiat-allah University of Medical Sciences |
|
Iran |
2020-05-04 |
2020-05-19 |
IR.BMSU.REC.1399.038, IRCT20160131026298N3 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
80 |
Ahmad Reza Sharifi Olounabadi, REZAMOHTASHAMI, AHMAD REZA SHARIFI OLOUNABADI, Reza Mohtashami |
2020-05-04 |
| SirCO-1: Sirolimus in COVID-19 Phase I |
Coronavirus disease 19 infection |
Standard medical care alone, sirolimus alone |
mTOR inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Thomas Jefferson University |
|
US |
2020-05-31 |
2020-08-31 |
15680, NCT04371640, SirCO-1 |
Phase 1 Clinical |
Recruiting |
0 |
3 Months |
40 |
Angela C Pallotto, RN, BSN, Edwin Lam, PharmD, Walter K Kraft, MD |
2020-05-04 |
| Evaluation effect of treatment with im (intramuscular) D3 on clinical, paraclinical symptoms and signs and inhospital outcome at patient admitted with COVID-19 |
Coronavirus disease 19 infection |
vitamin D alone |
|
|
Shahrood University of Medical Sciences |
|
Iran |
2020-05-21 |
|
IR.SHMU.REC.1399.013, IRCT20200411047024N1 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
|
100 |
Erfan Kazemi, Mohammad Hassan Emamian, hossien sheybani |
2020-05-04 |
| Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 |
Coronavirus disease 19 infection, Viral pneumonia |
hormones therapy alone, mechanical ventilation alone, oxygen therapy alone, supportive therapy alone, oseltamivir plus umbilical cord mesenchymal stem cells |
Exo-alpha sialidase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fuzhou general hospital |
|
China |
2020-03-01 |
2022-12-31 |
MSC-COVID-2020, NCT04371601 |
Phase 0 Clinical |
No longer recruiting |
1 |
34 Months |
60 |
Jianming Tan Tan, M.D and Ph.D |
2020-05-04 |
| Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , doxycycline , hydroxychloroquine , zinc sulfate |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St. Francis Hospital, New York |
|
US |
2020-04-28 |
2020-12-31 |
20-21, NCT04370782 |
Phase 4 Clinical |
Not yet recruiting |
0 |
8 Months |
750 |
Avni Thakore MD, Avni Thakore, MD, Elizabeth Haag, RN, Elizabeth S Haag, RN |
2020-05-04 |
| Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
St Jude Children's Research Hospital |
|
US |
2020-04-27 |
2022-06-30 |
COVID-19, NCT04371315 |
Phase Not Applicable |
Recruiting |
0 |
26 Months |
400 |
Diego Hijano, MD |
2020-05-04 |
| Study of Resilience and Loneliness in Youth (18 to 25 Years Old) During the SARS-CoV2 Pandemic Lock-down Measures |
Coronavirus disease 19 infection, Psychiatric disorder |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs) |
Erasme Hospital |
King Baudouin Foundation, Universite Libre de Bruxelles |
Belgium |
2020-04-20 |
2020-12-30 |
NCT04371250, SRB2020_158 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
600 |
Simone Marchini, MD |
2020-05-04 |
| COVID-HO: Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients |
Coronavirus disease 19 infection |
endotracheal intubation and ventilation alone, non-invasive ventilation alone |
|
|
Universiteit Hasselt |
|
Belgium |
2020-04-01 |
2020-12-01 |
COVID-HO, COVID-HO, NCT04371679 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
40 |
Lieven Herbots, Lieven Herbots, MD, PhD |
2020-05-04 |
| EXPOCOVIA: Prevalence of COVID-19 Infection Among HCW in a French University Hospital |
Coronavirus disease 19 infection |
reverse transcription polymerase chain reaction (RT-PCR) alone, serological testing alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
Fondation Santé Roquette |
France |
2020-04-30 |
2020-09-30 |
2020-A00951-38, 2020_35, EXPOCOVIA, NCT04371692 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
100 |
Annie SOBASZEK, MD, Annie SOBASZEK, MD,PhD |
2020-05-04 |
| MSCs in COVID-19 ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure |
Standard of care alone, remestemcel-L alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mount Sinai Medical Center |
Mesoblast Ltd |
US |
2020-04-30 |
2022-04-30 |
GCO 08-1078-0014, NCT04371393 |
Phase 3 Clinical |
Not yet recruiting |
0 |
24 Months |
300 |
Annetine C Gelijns, PhD, Mary Beth Marks, Michael Mack, MD, Peter Smith, MD |
2020-05-04 |
| Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Region Zealand |
|
Denmark |
2020-04-17 |
2020-04-24 |
ARTHROCANCELLATIONSUH2020, NCT04370678 |
Phase Not Applicable |
Completed |
1 |
|
79 |
Jesper S Nielsen, MD |
2020-05-04 |
| A trial to evaluate the effect of plasma therapy for the prevention and treatment of coronavirus infection |
Coronavirus disease 19 infection |
plasma therapy alone |
|
|
Columbia University |
Amazon.com Inc |
|
|
|
|
Phase 3 Clinical |
Status not specified |
0 |
|
450 |
|
2020-05-04 |
| COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings |
Coronavirus disease 19 infection, HIV infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Centre in HIV Epidemiology and Clinical Research |
The University of Liverpool, UNITAID, University of Montpellier, University of Witwatersrand |
South Africa, France, Australia, Switzerland, UK |
2020-05-15 |
2021-12-31 |
2020-04-COHIVE, COHIVE, NCT04371835 |
Phase Not Applicable |
Not yet recruiting |
0 |
19 Months |
1500 |
Alexandra Calmy, MD, PhD, Emmanuelle Papot, MD, Eric Delaporte, MD, PhD, Francois WD Venter, MD, Joana Woods, MD, Maria E Arriaga, PhD, Mark Polizzotto, MD, PhD, Saye Khoo, MD, PhD |
2020-05-04 |
| ACCORD 2: A Phase II Study for the Treatment of COVID 19 in Hospitalised Patients |
Coronavirus disease 19 infection |
Standard of Care alone, MEDI-3506 plus bemcentinib |
Axl tyrosine kinase receptor inhibitor, Interleukin 33 ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Southampton NHS Foundation Trust |
|
UK |
2020-04-28 |
|
2020-001736-95, ACCORD 2, ACCORD-2-001,Sub-002,-003 |
Phase 2 Clinical |
Recruiting |
1 |
|
825 |
Emma Perry |
2020-05-04 |
| London Ambulance Service Experience of COVID-19 |
Coronavirus disease 19 infection |
|
|
|
London Ambulance Service NHS Trust |
London School of Hygiene and Tropical Medicine |
UK |
2020-04-09 |
2021-04-08 |
LAS-INT-2020-01, NCT04372069 |
Phase Not Applicable |
No longer recruiting |
1 |
12 Months |
40 |
Rachael Fothergill, PhD |
2020-05-04 |
| HYdILIC: Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19 |
Coronavirus disease 19 infection |
antibiotic therapy alone, oxygen therapy alone, standard of care alone, steroid therapy alone, Variable regimens including diltiazem , hydroxychloroquine , niclosamide , paracetamol |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
University of Lille Nord de France |
France |
2020-05-31 |
2023-05-31 |
2020-002188-72, 2020_40, HYdILIC, NCT04372082 |
Phase 3 Clinical |
Not yet recruiting |
1 |
36 Months |
480 |
Karine Faure, MD,PhD |
2020-05-04 |
| AMBU-COVID: Proactive Care of Ambulatory COVID-19 Patients: Open-labeled, Randomized Trial |
Coronavirus disease 19 infection |
azithromycin alone, teleconsultation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire D Amiens |
|
France |
2020-04-29 |
2020-07-31 |
AMBU-COVID, NCT04371107, PI2020_843_0039 |
Phase 3 Clinical |
Not yet recruiting |
1 |
3 Months |
64 |
Jean-Philippe Lanoix, Jean-Philippe Lanoix, Pr |
2020-05-04 |
| Severity Score For COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Policlinico Universitario Agostino Gemelli |
|
Italy |
2020-04-29 |
2020-05-27 |
3112, NCT04372199 |
Phase Not Applicable |
Recruiting |
2 |
|
248 |
Massimo Montalto, Massimo Montalto, Professor |
2020-05-04 |
| Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19 |
Coronavirus disease 19 infection |
Hydroxychloroquine nasal spray alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Baqiyatallah University of Medical Sciences |
|
Iran |
2020-05-01 |
|
IR.BMSU.REC.1399.091, IRCT20080901001165N51 |
Phase 3 Clinical |
Recruiting |
1 |
|
80 |
Nematollah Jonaidi, Parisa Kianpour, Yunes Panahi |
2020-05-04 |
| Effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID-19) |
Coronavirus disease 19 infection |
deferiprone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sanandaj University of Medical Sciences |
|
Iran |
2020-05-04 |
|
IR.MUK.REC.1399.012, IRCT20180114038350N3 |
Phase 3 Clinical |
Recruiting |
1 |
|
80 |
Karim Naseri, Khaled Rahmani |
2020-05-04 |
| CHAMPS: COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Villanova University |
|
US |
2020-04-27 |
2040-04-27 |
CHAMPS, IRB FY2020-215, NCT04370821 |
Phase Not Applicable |
Not yet recruiting |
0 |
240 Months |
20000 |
Donna Havens, PhD,RN,FAAN, Janell Mensinger, PhD,FAED, Peter G. Kaufmann, PhD, Sandra Schultz |
2020-05-04 |
| DYNAMIC: Doxycycline Ambulatoire COVID-19 |
Coronavirus disease 19 infection |
GRANUDOXY alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CHU De Nantes |
|
France |
2020-05-01 |
2020-12-01 |
DYNAMIC, NCT04371952, RC20_0191 |
Phase 3 Clinical |
Not yet recruiting |
0 |
7 Months |
330 |
Amir KHAMMARI, Amir Khammari, Anne DOMPMARTIN-BLANCHERE, Brigitte DRENO, Brigitte DRENO, PUPH, Eve MAUBEC, Fabrice BONNET, Lionel PIROTH, Marie-Thérèse Leccia |
2020-05-04 |
| BCG-DENMARK-COVID: BCG vaccine for healthcare workers against COVID-19 |
Coronavirus disease 19 infection |
BCG vaccine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Southern Denmark |
AJ Vaccines A/S |
Denmark |
2020-04-30 |
|
2020-001888-90, 20201504, BCG-DENMARK-COVID |
Phase 3 Clinical |
Recruiting |
1 |
|
1500 |
Clinical Institute, OPEN |
2020-05-04 |
| RECOP: Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID Infection (Unit 'COVID Possible') |
Coronavirus disease 19 infection, Dyspnea |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Toulouse |
|
France |
2020-03-13 |
2021-03-31 |
NCT04371328, RC31/20/0094, RECOP |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
2000 |
Frédéric Balen, MD, Paul-Henri Auboiroux, MD |
2020-05-04 |
| Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 |
Coronavirus disease 19 infection, Non-insulin dependent diabetes |
insulin plus linagliptin |
Dipeptidyl peptidase IV inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rabin Medical Center |
|
Israel |
2020-05-15 |
2021-09-30 |
0303-20-RMC, NCT04371978 |
Phase 3 Clinical |
Not yet recruiting |
0 |
16 Months |
100 |
Alon Grossman, MD, Ran Abuhasira, Ran Abuhasira, MD |
2020-05-04 |
| Efficacy of Sn-protoporphyrin IX (SnPPIX) and Sulfonated Tetranaphthyl Porphyrin Against Covid-19 |
Coronavirus disease 19 infection, Viral pneumonia |
Sn-protoporphyrin IX alone, sulfonated tetra-anthracenyl porphyrin alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kafrelsheikh University |
|
Egypt |
2020-05-31 |
2020-08-31 |
NCT04371822, PROPOSED BY MAHMOUD ELKAZZ |
Phase 1 Clinical |
Not yet recruiting |
0 |
3 Months |
56 |
M.Sc. Mahmoud Elkazzaz, M.Sc.Biochemistry, M.Sc.Mahmoud Elkazzaz, M.Sc.Biochemistry, Mahmoud ELkazzaz |
2020-05-04 |
| Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sanford Health |
|
|
2020-04-30 |
2023-04-20 |
NCT04372017, SH HCQ |
Phase 3 Clinical |
Not yet recruiting |
0 |
35 Months |
1739 |
Christie Ellison, BSN, Susan Hoover, MD |
2020-05-04 |
| BREATH: Vitamin D Polymorphisms and Severity of COVID-19 Infection |
Coronavirus disease 19 infection, Vitamin D deficiency |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidade de Lisboa |
Cardiovascular Centre of Universidade de Lisboa (CCUL), Cardiovascular Centre of Universidade de Lisboa (CCUL), Center for Health Technology and Services Research, Centro Hospitalar Sao Joao, HeartGenetics, Genetics & Biotechnology, S.A., Hospital de Santa Maria, Instituto Gulbenkian de Ciencia (IGC), Nova Medical School |
Portugal |
2020-04-30 |
2021-03-31 |
BREATH, COVID19-BREATH, NCT04370808 |
Phase Not Applicable |
Not yet recruiting |
2 |
11 Months |
500 |
Ana Freitas, PhD, Ana Miranda, MD, Conceição Calhau, PhD, Fausto J Pinto, PhD, Fausto Pinto, PhD, Fátima Casaca, BSc, Helena Proença, MD, Melo Cristino, PhD, Tiago Guimarães, PhD |
2020-05-04 |
| Investigating the efficacy and safety of Azithromycin inhaled spray in controlling the symptoms of patients with COVID-19 |
Coronavirus disease 19 infection |
Azithromycin inhaled spray alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Baqiyatallah University of Medical Sciences |
|
Iran |
2020-05-01 |
|
IR.BMSU.REC.1399.092, IRCT20080901001165N50 |
Phase 3 Clinical |
Recruiting |
1 |
|
80 |
Morteza Izadi, Parisa Kianpour, Yunes Panahi |
2020-05-04 |
| A real-time, smartphone-based data collection study in order to uncover scientifically significant trends about the current coronavirus pandemic |
Coronavirus disease 19 infection |
smartphone-based data collection alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
American Lung Association, Northwestern University, University of California San Francisco |
|
|
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-05-04 |
| PROVIDE: Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers |
Coronavirus disease 19 infection |
hydroxychloroquine sulfate alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Josephs Healthcare Hamilton |
|
Canada |
2020-05-01 |
2020-08-30 |
3190, NCT04371523, PROVIDE |
Phase 3 Clinical |
Not yet recruiting |
0 |
3 Months |
1100 |
Kimberley Lewis, Waleed Al-Hazzani, Waleed Alhazzani |
2020-05-04 |
| Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
soybean extract alone |
|
|
Wuhan University |
|
China |
2020-03-01 |
|
ChiCTR2000030162 |
Phase 0 Clinical |
Terminated |
1 |
|
|
|
2020-05-04 |
| A phase I/IIa clinical study to assess cVLP vaccine in the treatment of patietns with COVID-19 infection |
Coronavirus disease 19 infection |
cVLP vaccine (COVID19 infection), AdaptVac alone |
|
|
AdaptVac |
EU Horizon 2020, ExpreS2ion Biotechnologies, Koebenhavns Universitet, Leiden University Medical Center, University Hospital Tubingen, Wageningen University and Research |
|
|
|
|
Phase 1/Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-05-04 |
| Predicting ICU Admission And Death For COVID-19 Patients |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Policlinico Universitario Agostino Gemelli |
|
Italy |
2020-03-01 |
2020-04-15 |
0017055/20, NCT04371562 |
Phase Not Applicable |
Completed |
1 |
1 Month |
300 |
|
2020-05-04 |
| J-COVID: Prospective, observational study on diagnosis and treatment of COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Japanese Red Cross Medical Center |
|
Japan |
2020-02-01 |
|
J-COVID, UMIN000040295 |
Phase Not Applicable |
Recruiting |
1 |
|
100 |
Takehiro Izumo |
2020-05-04 |
| A clinical study of hydroxychloroquine versus the standard of care for the treatment in patients hospitalized with COVID-19 infection |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Male |
Food and Drug Administration |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
368 |
|
2020-05-04 |
| A pilot study to assess the clinical activity, safety and tolerability of Selective Cytopheretic Device (SCD) among patients who have ARDS prior to CRRT and/or AKI with CRRT |
Adult respiratory distress syndrome, Coronavirus disease 19 infection |
Selective Cytopheretic Device (SCD) alone |
|
|
Seastar Medical Inc |
Empiristat Inc. |
US |
2020-04-28 |
|
SCD-005 |
Phase Not Applicable |
Recruiting |
0 |
|
35 |
|
2020-05-04 |
| Pharmacodynamics of the Nasalferon in healthy volunteers |
Coronavirus disease 19 infection |
recombinant interferon alfa 2b (Nasalferon) alone |
|
Healthy volunteers accepted, Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Center for Genetic Engineering and Biotechnology |
Ministerio de Salud Publica |
Cuba |
2020-05-04 |
2020-06-09 |
IG / IAGN / VS / 2001, RPCEC00000308 |
Phase 1 Clinical |
Not yet recruiting |
1 |
1 Month |
30 |
Carlos Alberto GonzAlez Delgado, Hugo Nodarse Cuni |
2020-05-04 |
| Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients |
Coronavirus disease 19 infection |
|
|
|
West China Hospital |
Science & Technology Department of Sichuan Province |
China |
2020-01-01 |
2020-12-31 |
2020YFS0009, ChiCTR2000029907 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
1000 |
Yao, Rong |
2020-05-04 |
| Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Zhangnan Hospital |
Hubei Clinical Research Center |
China |
2020-02-01 |
2021-05-01 |
ChiCTR2000029953 |
Phase Not Applicable |
Not yet recruiting |
1 |
15 Months |
400 |
Xianlong Zhou, Yan Zhao |
2020-05-04 |
| HOPE study: Evaluation of the effect and safety of HeberFERON versus Heberon alfa in patients infected with the SARS-CoV-2 coronavirus (COVID-19) |
Coronavirus disease 19 infection |
HeberFERON alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Center for Genetic Engineering and Biotechnology |
Ministerio de Salud Publica |
Cuba |
2020-04-10 |
2020-07-30 |
HOPE study, IG / IAG / CV / 2001, RPCEC00000307 |
Phase 2 Clinical |
Recruiting |
1 |
3 Months |
120 |
Idelsis Esquivel Moynelo, Irraldo Bello Rivero |
2020-05-04 |
| Triple combination therapy in patients infected with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including hydroxychloroquine sulfate , lopinavir + ritonavir , oseltamivir |
Exo-alpha sialidase inhibitor, HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Gunma University Hospital |
|
Japan |
2020-04-01 |
|
jRCTs031190227 |
Phase 2 Clinical |
Recruiting |
1 |
|
50 |
Nakamura Tetsuya, Tokue Yutaka |
2020-05-04 |
| Favipiravir in patients infected with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
favipiravir alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Gunma University Hospital |
|
Japan |
2020-03-14 |
|
jRCTs031190226 |
Phase 2 Clinical |
Recruiting |
1 |
|
50 |
Nakamura Tetsuya, Tokue Yutaka |
2020-05-04 |
| RACCO: A multicenter, open-label, randomized, controlled trial to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
ciclesonide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Japanese Ministry of Health, Labor and Welfare |
|
Japan |
2020-04-03 |
|
RACCO, jRCTs031190269 |
Phase 2 Clinical |
Recruiting |
1 |
|
90 |
Junko Terada, Sugiyama Haruhito |
2020-05-04 |
| Favipiravir for SARS-CoV-infected patients |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Japan Agency for Medical Research and Development |
|
Japan |
2020-03-02 |
|
jRCTs041190120 |
Phase 2 Clinical |
Recruiting |
1 |
|
86 |
Doi Yohei, Kondo Masashi |
2020-05-04 |
| CHARTER: COVID-19: can nebulized heparin reduce time to extubation in SARS-CoV-2 patients requiring mechanical ventilation |
Coronavirus disease 19 infection |
heparin alone, invasive mechanical ventilation alone, standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Vincents Hospital (Melbourne) Ltd |
Victorian State Government |
Australia |
2020-05-21 |
2021-07-25 |
ACTRN12620000517976p, CHARTER |
Phase 3 Clinical |
Not yet recruiting |
3 |
14 Months |
172 |
Dr Barry Dixon |
2020-05-04 |
| SARS-CoV2 in children presenting to hospital: a repeating point prevalence study during the COVID-19 pandemic in South East Queensland |
Coronavirus disease 19 infection |
PCR alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Gold Coast Hospital |
Griffith University |
Australia |
2020-04-29 |
2020-09-18 |
ACTRN12620000512921, HREC/2020/QGC/63198 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
400 |
A/Prof Shane George |
2020-05-04 |
| ARDS Caused by COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Clinic of Barcelona |
Ubikare company |
Spain |
2020-03-12 |
2020-12-31 |
COVID-19 ARDS, NCT04368975 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
500 |
Carlos Ferrando, Carlos Ferrando, PhD, Sara Darriba, PhD |
2020-05-01 |
| Clinical Application of Methylene Blue for Treatment of Covid-19 Patients |
Coronavirus disease 19 infection |
MCN (methylene blue, vitamin C, N-acetyl cysteine) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-19 |
2020-09-21 |
IR.MUMS.REC.1399.122, NCT04370288 |
Phase 1 Clinical |
Recruiting |
1 |
5 Months |
20 |
Ahmad Bagheri Moghaddam, M.D, Amir Yarahmadi, Ph.D, Daryoush Hamidi Alamdari, Ph.D |
2020-05-04 |
| Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia |
Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
Best Supportive Care alone, ravulizumab alone |
Complement C5 factor inhibitor, IgG receptor FcRn large subunit p51 modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Alexion Pharmaceuticals Inc |
|
|
2020-05-31 |
2021-02-28 |
ALXN1210-COV-305, NCT04369469 |
Phase 3 Clinical |
Not yet recruiting |
0 |
9 Months |
270 |
Alexion Pharmaceuticals, Inc. |
2020-05-01 |
| Repeated Measures Trial of Temporary Automated Manual Ventilation Versus Noninvasive Oxygenation or Conventional Vent |
Coronavirus disease 19 infection, Lung infection, Respiratory failure |
Mechanical ventilation alone, automated BVM compressor device, Spiro LLC/10x beta alone, rocuronium alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Massachusetts General Hospital |
|
|
2020-05-31 |
2020-11-30 |
2020P001051, NCT04369274 |
Phase 2 Clinical |
Not yet recruiting |
0 |
6 Months |
30 |
Blair Parry, CCRC, Keith A Marill, MD |
2020-05-04 |
| BATTLE: COVID-19: BCG as Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement |
Coronavirus disease 19 infection |
BCG vaccine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidade Estadual de Campina |
Botucatu Medical School, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq, Faculdade de Medicina de Ribeirão Preto, Federal University of Sao Paulo, Instituto de Infectologia Emílio Ribas, Paulinia Municipal Hospital, Pontificia Universidade Catolica de Campinas, State Hospital Dr. Leandro Franceschini |
Brazil |
2020-06-30 |
2022-05-31 |
BATTLE, COVID-19 BATTLE TRIAL, NCT04369794 |
Phase 4 Clinical |
Not yet recruiting |
1 |
23 Months |
1000 |
Bethania F Nascimento, BSN, Leonardo O Reis, MD, PhD |
2020-05-04 |
| Anxiety And Depression During COVID-19 In India |
Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Max Healthcare Institute Ltd, India |
|
India |
2020-04-24 |
2021-02-24 |
COVID-19/MHC/PSYCH/20-10, NCT04369300 |
Phase Not Applicable |
Not yet recruiting |
1 |
10 Months |
1000 |
|
2020-05-04 |
| MATCH: Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19 |
Coronavirus disease 19 infection |
famotidine plus hydroxychloroquine |
Histamine H2 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Northwell Health Inc |
|
US |
2020-04-07 |
2021-04-07 |
20-0268, MATCH, NCT04370262 |
Phase 3 Clinical |
Recruiting |
0 |
12 Months |
1170 |
Amanda Tice, RN, Asha Mellor, CCRC, Christina Brennan, MD, John Boockvar, MD, Joseph Conigliaro, MD, Julie DiGregorio, CCRP, Negin Hajizadeh, MD, Neubert Philippe, MD, Patricia Nadraus, RN, Richard Dima, MD, Tamika Wong, MPH |
2020-05-04 |
| Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest |
Coronavirus disease 19 infection, Hypoxia, Respiratory distress syndrome, Respiratory failure |
V/Q Vest alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Emory University |
Georgia Institute for Clinical Research, Georgia Institute of Technology |
US |
2020-05-31 |
2021-03-31 |
NCT04369599, STUDY00000402 |
Phase Not Applicable |
Not yet recruiting |
0 |
10 Months |
24 |
Maxwell Weinmann, MD |
2020-05-04 |
| Curie-O-SA: COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Institut Curie |
|
France |
2020-04-28 |
2021-01-28 |
Curie-O-SA, IC 2020-07, NCT04369066 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
2500 |
Isabelle Turbiez, Olivier Lantz, MD, Pierre Fumoleau, PhD |
2020-05-04 |
| XPro-1595 for the Treatment of Pulmonary Complications From COVID-19 |
Coronavirus disease 19 infection, Lung disease |
INB-03 alone, standard of care alone |
TNF alpha ligand inhibitor |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
INmune Bio Inc |
|
|
2020-06-30 |
2021-01-31 |
NCT04370236, XPRO1595-COVID-19 |
Phase 2 Clinical |
Not yet recruiting |
0 |
7 Months |
150 |
Christopher Barnum, PhD |
2020-05-01 |
| COVID-19.KDIR.01: Long-term Analysis and Evaluation of morphologic and clinical Parameters in COVID-19 Patients: prospective development of a practical risk score |
Coronavirus disease 19 infection, Viral pneumonia |
CT scan alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stuttgart Cancer Center |
|
Germany |
2020-04-17 |
|
COVID-19.KDIR.01, DRKS00021537, F-2020-047, U1111-1251-0942 |
Phase Not Applicable |
Recruiting |
1 |
|
150 |
Götz Martin Richter |
2020-05-04 |
| SARS-CoV-2 in tears in patients with COVID-19 |
Coronavirus disease 19 infection, Ocular disease |
RT-PCR assay alone, funduscopy alone, slit-lamp examination alone |
|
|
Universitatsklinikum Schleswig-Holstein Campus Kiel |
|
Germany |
2020-04-29 |
|
D 469/20, DRKS00021416 |
Phase Not Applicable |
Recruiting |
1 |
|
30 |
Mr. Prof. Dr. med. Johann Baptist Roider, Ms. Dr. med. Kristin Hosel |
2020-05-04 |
| ATHLOS: Telerehabilitation in Patients With COVID-19 After Hospitalization |
Coronavirus disease 19 infection |
aerobic exercise alone, breathing exercise alone, resistive training exercise alone, telerehabilitation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory |
University of Athens, University of Ioannina, University of Thessaly |
Greece |
2020-04-30 |
2021-03-31 |
1, ATHLOS, NCT04368845 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
100 |
ELENI KAPRELI, PhD, PT, ELENI KORTIANOU, PhD, PT, Eleni Kortianou |
2020-05-04 |
| Management of Covid-19 Patients During Home Isolation |
Coronavirus disease 19 infection |
oxygen alone, physical therapy alone |
|
Young Adults (18-44 yrs) |
Cairo University |
|
Egypt |
2020-03-15 |
2020-05-20 |
2318087, NCT04368923 |
Phase 2 Clinical |
No longer recruiting |
1 |
2 Months |
60 |
Mahmoud Sedky |
2020-05-04 |
| COVID-OZO: Ozone Auto-hemotherapy for COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
ozone auto-hemotherapy alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
L'Institut d Investigacio Biomedica de Girona |
Hospital Nuestra Señora del Rosario, Sociedad Española de Ozonoterapia |
Spain |
2020-05-04 |
2020-12-25 |
COVID-19 NETWORKING GROUP, COVID-OZO, NCT04370223 |
Phase 3 Clinical |
Not yet recruiting |
4 |
7 Months |
208 |
Alberto Hernández, MD, PhD, Marc Vives, MD, Marc Vives, MD, PhD |
2020-05-04 |
| JoCORE: Acute Cardiovascular Events Triggered by COVID-19-Related Stress |
Acute stress disorder, Cardiovascular disease, Coronavirus disease 19 infection, Myocardial infarction, Shock, Sudden cardiac death, Ventricular tachycardia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jordan Collaborating Cardiology Group |
|
Jordan |
2020-04-30 |
2020-07-30 |
JCCG.JOCORE.4.4040, JoCORE, NCT04368637 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
50 |
Ayadeh Madanat, MD, Ayman J Hammoudeh, MD, FACC, Ayman J. Hammoudeh, MD, FACC |
2020-05-04 |
| VIRUS: Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19 |
Coronavirus disease 19 infection, Respiratory failure |
clinical-echo score prediction alone, pleuro-pulmonary ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CHU De Nantes |
WINFOCUS-France |
France |
2020-04-09 |
2020-06-30 |
NCT04370249, RC20_0164, VIRUS |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
400 |
Philippe LE CONTE, Philippe LE CONTE, MD-PHD, Philippe PES, MD |
2020-05-04 |
| CONFIDODO: Sleep Quality During COVID-19 Containment in Children Whether or Not Usually Followed in Child Psychiatry |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Sleep disorder |
routine psychiatric care alone |
|
Healthy volunteers accepted, Children (6-12 yrs) |
Centre Hospitalier René-Dubos |
|
France |
2020-05-31 |
2020-06-30 |
CHRD 0520, CONFIDODO, NCT04370210 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
464 |
Erwan VION, Maryline Delattre, Véronique Da Costa |
2020-05-04 |
| Project D: Observational Study to Assess the Seroconversion Status of Health Care Workers and Suspected or Confirmed Cases of COVID-19 Patients |
Coronavirus disease 19 infection |
COVID-19 testing alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Max Healthcare Institute Ltd, India |
|
India |
2020-04-22 |
2020-07-30 |
COVID-19/MHC-2/2020, NCT04368884, Project D |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
1000 |
Samreen Siddiqui, PhD, Sujeet Jha, MRCP (U.K), Swati Waghdhare, MD |
2020-05-04 |
| Observational Study of COVID-19 Treatment Efficacy |
Coronavirus disease 19 infection, Respiratory distress syndrome |
hydroxychloroquine alone, remdesivir alone, azithromycin plus hydroxychloroquine |
Coronavirus non structural protein 8 modulator, RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
OSF Healthcare System |
|
US |
2020-04-14 |
2021-04-14 |
1589936, NCT04369989 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
1000 |
David Hall |
2020-05-04 |
| TEACH: Treating COVID-19 With Hydroxychloroquine |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
NYU Langone Health |
SUNY Downstate Medical Center |
US |
2020-04-15 |
2020-06-30 |
20-00463, NCT04369742, TEACH |
Phase 2 Clinical |
Recruiting |
0 |
2 Months |
626 |
Jack A. DeHovitz, MD, MPH, MHCDS, FACP, Mark Mulligan, MD, Mark Mulligan, MD, FIDSA, Robert Ulrich, MD |
2020-05-04 |
| COVERSCAN: Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection |
Coronavirus disease 19 infection |
MRI alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Perspectum Diagnostics Ltd |
|
UK |
2020-04-21 |
2023-05-31 |
20/SC/0185, COVERSCAN, NCT04369807 |
Phase Not Applicable |
Recruiting |
2 |
37 Months |
507 |
Mary Norris Xu, BSc, RN, Rajarshi Banerjee, MSc, DPhil, Sandeep Kapur, BSc, MBBS |
2020-05-04 |
| Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant |
Coronavirus disease 19 infection |
SARS-CoV recombinant vaccine (nanoparticle), Novavax alone, Matrix M plus SARS-CoV recombinant vaccine (nanoparticle), Novavax |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Novavax Inc |
|
Australia |
2020-05-15 |
2021-07-31 |
2019NCOV-101, NCT04368988 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
2 |
14 Months |
131 |
Biljana Georgievska |
2020-05-04 |
| Stroke-Covid19: Covid-19 Epidemic on Acute Stroke Management |
Coronavirus disease 19 infection, Stroke |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
2020-03-03 |
2020-04-30 |
7826, NCT04370197, Stroke-Covid19 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
300 |
Raoul POP, MD, Rémy BEAUJEUX, MD, PhD, Saïd CHAYER, PhD, HDR |
2020-05-04 |
| PROTECT: Improving prenatal care during confinement |
Coronavirus disease 19 infection, Parturition |
remote consultation alone |
|
Healthy volunteers accepted, Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Central Hospital, Nancy, France |
|
|
2020-05-01 |
2021-09-30 |
2020-A01023-36, NCT04368832, PROTECT |
Phase Not Applicable |
Not yet recruiting |
0 |
17 Months |
108 |
Gaëlle Ambroise, Nadine JUGE |
2020-05-04 |
| Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults |
Coronavirus disease 19 infection |
Variable regimens including BNT-162a1 , BNT-162b1 , BNT-162b2 , BNT-162c2 |
COVID19 Spike glycoprotein modulator |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
BioNTech SE |
Pfizer Inc |
US |
2020-04-28 |
2023-01-27 |
C4591001, NCT04368728 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
0 |
33 Months |
8640 |
Pfizer CT.gov Call Center |
2020-05-04 |
| Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers: Randomized, Controlled Trial |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
SERVICES INSTITUTE OF MEDICAL SCIENCES |
|
Pakistan |
2020-04-30 |
2020-10-31 |
16082019, NCT04370015 |
Phase 2 Clinical |
Not yet recruiting |
1 |
6 Months |
374 |
Khadija I Khawaja, FCPS, Saira Burney, FRCP (Edin) |
2020-05-04 |
| CORRECT: COvid (Covid-19) Registry REChts der Isar intensive care Trial |
Adult respiratory distress syndrome, Coronavirus disease 19 infection |
extracorporeal organ support alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Technical University of Munich |
|
Germany |
2020-03-30 |
|
178/20S, CORRECT, DRKS00021612 |
Phase Not Applicable |
Recruiting |
1 |
|
500 |
Sebastian Rasch |
2020-05-04 |
| TeleCoviDiab: Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic |
Coronavirus disease 19 infection, Insulin dependent diabetes, Non-insulin dependent diabetes |
teleconsultation alone, telemedicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital of Strasbourg |
|
France |
2020-05-31 |
2020-12-31 |
7775, NCT04370171, TeleCoviDiab |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
200 |
Eric DEMONSANT |
2020-05-04 |
| SeCo: Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers |
Coronavirus disease 19 infection |
Anti-SARS-CoV2 S protein IgG ELISA alone, SARS-CoV-2 PCR alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Medicine Greifswald |
EUROIMMUN GmbH, Friedrich Loeffler Institute |
Germany |
2020-04-27 |
2025-05-31 |
BB 068/20, NCT04370119, SeCo |
Phase Not Applicable |
Recruiting |
2 |
61 Months |
4000 |
Andreas Greinacher, Prof.Dr., Christine Rutscher, Dipl.-Med., Henry Völzke, Prof.Dr., Karsten Becker, Prof.Dr., Lena Ulm, Dr., Marek Zygmunt, Prof.Dr., Martin Beer, Prof.Dr., Martin Groschup, Prof.Dr., Matthias Nauck, Prof.Dr., Mladen V. Tzvetkov, Prof.Dr., Nicole Endlich, Prof.Dr., Nils-Olaf Hübner, Prof.Dr., Thomas C. Mettenleiter, Prof.Dr., Wolfgang Schlumberger, Dr. |
2020-05-04 |
| PAN-COVID: A global registry of women affected by COVID-19 in pregnancy and their babies, to guide treatment and prevention |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Imperial College London |
United Kingdom Research & Innovation |
Canada, Greece, Lebanon, Mexico, Romania, US, Japan, UK, Belgium, Indonesia, Germany, Russian Federation, Austria, Czech Republic, Brazil, Netherlands, South Africa, Tunisia, Nigeria, Bosnia and Herzegovina, Colombia, Latvia, United Arab Emirates, Hungary, Italy, Spain, Malta, Peru, Thailand, Uganda, Australia, Ireland, Qatar, Argentina, India, Israel, Egypt, Estonia, Chile, Portugal, Guatemala, Ecuador |
2020-01-01 |
2021-09-30 |
20QC5917, IRAS 282655, ISRCTN68026880, PAN-COVID |
Phase Not Applicable |
Recruiting |
42 |
21 Months |
1000 |
Dr Mullins |
2020-05-04 |
| POCUSars-CoV-2: Accuracy of Lung Ultrasound in the Diagnosis of COVID-19 Pneumonia |
Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia |
lung ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Latisana Hospital |
|
Italy |
2020-04-23 |
2020-05-31 |
CEUR-2020-OS-086, NCT04370275, POCUSars-CoV-2 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
235 |
Carmine C Di Gioia, MD, Daniele Orso, MD, Roberto Copetti, MD, Director |
2020-05-04 |
| In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity |
Coronavirus disease 19 infection |
|
|
Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Applied Biology Inc |
Hospital Universitario Ramon y Cajal |
Spain |
2020-05-01 |
2020-12-01 |
AB-IVD-COV-001, NCT04368897 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
200 |
Andy Goren, MD, Carlos Wambier, MD, Sabina Herrera, MD |
2020-05-04 |
| Hungarian CoronaVirus Disease-19 Epidemiological Research |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Semmelweis University Heart and Vascular Center |
Semmelweis University, University Of Pécs, University of Debrecen, University of Szeged |
Hungary |
2020-05-01 |
2021-08-01 |
H-UNCOVER, NCT04370067 |
Phase Not Applicable |
Not yet recruiting |
4 |
15 Months |
11200 |
Andor Sebestyén, MD,PhD, Annamaria Kosztin, MD,PhD, Béla Merkely, PhD,DSc, Csaba Lengyel, MD,PhD, Ervin László Berényi, MD,PhD |
2020-05-04 |
| Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: a Prospective Study |
Coronavirus disease 19 infection |
real time reverse transcriptase polymerase chain reaction(rRT-PCR) alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Max Healthcare Institute Ltd, India |
|
India |
2020-04-28 |
2021-05-30 |
COVID-19/RFTC/MHC/2020, NCT04368871 |
Phase Not Applicable |
Not yet recruiting |
1 |
13 Months |
200 |
Bharat Aggarwal, Rajesh Saxena |
2020-05-04 |
| GROCO: Obstetric and Perinatal Outcomes of Women With COVID-19 |
Coronavirus disease 19 infection |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux De Marseille |
|
France |
2020-04-23 |
2021-04-22 |
2020-18, GROCO, ID RCB, NCT04369859 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
1300 |
Florence BRETELLE, PU-PH, Jean-Olivier ARNAUD, Director |
2020-05-04 |
| C5-COV: C5a Receptor Expression - COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux De Marseille |
Innate Pharma SA |
France |
2020-03-31 |
2020-11-30 |
2020-14, C5-COV, IDRCB, NCT04369820 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
70 |
Emilie EGP GARRIDO-PRADALIE, Julien CARVELLI, Julien JC CARVELLI, MD, Kahéna AMICHI, Kahéna KA AMICHI, Laurent PAPAZIAN, Lionel VELLY, Marc GAINNIER, Nicolas SCHLEINITZ, Pierre-Yves CORDIER |
2020-05-04 |
| C19Survey: The Psychological, Social, and Economic Impacts of COVID-19 |
Coronavirus disease 19 infection, Psychiatric disorder |
online survey alone |
|
Healthy volunteers accepted, Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Ottawa |
CHEO Research Institute, Centre for Addiction and Mental Health, Ciusss du Nord-De-L'île-De-Montréal, Hopital Du Sacre-Coeur De Montreal, Johns Hopkins University, McGill University, Ottawa Heart Institute Research Corp, Ottawa Hospital Research Institute, Southlake Regional Health Centre, Sunnybrook Health Sciences Centre, The Royal's Institute of Mental Health Research, Universite De Montreal |
Canada |
2020-04-03 |
2021-04-03 |
2131, C19Survey, NCT04369690 |
Phase Not Applicable |
Recruiting |
10 |
12 Months |
1000 |
Addo Boafo, MD, Alexander Daros, PhD, CPsych, Cynda Rushton, RN, PhD, Denis Lafortune, PhD, Edward Spilg, FRCP, MSc, Elizaveta Solomonova, PhD, Janet Jeffrey, RN, PhD, Jennifer Phillips, PhD, Jodi Edwards, PhD, Kaitlyn Lopes, Lena Quilty, PhD, CPsych, Mamta Gautam, FRCP MBA, Marie-Hélène Pennestri, PhD, Mysa Saad, MSc, Raj Bhatla, MD FRCPC, Richard H Swartz, MD, PhD, Richard Swartz, MD, PhD, Roger Godbout, PhD, Rébecca Robillard, Rébecca Robillard, PhD, Samuel Paul Louis Veissière, PhD, Tetyana Kendzerska, MD PhD, Tetyana Kendzerska, MD, PhD, Wendy Gifford, RN, PhD, Zachary Kaminsky, PhD |
2020-05-04 |
| DigitalDoc: The Digital Doc in the Emergency Department: The solution for patient care in the Covid-19 pandemic? |
Coronavirus disease 19 infection |
telemedicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Maxima Medical Center |
|
Netherlands |
2020-04-08 |
2020-09-01 |
DigitalDoc, NL8522 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
50 |
Bart Candel |
2020-05-04 |
| Neuroinvasion in COVID-19 |
Coronavirus disease 19 infection, Respiratory disease |
RT-PCR alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zuyderland Medical Center, Heerlen |
|
Netherlands |
2020-04-26 |
2020-06-26 |
NL8526 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
10 |
Floris Smeets |
2020-05-04 |
| Volatile Anesthetics in COVID-19 – a pilot study |
Coronavirus disease 19 infection, Respiratory distress syndrome |
isoflurane alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Medisch Centrum Utrecht |
|
Netherlands |
2020-04-26 |
2020-05-31 |
NL8523 |
Phase 2 Clinical |
Not yet recruiting |
1 |
1 Month |
20 |
Jan Dieleman |
2020-05-04 |
| Duke COVID-19 Shared Data and Specimen Repository |
Coronavirus disease 19 infection |
|
|
|
Duke University |
|
US |
2020-05-05 |
2025-04-30 |
NCT04368234, PRO00105316 |
Phase Not Applicable |
Recruiting |
0 |
59 Months |
100000 |
Chris Woods, MD, Lynn Sutton |
2020-05-04 |
| COVILUS: Lung Ultrasound to Diagnose COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
lung ultrasound alone, reverse transcription polymerase chain reaction test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire D Amiens |
|
France |
2020-04-28 |
2020-09-28 |
COVILUS, NCT04368338, PI2020_843_0030 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
100 |
Stéphane Bar, Dr, Stéphane Bar, MD |
2020-05-04 |
| SCOPe: To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Max Healthcare Institute Ltd, India, Max Super Speciality Hospital |
|
India |
2020-04-25 |
2020-07-25 |
CTRI/2020/04/024859, NCT04367064, SCOPE/MHC/COVID-19/2020, SCOPe |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
1000 |
Dr Ram Shankar Mishra, Rajesh Saxena, Rajesh Saxena, MBA, Ram Shankar Mishra, DNB, FRCP, Sandeep Budhiraja, MRCP, FACP |
2020-05-04 |
| ELCOVID: Electrocardiogram Analysis in COVID-19 Patients |
Cardiovascular disease, Coronavirus disease 19 infection |
blood test alone, cardiac magnetic resonance imaging alone, radiographic examination alone, transthoracic echocardiography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azienda Ospedaliero-Universitaria di Ferrara |
|
Italy |
2020-04-14 |
2021-12-01 |
385/2020/OSS/AOUFE, ELCOVID, NCT04367129 |
Phase Not Applicable |
Recruiting |
1 |
19 Months |
1000 |
Matteo Bertini, MD, PhD, Michele Malagù, MD |
2020-05-04 |
| EuroECMO-COVID: European/Euro-ELSO Survey on Adult and Neonatal/Pediatric COVID-19 Patients in ECMO |
Cardiogenic shock, Coronavirus disease 19 infection, Lung disease, Septic shock |
extracorporeal membrane oxygenation alone |
|
|
Maastricht University Medical Center |
Antwerp University Hospital, Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Azienda Ospedaliero-Universitaria Ospedali Riunit, Azienda Ospedaliero-Universitaria di Udine, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Cardiocentro Ticino, Centre Hospitalier Universitaire Saint Pierre, Centre Hospitalier Universitaire de Liege, Centro Hospitalar Sao Joao, Charles University, Chelyabinsk Regional Clinical Hospital, City Clinical Hospital No. 67, Moscow, Russia, City Hospital No 40, City Hospital No 41, Ekaterinburg, Department of Cardiovascular Surgery, German Heart Center Munich, Erasme Hospital, Erasmus University Medical Center Rotterdam, European chapter of the Extracorporeal Life Support Organization, G Gaslini Children's Hospital, G. Pasquinucci Heart Hospital, Massa, General University Hospital, Prague, Great Ormond Street Hospital for Children NHS Foundation Trust, Guy's & St Thomas' Hospital NHS Trust, Hannover Medical School, Heart Center Leipzig GmbH, Heim Pal Children's Hospital, Henri Mondor Hospital, Herlev Hospital Region Hovedstaden, Hopital Prive La Louviere, Hopital Universitaire de la Pitie Salpetriere, Hopitaux Universitaires De Geneve, Hospices Civils De Lyon, Hospital Miguel Servet, Hospital San Gerardo, Hospital Sant Joan de Deu, Hospital Universitario Ramon y Cajal, Hospital Vall D'Hebron, Hôpital Civil Marie Curie de Charleroi, IRCCS Policlinico San Matteo, Istituto Scientifico H San Raffaele, Karolinska University Hospital, Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash, Klinik Hirslanden, Klinikum Kassel GmbH, Krasnodar Regional Hospital no 1, Landesklinikum Sankt Polten, Leiden University Medical Center, Medical University of Vienna, Medical University of Warsaw, Newcastle Upon Tyne Hospitals NHS Trust, Niguarda Hospital, Novosibirsk City Hospital #2, Onze-Lieve-Vrouwziekenhuis Aalst Hospital, Ospedale Maurizio Bufalini, Ospedale Papa Giovanni XXIII, Ospedale Pediatrico Bambino Gesù (IRCCS), Ospedale S. Giovanni Bosco, Ospedale San Donato, Ospedale Umberto, Ospedale dell'Angelo, Paediatric Intensive Care Glasgow, Politecnico Di Milano, Rennes University Hospital, Rijksuniversiteit te Groningen, Royal Brompton & Harefield NHS Trust, San Bortolo Hosp, San Camillo Hospital, Rome, San Giorgio Clinic, Skåne University Hospital, St. Orsola Hospital, The Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Tirol Kliniken, Universitair Medisch Centrum Utrecht, Universitair Ziekenhuis Brussel, Universitair Ziekenhuis Gent, Universitaire Ziekenhuizen Leuven, Universitat Duisburg Essen, Universitatsklinikum Essen, University General Hospital of Alexandroupolis, University Hospital Basel, University Hospital Regensburg, University Hospital Tubingen, University Hospital, Aachen, University Hospital, Bordeaux, University Hospital, Montpellier, University Hospitals of Leicester - Leicester Royal Infirmary, University of Bern, University of Erlangen-Nurnberg Medical School, University of Lausanne Hospitals, University of Zurich, Universitätklinikum Düsseldorf, Universitätsklinikum Koln, Vilnius University Hospital Santariškių Klinikos |
Germany, Switzerland, Sweden, Denmark, Portugal, Spain, Russian Federation, UK, Israel, Italy, Czech Republic, Hungary, France, Austria, Greece, Poland, Netherlands, Lithuania, Belgium |
2020-04-10 |
2021-04-30 |
EuroECMO-COVID, METC 2020-1343, NCT04366921 |
Phase Not Applicable |
Recruiting |
97 |
12 Months |
150 |
Aaron Blandino, Ortiz, Alain Combes, Prof., Alberto Weber, Prof. Dr., Alessandro Paradiso, Dr., Alexander Kersten, Dr., Alexander Skopets, Alexandr Turchaninov, Alexandra Shilova, Allesandro Circelli, Dr., Andrea Montalto, Dr., Andrea Moscatelli, Angelo Polito, Antioco Cappai, Dr., Antonella Degani, Antonio Loforte, Dr., Aron Frederik Popov, Prof., Bernard Stockman, Dr., Christian Napp, Dr., Christoph Krapf, Dr., Claire Westrope, Daniel De Backer, Dr., Daniil Shelukhin, Dario Candura, Dr., Dario Fina, Dr., David Schibilsky, Dr., Davide Ghitti, Dr., De Piero, Drs., Dimitri Vandeweghe, Dimitrios Soufleris, Dinis Reis Miranda, Dr., Diyar Saeed, Prof., Edgars Grins, Esther Dreier, Dr., Fabio Taccone, Prof., Felix Hennig, Dr., Finn Moeller Pedersen, Dr., Gabriel Saiydoun, Dr., Gerdy Debeuckelaere, Giacomo Cavallaro, Gianluca Agus, Dr., Gil Bolotin, Dr., Giovanni Chiarini, Dr., Giovenni Landoni, Grünenfelder Jürg, Prof. Dr., Halbe Maximillian, Dr., Harlinde Peperstraete, Ignazio Condello, Igor Komilov, Ivan Akufov, J.J. van der Heijden, Dr., Jacinta Maas, Dr., Jan Belohlavek, Prof., Jan Schmitto, Prof., Jenni Hansjoerg, Jolanda Consiglio, Jordi Riero del Brio, Dr., Judit Llevadias, Justyna Swol, Dr., Katherine Brown, Lars Broman, Dr., Leen Vercaemst, Dr., Lo Coco, Drs., Lorusso, Prof. Dr., Luis Filipe Pinto, Dr., Maged Makhoul, Dr., Malaika Mendoca, Mara Scandroglio, Marc Lagny, Marco Giani, Dr., Marco Moscarelli, Dr., Marco Piccichè, Marco Ranucci, Dr., Maria Elena De Piero, Dr., Mariusz Kowaleswsky, Dr., Mark Davidson, Martin Kneyber, Matteo Di Nardo, Matteo Pozzi, Dr., Matthias Thielman, Prof., Maximillian Malfertheiner, Dr., Michael Piagnerelli, Mirko Belliato, Dr., Nicholas Bartlett, Dr., Nikolaos Bonaros, Prof., Olivier Brissaud, Olivier Germay, Pablo Ruiz, Dr., Paolo Del Sarto, Paolof Meani, Dr., Patrick Biston, Dr., Peter Schellongowski, Dr., Philipp Hen, Dr., Phillipe Gaudard, Pierre Tissieres, Ralf Muellenbach, Prof, Reina Gianfranco, Dr., Robertas Samalavicius, Dr., Roberto Carozza, Roberto Rona, Dr., Romain Courcelle, Roman Komelyuk, Sandrelli Luca, Dr., Sandro Sponga, Dr., Sergei Minin, Simone Schafer, Dr., Susana Segura Matute, Sven Maier, Dr., Thierry Folliguet, Prof., Thomas Doebele, Torje Iuliu, Dr., Udo Boeken, Prof., Vaclav Vobruba, Verna Aquino, Veronika Maraczi, Vito Fanelli, Dr., Xavier Bechtold |
2020-05-04 |
| COVID-19 outbreak and solid organ transplantation (SOT): an international, web-based survey |
Coronavirus disease 19 infection, Organ transplantation |
|
|
|
Policlinico Universitario Agostino Gemelli |
|
Italy |
2020-03-24 |
2020-04-17 |
COVID-19_V1, NCT04367896 |
Phase Not Applicable |
Completed |
1 |
|
1819 |
|
2020-05-01 |
| COVID PRAYER: The COVID-19 ICU PRAYER Study |
Coronavirus disease 19 infection |
remote intercessory multi-denominational prayer alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kansas City Heart Rhythm Institute |
|
US |
2020-05-01 |
2020-08-31 |
COVID PRAYER, COVID PRAYER STUDY, NCT04361838 |
Phase Not Applicable |
Not yet recruiting |
0 |
4 Months |
1000 |
Dhanunjaya Lakkireddy, MD, Donita Atkins, RN, BSN |
2020-05-01 |
| COVID19-CHIEF: COVID-19 Infection in Patients With Hepatocellular Carcinoma |
Coronavirus disease 19 infection, Hepatocellular carcinoma, Viral pneumonia |
nasopharyngeal Covid-19 RT-PCR alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire D Amiens |
Central Hospital, Nancy, France, Centre Hospitalien Sud Francilien, Centre Hospitalier Intercommunal Creteil, Centre Hospitalier Regional Universitaire de Lille, Centre Hospitalier Universitaire De Nice, Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation, Centre Hospitalier Universitaire de Toulouse, Hospices Civils De Lyon, Hospital Boisguillaume, Hôpital Paul Brousse, Jean Verdier Hospital, Rennes University Hospital, University Hospital, Bordeaux, University Hospital, Grenoble, University Hospital, Montpellier |
France |
2020-04-27 |
2020-10-31 |
COVID19-CHIEF, NCT04367805, PI2020_843_0042 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
50 |
Aurore BARON, MD, Christine SILVAIN, Pr, Eric ASSENAT, Pr, Eric NGUYEN KHAC, Pr, Giuliana AMADDEO, MD, Jean Pierre BRONOWICKI, Pr, Jean-Frédéric BLANC, MD, Jean-Marie PERON, Pr, Julien EDELINE, MD, Mohamed BOUATTOUR, MD, Nathalie GANNE-CARRIE, Pr, Olivier GANRY, Pr, Olivier Ganry, Pr, Philippe MATHURIN, Pr, Philippe MERLE, Pr, Pierre MICHEL, Pr, Rodolphe ANTY, Pr, Thomas DECAENS, Pr, Éric VIBERT, Pr |
2020-05-01 |
| ColchiVID: Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease |
Coronavirus disease 19 infection, Inflammatory disease |
colchicine (Perrigo) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Instituto Nacional de Ciencias Medicas y Nutricion |
|
Mexico |
2020-04-27 |
2021-04-27 |
337420-21-1, ColchiVID, NCT04367168 |
Phase 2 Clinical |
Not yet recruiting |
1 |
12 Months |
174 |
Jose J Torres-Ruiz, MD, MSc, Marina Rull-Gabayet, MD |
2020-05-02 |
| Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR |
Coronavirus disease 19 infection |
Dry flocked nasopharyngeal Swab alone, Flocked nasopharyngeal eSwab alone, Flocked oropharynx eSwab alone |
|
Healthy volunteers accepted |
Jessa Hospital |
|
Belgium |
2020-04-20 |
2020-05-20 |
20.43, NCT04361448 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
30 |
Koen Magerman, Reinoud Cartuyvels |
2020-05-04 |
| COHORT: Covid-19 Hospitalized Patients Registry |
Coronavirus disease 19 infection |
|
|
|
University Hospital Halle |
|
Germany |
2020-05-03 |
|
2020-039, COHORT, DRKS00021575 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
750 |
Daniel Sedding |
2020-05-01 |
| COVBIO: Thrombosis and Covid-19 |
Coronavirus disease 19 infection, Thrombosis |
thromboelastometry alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospices Civils De Lyon |
|
France |
2020-05-31 |
2020-12-31 |
69HCL20_0401 - COVBIO, COVBIO, ID-RCB, NCT04366778 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
300 |
Yesim DARGAUD, Pr, Yseim DARGAUD, Pf |
2020-05-01 |
| Social Media and COVID-19 |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Yale-NUS College |
|
Singapore |
2020-03-08 |
2020-05-31 |
2020-CERC-001B, NCT04367363 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
150 |
Jean Liu, PhD |
2020-05-01 |
| Cardiac Injury in COVID-19: a Pathology Study |
Coronavirus disease 19 infection, Heart injury, Lung disease, Myocardial infarction, Myocarditis, Pulmonary heart disease |
EKG alone, RNAscope in situ hybridization alone, autopsy alone, cardiac catheterization alone, cardiac sampling alone, dual immunofluorescence alone, echocardiography alone, reverse transcription polymerase chain reaction alone, transmission electron microscopy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ospedale Papa Giovanni XXIII |
CVPath Institute |
Italy |
2020-04-30 |
2021-03-31 |
56/20, NCT04367792 |
Phase Not Applicable |
Recruiting |
1 |
11 Months |
50 |
Andrea Gianatti, MD, Antonio Bellasi, MD, CTC CLINICAL TRIAL CENTER, Giulio Guagliumi, MD, Lara Faggi, PhD |
2020-05-04 |
| MARCO: A Phase Ib/II, Randomized, Placebo-Controlled, Dose-Finding Study Followed by a Dose Level Expansion to Assess the Safety and Efficacy of NoveCite MSCs in Subjects with Acute Respiratory Distress Syndrome (ARDS) Due to SARS-CoV-2 Disease (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Allogeneic NoveCite mesenchymal stem cell therapy (acute respiratory distress syndrome/COVID-19), Citius Pharmaceuticals alone |
|
|
Citius Pharmaceuticals Inc |
|
US |
|
|
MARCO |
Phase 1/Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-05-04 |
| X-Covid 19: Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients |
Coronavirus disease 19 infection, Thromboembolism |
enoxaparin sodium alone |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Niguarda Hospital |
|
Italy |
2020-05-31 |
2020-11-30 |
2020-001708-41, NCT04366960, X-Covid 19 |
Phase 3 Clinical |
Not yet recruiting |
1 |
6 Months |
2712 |
Nuccia Morici, MD |
2020-05-02 |
| A double-blinded, randomized and placebo-controlled study of trans sodium crocetinate (intravenous), Diffusion Pharmaceuticals in hospitalized COVID-19 patients who have not yet been admitted to an ICU |
Coronavirus disease 19 infection |
trans sodium crocetinate (intravenous), Diffusion Pharmaceuticals alone |
|
|
Diffusion Pharmaceuticals LLC, West Virginia University Healthcare |
|
US, Eastern Europe |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Dr. Alex Kadl, Dr. Andrew Southerland |
2020-04-30 |
| Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
remestemcel-L alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mesoblast International Sarl |
Mesoblast Ltd |
US |
|
|
MSB-MSC-ARDS001, NCT04366830 |
Phase Not Applicable |
No longer recruiting |
0 |
|
50 |
Mahboob Rahman, MD |
2020-05-02 |
| A trial to assess COVID-19 vaccine (inactivated, Vero cells/intramuscular), Beijing Biological Products Institute/National Institute for Viral Disease Control and Prevention of Chinese Center for Disease Control and Prevention for covid-19 |
Coronavirus disease 19 infection |
COVID-19 vaccine (inactivated, Vero cells/intramuscular), Beijing Biological Products Institute/National Institute for Viral Disease Control and Prevention of Chinese Center for Disease Control and Prevention alone |
|
|
China National Pharmaceutical Group Corporation |
|
China |
|
|
|
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
32 |
|
2020-05-04 |
| LUCID: Lung Ultrasound in Covid-19 Pneumonia |
Coronavirus disease 19 infection, Cough, Dyspnea, Respiratory disease, Viral pneumonia |
computed tomography alone, lung ultrasoound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vivantes Humboldt-Klinikum |
|
Germany |
2020-04-24 |
|
DRKS00021585, Eth08-20, LUCID |
Phase Not Applicable |
Recruiting |
1 |
|
220 |
Andreas Umgelter |
2020-05-02 |
| SARS-CoV-2 and Surgery |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jagiellonian University |
|
Poland |
2020-03-30 |
2020-07-01 |
1072.6120.103.2020, NCT04368026 |
Phase Not Applicable |
Recruiting |
2 |
3 Months |
350 |
Tomasz Stefura, Tomasz Stefura, MD |
2020-05-02 |
| A larger, double-blinded, randomized, placebo-controlled study of trans sodium crocetinate (intravenous) to confirm safety in COVID-19 patients who have been admitted to Intensive Care Units (ICUs) |
Coronavirus disease 19 infection |
trans sodium crocetinate (intravenous), Diffusion Pharmaceuticals alone |
|
|
Diffusion Pharmaceuticals LLC, West Virginia University Healthcare |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Dr. Alex Kadl, Dr. Andrew Southerland |
2020-04-30 |
| COR-DIAL-1: Rapid Detection of COVID-19 by Portable and Connected Biosensor |
Coronavirus disease 19 infection |
RT-PCR alone, nasopharyngeal swab sampling alone, viral biosensor alone |
|
|
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-05-31 |
2020-09-30 |
2020-A01147-32, 2020_36, COR-DIAL-1, NCT04367142 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
200 |
David Devos, MD,PhD, Enagnon Kazali ALIDJINOU, MD |
2020-05-02 |
| MolCOVID: Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Boisguillaume |
|
France |
2020-04-30 |
2020-05-31 |
2020/0094/OB, MolCOVID, NCT04367545 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
50 |
Julien BLOT, Thierry FREBOURG, Pr |
2020-05-01 |
| EVIDENCE: COVID-19 Detection Test in Oncology |
Coronavirus disease 19 infection, Solid tumor |
enzyme-linked immunosorbent assay (ELISA) alone, rapid diagnostic test (RDT) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The UNICANCER Group |
|
France |
2020-05-31 |
2021-05-31 |
2020-A01002-37, EVIDENCE, NCT04367870, UC-TRA-2002 |
Phase Not Applicable |
Not yet recruiting |
11 |
12 Months |
2500 |
Alexandra JACQUET, Aurélien NORET, François-Clément BIDARD, Frédéric VIRET, Georges EMILE, Jean-Baptiste BACHET, Jean-Marc FERRERO, Lionel MOREAU, WILLIAM JACOT |
2020-05-03 |
| ScreenNC: A Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19 |
Coronavirus disease 19 infection |
COVID-19 testing alone, PCR test alone, sequencing alone, swab test alone, viral load testing alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of North Carolina |
|
US |
2020-04-28 |
2021-04-30 |
20-0937, NCT04367740, ScreenNC |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
10000 |
David B Peden, MD |
2020-05-01 |
| ACCORD: ACcelerating COVID-19 Research and Development platform |
Coronavirus disease 19 infection |
bemcentinib alone |
Axl tyrosine kinase receptor inhibitor |
|
BerGenBio AS |
Department of Health and Social Care, IQVIA Holdings Inc, United Kingdom Research & Innovation |
UK |
|
|
ACCORD |
Phase 2 Clinical |
Planned |
1 |
|
120 |
|
2020-04-30 |
| BACT-ovid: Bacteriotherapy in the Treatment of COVID-19 |
Coronavirus disease 19 infection |
bacteriotherapy alone, Variable regimens including SivoMixx , azithromycin , darunavir , darunavir + cobicistat , hydroxychloroquine , lopinavir + ritonavir , ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universita degli Studi di Roma La Sapienza |
|
Italy |
2020-03-01 |
2020-07-31 |
BACT-ovid, DPHID-UNIROMA05, NCT04368351 |
Phase Not Applicable |
No longer recruiting |
1 |
5 Months |
70 |
Gabriella d'Ettorre, MD, PhD, Giancarlo Ceccarelli |
2020-05-01 |
| Comorbidites among COVID-19 Mortality Cases |
Coronavirus disease 19 infection |
|
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-30 |
|
54554, NMRR-20-766-54554 |
Phase Not Applicable |
Status not specified |
1 |
|
|
Hamizatul Akmal Binti Abd Hamid, P Robert Lourdes, Tania Gayle |
2020-05-01 |
| Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection |
Coronavirus disease 19 infection |
angiotensin converting enzyme inhibitor therapy alone, angiotensin-receptor blocker therapy alone, influenza vaccine alone |
|
Healthy volunteers accepted |
Consorci Sanitari de Terrassa |
Catalan Health Service, Jordi Gol i Gurina Foundation |
Spain |
2020-03-01 |
2023-08-31 |
02-20-161-021, NCT04367883 |
Phase Not Applicable |
Recruiting |
1 |
42 Months |
2574 |
Anna Puigdellívol-Sánchez, Ph D, Anna Puigdellívol-Sánchez, Ph.D., Mar Muñoz |
2020-05-02 |
| Health Behavior Change During COVID-19 Pandemic |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
SWPS University of Social Sciences and Humanities |
|
Gambia, Australia, Romania, Israel, Germany, Switzerland, Poland, Canada, Italy, Portugal, France, Singapore, China, Malaysia |
2020-03-25 |
2021-03-24 |
3228-1BPSYPSBEH-30, NCT04367337 |
Phase Not Applicable |
Recruiting |
14 |
12 Months |
5600 |
Adriana Baban, PhD, Aleksandra Luszczynska, PhD, Bruno Quintard, PhD, Charles Abraham, PhD, Jan Keller, PhD, Karen Morgan, PhD, Katarzyna Byrka, PhD, Konstadina Griva, PhD, Konstantin Schenkel, MA, Margarida Gaspar de Matos, PhD, Martyna Kuszneruk, MA, Michelle Jongenelis, PhD, Nina Knoll, PhD, Noa Vilchinsky, PhD, Sabrina Cipolletta, PhD, Stephan Dombrowski, PhD, Urte Scholz, PhD, Vishna Shah, PhD, Yiquin Gan, PhD, Yiqun Gan, PhD, Zofia Szczuka, MA |
2020-05-02 |
| Stigmatization of Covid-19 patients |
Coronavirus disease 19 infection |
|
|
|
Hospital Raja Permaisuri Bainun |
|
Malaysia |
2020-06-01 |
|
54697, NMRR-20-777-54697 |
Phase Not Applicable |
Status not specified |
1 |
|
|
Chang Chee Tao, Ms. Chew Chii Chii |
2020-05-02 |
| Psychological Impairment Due to Covid-19 |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Psychiatric disorder |
|
|
Healthy volunteers accepted |
Universitatsklinikum Essen |
|
|
2020-05-06 |
2020-05-30 |
NCT04368312, TEMP553914-BO |
Phase Not Applicable |
Not yet recruiting |
0 |
|
100 |
Johannes Siebermair, MD |
2020-05-02 |
| COVIVA: COVID-19 Survival |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Basel |
|
Switzerland |
2020-03-19 |
2021-06-30 |
COVIVA, NCT04366765, UHOSPITAL SWITZ |
Phase Not Applicable |
Recruiting |
1 |
15 Months |
1500 |
Gabriela Kuster Pfister, MD, Raphael Twerenbold, MD |
2020-05-02 |
| SAVIOR: Study Assessing Vagus Nerve Stimulation in COVID-19 Respiratory Symptoms |
Coronavirus disease 19 infection, Respiratory disease |
GammaCore alone, vagus nerve stimulation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Valencia |
|
Spain |
2020-04-20 |
2020-07-31 |
NCT04368156, SAVIOR, SAVIOR |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
90 |
Carlos Tornero, Carlos Tornero, PhD, Natividad Pozo, PhD |
2020-05-01 |
| IMPROVE: Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 |
Coronavirus disease 19 infection, Thromboembolism |
enoxaparin sodium alone, unfractionated heparin alone |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Columbia University |
|
US |
2020-05-31 |
2021-04-30 |
AAAS8980, IMPROVE, NCT04367831 |
Phase 4 Clinical |
Not yet recruiting |
0 |
11 Months |
100 |
Ajay Kirtane, MD, Kate Dalton, Sahil A. Parikh, Sahil Parikh, MD |
2020-05-04 |
| Registry to Study Factors That May Impact COVID-19 Occurrence and Severity |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
IQVIA RDS Pty Ltd |
|
US |
2020-04-02 |
2022-06-01 |
IQVIA-COVIDREGISTRY-2020, NCT04368065 |
Phase Not Applicable |
Recruiting |
0 |
26 Months |
100000 |
Barbara Arone, MS, Nancy Dreyer, PhD, MPH |
2020-05-01 |
| Use of Convalescent Plasma in the treatment of COVID-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
HILTON PHARMA (PVT) LTD, National Institute of Blood Disease Center |
|
Iran |
2020-04-14 |
|
4-87/NBC-COVID19-/20/03, IRCT20200414047072N1 |
Phase 2 Clinical |
Recruiting |
1 |
|
357 |
Dr. Arshi Naz, Dr. Neeta Maheshwary, Professor Dr. Tahir S Shamsi, Saba Fatima |
2020-05-01 |
| ATTRACT: A phase II, randomized, double-blind, placebo-controlled clinical trial of VP-01 for the tretment of patients with COVID-19, SARS CoV-2 infection |
Coronavirus disease 19 infection, Respiratory failure |
VP-01 alone |
Angiotensin II AT-2 receptor agonist |
|
Vicore Pharma AB |
|
UK |
|
|
ATTRACT |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
100 |
Professor Joanna Porter |
2020-04-30 |
| Chula Covid-19 Rapid Test for Pandemic Control |
Coronavirus disease 19 infection |
RT-PCR alone |
|
Healthy volunteers accepted |
Burapha University, Chaophraya Yommaraj Hospital, Chulalongkorn University, H.R.H. Maha Chakri Sirindhorn Medical Center, King Chulalongkorn Memorial Hospital, Lampang Hospital, Nan Hospital, National Cancer Institute, Thailand, Paholpolpayuhasena Hospital, Police General Hospital, Samitivej Sukhumvit Hospital, Samut Sakhon Hospital, Sikhio Hospital, Songkhla Hospital |
|
Thailand |
2020-03-20 |
|
TCTR20200426002 |
Phase Not Applicable |
Recruiting |
1 |
|
200 |
Krit Pongpirul, Narin Hiransuthikul |
2020-05-04 |
| Intravascular Access in Suspected/Confirmed COVID-19 Patient |
Cardiac arrest, Coronavirus disease 19 infection |
NIO needle set alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lazarski University |
Medical University of Bialystok, Poznan University of Medical Sciences, Wroclaw Medical University |
Poland |
2020-04-14 |
2020-05-20 |
IO_PPE_1, NCT04366947 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
60 |
Lukasz Szarpak, Lukasz Szarpak, PhD |
2020-05-01 |
| COVID-19BRAIN: Neuroradiolological Analysis of COVID-19 Patients |
Brain disease, Coronavirus disease 19 infection |
neurological examination alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
2020-04-03 |
2021-04-30 |
7759, COVID-19BRAIN, NCT04368390 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
100 |
Saïd CHAYER, PhD, HDR, Stephane Kremer, MD, PhD, Stéphane KREMER, MD, PhD |
2020-05-01 |
| A clinical trial of recombinant protein vaccine for the prevention of COVID-19 infection |
Coronavirus disease 19 infection |
recombinant protein vaccine (COVID-19), UMN Pharma Inc alone |
|
|
Shionogi & Co Ltd |
|
Japan |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-30 |
| Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic |
Coronavirus disease 19 infection |
injection molded polypropylene flocked nylon nasopharyngeal swab alone |
|
Healthy volunteers accepted, Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Virginia |
|
US |
2020-04-24 |
2020-07-31 |
HSR200127, NCT04368260 |
Phase Not Applicable |
Recruiting |
0 |
3 Months |
40 |
Amy Mathers, MD, Limor Steinberg |
2020-05-01 |
| COVIDSMELL: Study of the Pathogenesis of Olfactory Disorders in COVID-19 |
Ageusia, Coronavirus disease 19 infection, Dysomia |
nasal swab sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Institut Pasteur |
Assistance Publique Hopitaux de Paris |
France |
2020-04-30 |
2022-09-15 |
2020-021, COVIDSMELL, NCT04366934 |
Phase Not Applicable |
Not yet recruiting |
1 |
28 Months |
24 |
Charlotte HAUTEFORT, MD, Françoise LAZARINI, PhD |
2020-05-01 |
| RESCUE 1-19: Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 |
Coronavirus disease 19 infection, Edema, Viral pneumonia |
low dose radiation therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Emory University |
National Cancer Institute |
US |
2020-04-23 |
2020-07-01 |
NCI-2020-02676, NCT04366791, P30CA138292, RAD5002-20, RESCUE 1-19, STUDY00000476 |
Phase 1/Phase 2 Clinical |
Recruiting |
0 |
2 Months |
10 |
Autumn Lunceford, Clayton B Hess, MD, MPH, Clayton B. Hess, Clayton B. Hess, MD MPH, Clayton Hess, MD, MPH, Mohammad K Khan, MD, PhD, Mohammad K. Khan, MD PhD |
2020-05-02 |
| Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement |
Coronavirus disease 19 infection |
electromyography alone, electroneurography alone, muscle ultrasound alone, transthoracic echocardiography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Tubingen |
|
Germany |
2020-03-20 |
2022-03-31 |
246/2020BO2, NCT04367350 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
500 |
Alexander Grimm, MD, Helene Häberle, MD, Markus Krumbholz, MD, Sophia Willikens, MD, Sven Poli, MD |
2020-05-01 |
| African Covid-19 Critical Care Outcomes Study |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Cape Town |
University Of Kwazulu-Natal |
South Africa |
2020-05-01 |
2020-12-31 |
ACCCOS, NCT04367207 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
2000 |
Bruce Biccard, Bruce M Biccard |
2020-05-01 |
| DEPRECOVID: Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Gynecological disorder |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation |
|
France |
2020-05-31 |
2020-12-31 |
2020-A01065-34, DEPRECOVID, NCT04368208 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
900 |
bertarnd GACHON, MD, PhD student |
2020-05-04 |
| IRCEP: International Registry of Coronavirus (COVID-19) Exposure in Pregnancy |
Coronavirus disease 19 infection |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Pregistry |
Harvard TH Chan School of Public Health |
US |
2020-05-01 |
2024-04-30 |
0001, IRCEP, NCT04366986 |
Phase Not Applicable |
Not yet recruiting |
0 |
48 Months |
25000 |
Diego Wyszynski, MD, MHS, PhD, Sonia Hernandez-Diaz, MD, DrPH |
2020-05-01 |
| reCoVery: Repurposing of Chlorpromazine in Covid-19 Treatment |
Coronavirus disease 19 infection |
chlorpromazine alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Sainte Anne |
Hôpital Cochin |
France |
2020-04-29 |
2020-09-30 |
D20-P016, NCT04366739, reCoVery |
Phase 3 Clinical |
Not yet recruiting |
1 |
5 Months |
40 |
Marion Plaze, MD, PHD, Raphaël Gaillard, MD, PHD |
2020-05-01 |
| COVCKD: Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19 |
Coronavirus disease 19 infection, Kidney dialysis |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Region Midtjylland |
Aalborg Hospital, Aarhus University Hospital, Central Jutland Regional Hospital |
Denmark |
2020-03-15 |
2021-12-01 |
COVCKD, FHM-1-2020, NCT04367714 |
Phase Not Applicable |
Recruiting |
1 |
20 Months |
300 |
Frank Mose, Frank Mose, MD |
2020-05-01 |
| MY-CO-VID: Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU |
Aspergillus infection, Coronavirus disease 19 infection, Mucor infection, Pneumocystis carinii infection |
biological sampling alone, polymerase chain reaction alone, real-time polymerase chain reaction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rennes University Hospital |
|
France |
2020-04-30 |
2021-05-31 |
35RC20_8885_MY_CO_VID, MY-CO-VID, NCT04368221 |
Phase Not Applicable |
Not yet recruiting |
15 |
13 Months |
250 |
Achille Kouatchet, Alain Mercat, Anna Novara, Antoine Berry, Beatrice Riu-Poulenc, Carole Schwebel, Christophe Hennequin, Cécile Aubron, Daniele Monbon, Emmanuel Canet, Eric Dannaoui, Feraht Meziani, Florence Persat, Florence Robert-Gangneux, Florent Morio, Francoise Botterel, Frederic Dalle, Frédéric Dalle, Gilles Nevez, Gilles Nevez Nevez, Guillaume Desoubeaux, Jean Christophe Richard, Jean-Francois Timsit, Jean-Marc Tadié, Jean-Philippe Bouchara, Jean-Pierre GANGNEUX, MD, PhD, Jean-Pierre Gangneux, Keyvan Razazi, Laurent Argaud, Marie LE NAOU, Martine Wallon, Muriel Cornet, Muriel Sarrah Fartoukh, Nicolas Terzi, Nicolas de Prost, Patrice Le Pape, Pierre-Francois Dequin, Pierre-François Dequin, Sandrine Houzé, Sophie Brun, Stephane Gaudry, Stéphane Gaudry, Valerie Letcher-Bru, Valérie Letcher-Bru, Xavier Iriart, Yves Cohen, Yves Le Tulzo, cecile Aubron, cécile Aubron |
2020-05-04 |
| THROMBOCOVID: Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy |
Coronavirus disease 19 infection, Lung disease, Thromboembolism, Viral pneumonia |
venous ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire D Amiens |
|
France |
2020-04-22 |
2020-09-22 |
NCT04366752, PI2020_843_0036, THROMBOCOVID |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
100 |
Clement Brault, MD, Julien Maizel, Pr, Michel Slama, Pr, Simon Soudet, MD, Yoann Zerbib, MD |
2020-05-01 |
| IMSEQ: COVID-19 Immune Repertoire Sequencing |
Coronavirus disease 19 infection |
blood sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Institute of Tropical Medicine, Belgium |
Antwerp University Hospital |
Belgium |
2020-04-01 |
2020-12-31 |
IMSEQ, IMSEQ, NCT04368143 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
100 |
Koen Vercauteren |
2020-05-01 |
| The effect of NBS powder in treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
NBS powder alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hamadan University of Medical Sciences |
|
Iran |
2020-05-09 |
|
IR.UMSHA.REC.1399.046, IRCT20200426047206N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
46 |
Farid Azizi Jalilian |
2020-05-04 |
| PIC-19: Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
Variable regimens including acetylsalicylic acid , clopidogrel , fondaparinux sodium , tirofiban |
Factor Xa antagonist, GP IIb IIIa antagonist, P2Y12 purinoceptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universita degli Studi di Milano |
Fondazione Un Cuore per Milano |
Italy |
2020-04-06 |
2020-04-23 |
18275/2020, NCT04368377, PIC-19 |
Phase 2b Clinical |
Completed |
1 |
|
5 |
Pierachille Santus |
2020-05-02 |
| Effect of natural from Tahini oil product on corona |
Coronavirus disease 19 infection |
Tahini oil alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Gonabad University of Medical Sciences |
|
Iran |
2020-04-30 |
|
IR.GMU.REC.1399.014, IRCT20140407017169N2 |
Phase Not Applicable |
Recruiting |
1 |
|
100 |
Ahmadi Reza, Hossein Mohammadzadeh- Moghadam, Hossein Mohammadzadeh-moghadam |
2020-05-04 |
| BEVACOR: Pilot study of bevacizumab as a treatment for respiratory distress in patients with COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
bevacizumab alone |
VEGF ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundación Para La Investigación Biomédica De Córdoba |
|
Spain |
2020-04-24 |
|
2020-001541-39, BEVACOR, BEVACOR |
Phase 2 Clinical |
Recruiting |
1 |
|
22 |
Antonio Luque |
2020-05-01 |
| Is there a benefit in treating novel corona virus (Sars-CoV2) infections with the established antihypertensive valsartan? |
Coronavirus disease 19 infection |
valsartan alone |
Angiotensin I receptor antagonist, Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum St Georg |
|
Germany |
2020-04-22 |
|
2020-001431-27, CovidVal01 |
Phase 2 Clinical |
No longer recruiting |
1 |
|
300 |
Geschäftsführung |
2020-05-04 |
| Telemedicine in the Covid-19 pandemic in Brazil in a medical clinic in the supplementary health sector in São Paulo, Brazil |
Coronavirus disease 19 infection |
telemedicine alone, azithromycin plus hydroxychloroquine |
|
|
Centro Medico Mazzei |
|
Brazil |
2020-04-01 |
|
3.947.259, 30246520.0.0000.0069, A36899523876, RBR-658khm |
Phase 2 Clinical |
Recruiting |
1 |
|
90 |
Michelle Chechter |
2020-05-01 |
| SIDIACO: The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients |
Coronavirus disease 19 infection, Non-insulin dependent diabetes, Respiratory failure, Viral pneumonia |
nutrition intake alone, sitagliptin alone, standard of care alone, insulin plus sitagliptin |
Dipeptidyl peptidase IV inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universita degli Studi di Milano |
|
Italy |
2020-04-30 |
2020-12-30 |
FBF SACCO, NCT04365517, SIDIACO |
Phase 3 Clinical |
Not yet recruiting |
1 |
8 Months |
170 |
Paolo Fiorina, MD, PhD, Teresa Letizia, Dr. |
2020-05-02 |
| MERMAIDS 2: European Study of Major Infectious Disease Syndromes Related to COVID-19 |
Coronavirus disease 19 infection, Respiratory disease, Respiratory tract infection |
biological sampling alone |
|
|
Universitair Medisch Centrum Utrecht |
|
Netherlands |
2020-05-01 |
2022-04-30 |
MERMAIDS 2, NCT04364711, RECOVER - MERMAIDS 2.0 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
2000 |
MJM Bonten |
2020-04-30 |
| Intravascular Access of COVID-19 Patient Under Personal Protective Equipment |
Coronavirus disease 19 infection |
NIO alone, Standard intravenous cannula alone, intraosseous access alone, intravenous access alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lazarski University |
Medical University of Bialystok, Poznan University of Medical Sciences, Wroclaw Medical University |
Poland |
2020-01-12 |
2020-02-25 |
IO_PPE_MS_1, NCT04366297 |
Phase Not Applicable |
Completed |
1 |
1 Month |
41 |
Jacek Smereka, PhD, Łukasz Szarpak, Assoc Prof PhD |
2020-04-30 |
| PROBIOZOVID: Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora |
Coronavirus disease 19 infection |
oxygen-ozone therapy alone, standard of care alone, Variable regimens including Ozone , SivoMixx , azithromycin , darunavir , darunavir + cobicistat , hydroxychloroquine , lopinavir + ritonavir , ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azienda Policlinico Umberto I |
|
Italy |
2020-03-26 |
2020-12-31 |
110/2020, NCT04366089, PROBIOZOVID |
Phase 2 Clinical |
Recruiting |
1 |
9 Months |
152 |
Andrea Calò, MD, Carmela Imperiale, MD, Claudio M Mastroianni, MD PhD, Fabio Araimo, MD, Francesco Pugliese, MD PhD, Francesco Pugliese, MD, PhD, Gabriella d'Ettorre, MD PhD, Giancarlo Ceccarelli, MD PhD MSc, Gregorio Egidio Recchia, MD, Paolo Tordiglione, MD PhD, Roberto Poscia MD, Serena Zancla, MD, Vera MAuro, MD |
2020-05-01 |
| The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial |
Coronavirus disease 19 infection |
hydroxychloroquine alone, standard preventive measures alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
University of the Philippines |
|
Philippines |
2020-04-30 |
2021-05-31 |
NCT04364815, RGAO-2020-0339 |
Phase 3 Clinical |
Not yet recruiting |
1 |
13 Months |
960 |
Belen L Dofitas, MD |
2020-04-30 |
| COVID-19 Seremban 3MCO |
Coronavirus disease 19 infection |
|
|
|
Pejabat Kesihatan Daerah Seremban |
|
Malaysia |
2020-04-29 |
2020-09-01 |
54671, NMRR-20-786-54671 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
|
Dr MOHD 'AMMAR IHSAN BIN AHMAD ZAMZURI |
2020-05-01 |
| COVID-T: COVID-19 Search in Conjunctival Cells |
Coronavirus disease 19 infection, Lung disease |
computed tomography alone, conjunctival swab alone, nasopharyngeal swab alone, real time-PCR alone, x-ray alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Policlinico Universitario Agostino Gemelli |
|
Italy |
2020-03-26 |
2020-05-30 |
0013008/20, COVID-T, NCT04364594 |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
50 |
|
2020-04-30 |
| SCOPe: To Study the Clinical characteristics and treatment Outcome of COVID-19 Patients admitted in hospitals of Max Healthcare |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Max Super Speciality Hospital |
|
India |
2020-04-25 |
|
CTRI/2020/04/024859, SCOPe |
Phase Not Applicable |
Not yet recruiting |
1 |
|
1000 |
Dr Ram Shankar Mishra, Dr Sandeep Budhiraja, Rajesh Saxena |
2020-04-29 |
| PRON-COVID: The Prone Position in Covid-19 Affected Patients |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
continuous positive airway pressure therapy alone, oxygen therapy alone, prone positioning alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University of Milano-Bicocca |
|
Italy |
2020-03-20 |
2020-05-31 |
NCT04365959, PRON-COVID, PRON-COVID |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
56 |
Giuseppe Foti, Prof. |
2020-05-01 |
| To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID-19 cases. A Pilot Study |
Coronavirus disease 19 infection |
ivermectin alone |
Chloride channel modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Max Super Speciality Hospital |
|
India |
2020-04-25 |
|
CTRI/2020/04/024858 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
50 |
Dr Ram Shankar Mishra, Dr Sandeep Budhiraja, Rajesh Saxena |
2020-04-29 |
| Bid data analytic COVID-19 |
Coronavirus disease 19 infection |
predictive visual analytic method alone |
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-30 |
2020-08-31 |
54648, NMRR-20-790-54648 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
|
Dr Mohd Azahadi Omar, Encik MOHAMAD FUAD BIN MOHAMAD ANUAR |
2020-04-29 |
| RNA-based vaccine for COVID-19 |
Coronavirus disease 19 infection |
RNA-based vaccine alone |
|
|
Institute For Medical Research (Inc In Malaysia) |
|
Malaysia |
2020-06-01 |
2022-12-31 |
54569, NMRR-20-764-54569 |
Phase Not Applicable |
Status not specified |
1 |
31 Months |
|
Dr MASITA BINTI ARIP, Ms Ching Yee Ming |
2020-04-30 |
| COVID-19 NGS: NGS Diagnostic in COVID-19 Hosts: Genetic Cause Relating to the Course of Disease Progression |
Coronavirus disease 19 infection |
DNA methylation analysis alone, T-cell receptor repertoire sequencing alone, methylation beadchip (EPIC) array alone, next generation sequencing alone, whole genome sequencing alone, whole transcriptome sequencing alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Tubingen |
|
Germany |
2020-04-30 |
2021-08-31 |
COVID-19 NGS, COVID-19 NGS, NCT04364828 |
Phase Not Applicable |
Not yet recruiting |
1 |
16 Months |
1000 |
Michael Bitzer, Prof. Dr., Olaf Rieß, Prof. Dr. |
2020-05-04 |
| COVID-19: investigation into biochemical and hematological parameters in clinical laboratory |
Coronavirus disease 19 infection |
|
|
|
UNIVERSITI INDUSTRI SELANGOR (UNISEL) - SHAH ALAM CAMPUS |
|
Malaysia |
2020-04-29 |
2020-05-29 |
54641, NMRR-20-760-54641 |
Phase Not Applicable |
Status not specified |
1 |
1 Month |
|
CHIA ZHEN ZHAN |
2020-04-29 |
| Lung Recruitment Device for COVID-19 |
Coronavirus disease 19 infection |
Chest physiotherapy alone |
|
|
|
Dymedso Inc, Fonds de la Recherche en Sante du Quebec |
|
2020-05-01 |
2020-12-31 |
MP-21-2020-2871, NCT04361435 |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
50 |
Atsushi Kawaguchi, MD PhD, Philippe Jouvet, MD PhD MBA, Saly Salti, MSc |
2020-04-30 |
| LAPTRANSCOV: Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients |
Coronavirus disease 19 infection |
RT-PCR alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier René-Dubos |
|
France |
2020-05-31 |
2020-10-31 |
CHRD 0420, LAPTRANSCOV, NCT04361396 |
Phase Not Applicable |
Recruiting |
2 |
5 Months |
40 |
Christophe Poncelet, Maryline Delattre, Nelson Trelles, Veronique Da Costa |
2020-05-01 |
| Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Psychiatric disorder |
non-pharmacological intervention treatment alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Modum Bad |
University of Oslo |
Norway |
2020-03-31 |
2020-04-07 |
NCT04365881, REK12345 |
Phase Not Applicable |
Completed |
1 |
|
10084 |
Asle Hoffart, PhD, Omid V. E. Ebrahimi, Cand Psychol, Sverre Urnes Johnson, PhD |
2020-05-01 |
| NutriCovid30: Nutritional Evaluation for Covid-19 Infection at D30 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Grenoble |
Universite Grenoble Alpes |
France |
2020-05-31 |
2020-11-30 |
2020-A01120-39, NCT04365816, NutriCovid30 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
600 |
Marie-France VAILLANT, PhD |
2020-05-04 |
| AIC: Azithromycin in Hospitalized COVID-19 Patients |
Coronavirus disease 19 infection |
azithromycin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-04-20 |
2020-05-05 |
AIC, AZITHROMYCIN IN COVID-19, NCT04359316 |
Phase 4 Clinical |
Not yet recruiting |
1 |
|
40 |
Mehran Lack, MD, Mohammad Fathi, MD, Nader Markazi, MD, Nasser Malekpour Alamdari, MD, Sanaz Zargar Balaye Jam, MD, Sasan Tavana, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA |
2020-04-29 |
| An International, multicenter clinical study to evaluate the efficacy and safety of Polyoxidonium in hospitalized COVID-19 patients |
Coronavirus disease 19 infection |
Polyoxidonium alone |
|
|
NPO Petrovax Pharm LLC |
|
Russian Federation |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
|
|
2020-04-29 |
| CYNK001COVID: Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 |
Coronavirus disease 19 infection, Lower respiratory tract infection |
CYNK-001 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Celularity Inc, Sorrento Therapeutics Inc |
Infectious Disease Research Institute, Lung Biotechnology Inc |
US |
2020-04-30 |
2021-11-30 |
CYNK-001-COVID-19, CYNK001COVID, NCT04365101 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
0 |
19 Months |
86 |
Corey Casper, MD MPH, Erica Rave, MS, IDRI |
2020-04-29 |
| OzonoCOVID19: Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID 19) in Non-intubated Patients |
Coronavirus disease 19 infection |
Base WHO recommended treatment. alone, Systemic indirect endovenous ozone therapy alone, ozone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad Católica San Antonio de Murcia |
Sociedad Española de Ozonoterapia |
Spain |
2020-04-30 |
2020-06-30 |
NCT04359303, OzonoCOVID19, P.INV. OZONO-COVID19 VER.1.2 |
Phase 3 Clinical |
Not yet recruiting |
1 |
2 Months |
50 |
Francisco J Hidalgo Tallón, MD, PhD, Jose Baeza Noci, MD, PhD |
2020-04-30 |
| COVIDHIV: Clinical Characterization Protocol for COVID-19 in People Living With HIV |
Coronavirus disease 19 infection, HIV infection |
auto-questionnaires alone, biological collection alone, qualitative interviews alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-10-31 |
2020-A00984-35, COVIDHIV, NCT04361604 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
270 |
Antoine Chéret, Dr |
2020-04-29 |
| A Single-center, Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients |
Coronavirus disease 19 infection, Diabetes mellitus, Viral pneumonia |
multivariate analysis alone, real-time RT-PCR test alone, univariate analysis alone |
|
|
Tongji Hospital |
|
China |
2020-02-02 |
2020-04-01 |
NCT04365634, TJ20200202 |
Phase Not Applicable |
Completed |
1 |
2 Months |
306 |
Meifang Han, Professor, Qin Ning |
2020-05-02 |
| Metabolon Study to Provide Better Understanding of COVID-19 |
Coronavirus disease 19 infection |
|
|
|
Institute For Systems Biology, Metabolon Inc |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
James R. Heath, Ph.D, Jason Goldman, M.D |
2020-04-29 |
| HASCOPT: Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial |
Coronavirus disease 19 infection, Respiratory failure |
azithromycin plus hydroxychloroquine |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital St. Joseph, Marseille, France |
|
France |
2020-04-30 |
2021-01-31 |
HASCOPT, HASCOPT2020, NCT04365231 |
Phase 3 Clinical |
Not yet recruiting |
1 |
9 Months |
50 |
Laurence CUREL, Maria mg Gackiere, Raoul RD Desbriere, MD, Xavier-Côme xcd Donato |
2020-04-29 |
| Effect of RBT-9 on Preventing Progression of COVID-19 in High-Risk Individuals |
Coronavirus disease 19 infection |
RBT-9 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Renibus Therapeutics Inc |
|
|
2020-06-01 |
2021-12-31 |
NCT04364763, REN-005 |
Phase 2 Clinical |
Not yet recruiting |
0 |
19 Months |
252 |
|
2020-04-29 |
| A study to assess the efficacy of tocilizumab in severe patients with Corona Virus Disease19 (COVID-19) |
Coronavirus disease 19 infection |
routine therapy alone, tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
|
2nd People's Hospital of Fuyang City, Anhui Provincial Hospital |
China National Center For Biotechnology Development, Department of Science and Technology of Anhui Province |
China |
|
|
|
Phase Not Applicable |
Status not specified |
2 |
|
21 |
|
2020-04-29 |
| COVID-RPC: Observational, Cohort of COVID-19 Patients at Raymond-Poincare |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-05-31 |
20SBS-COVID-RPC, COVID-RPC, NCT04364698 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
500 |
Aurelien Dinh, MD, Simon Bessis, MD |
2020-04-29 |
| Convalescent Plasma for COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Ente Ospedaliero Cantonale, |
|
Switzerland |
2020-04-27 |
2020-06-30 |
2020-00895, NCT04365439 |
Phase 2 Clinical |
Not yet recruiting |
2 |
2 Months |
10 |
Beatrice Bernasconi, Enos Bernasconi, Enos Bernasconi, M.D., Stefano Fontana, M.D. |
2020-04-29 |
| Covid-19 Associated Coagulopathy |
Blood clotting disorder, Coronavirus disease 19 infection |
enoxaparin sodium alone |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Iowa |
|
US |
2020-04-16 |
2021-04-16 |
202004235, NCT04360824 |
Phase 4 Clinical |
Not yet recruiting |
0 |
12 Months |
170 |
Usha Perepu |
2020-04-29 |
| Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Andalusian Network for Design and Translation of Advanced Therapies |
|
Spain |
2020-04-30 |
2021-12-31 |
NCT04366245, PC/COVID-19 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
20 Months |
72 |
Ana Cardesa Gil |
2020-04-29 |
| Proving the efficacy of Homeopathic treatment in prevention and cure of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including Ars Alb , Bryonia Alba , Camphora , Helleborus niger , Justicia Adhatoda |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Welling Healthcare Private Limited |
|
India |
2020-05-04 |
|
CTRI/2020/04/024857 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
|
100 |
Angelo Smith, Dr Sourabh R Welling |
2020-04-29 |
| HIGH-PRONE-COVID-19: Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
prone decubitus alone, usual care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Tours |
|
France |
2020-04-27 |
2020-11-24 |
2020-A01121-38, DR200125, HIGH-PRONE-COVID-19, HIGH-PRONE-COVID-19, NCT04358939 |
Phase Not Applicable |
Recruiting |
13 |
6 Months |
248 |
Agathe DELBOVE, MD, Anne-Charlotte TELLIER, MD, Arnaud THILLE, MD-PhD, Christophe GUITTON, MD, Damien ROUX, MD-PhD, Erwan L'HER, MD-PhD, Gaetan PLANTEFEVE, MD, Guillaume VOIRIOT, MD, Jean DELLAMONICA, MD-PhD, Jean REIGNIER, MD-PhD, Mai-Anh NAY, MD, Saadalla NSEIR, MD, Stephan EHRMANN, MD-PhD, Yoanatan PEREZ, MD, Yonatan PEREZ, MD |
2020-04-30 |
| COVID-19 CAir: SARS-CoV-2 Associated Respiratory Failure Recovery |
Coronavirus disease 19 infection, Respiratory failure |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Zurich |
|
Switzerland |
2020-05-31 |
2020-12-31 |
2020-00745, COVID-19 CAir, NCT04365595 |
Phase Not Applicable |
Recruiting |
1 |
7 Months |
200 |
Christian F Clarenbach, MD, Dario Kohlbrenner, MSc |
2020-04-30 |
| COP-COVID-19: Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone, supportive management alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Universitario Dr. Jose E. Gonzalez |
|
Mexico |
2020-04-27 |
2021-05-30 |
COP-COVID-19, IF20-00002, NCT04358783 |
Phase 2 Clinical |
Not yet recruiting |
1 |
13 Months |
30 |
Adrian Camacho-Ortiz, MD, Eduardo Pérez Alba, MD, Laura Marina Nuzzolo Shihadeh, MD |
2020-04-30 |
| COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box, Randomized, Controlled Trial |
Coronavirus disease 19 infection |
COVID-19 barrier box alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of British Columbia |
|
Canada |
2020-05-31 |
2021-04-30 |
H20-01270, NCT04366141 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
120 |
Anton Chau, MD, Tim Jen, MD |
2020-04-30 |
| A Proof of Concept study of Nu.Q COVID-19 Triage Test in COVID-19 patients |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
Volition’s Nu.QTM nucleosome assays alone |
|
|
VolitionRX Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-29 |
| REP-COVID RE_COVID: Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation |
Coronavirus disease 19 infection |
plasma exchange alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fundació Clínic Per A La Recerca Biomèdica |
Instituto de Salud Carlos III |
Spain |
2020-04-23 |
|
2020-001722-66, REP-COVID RE_COVID, REP_COVID |
Phase 2 Clinical |
No longer recruiting |
1 |
|
116 |
CTU |
2020-05-04 |
| JAKINKOV: Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation |
Coronavirus disease 19 infection, Inflammatory disease, Respiratory distress syndrome, Viral pneumonia |
anakinra alone, Jakavi plus Kineret |
Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer |
Assistance Publique Hopitaux De Marseille |
France |
2020-05-01 |
2020-08-31 |
2020-001963-10, 2020-CHITS-003, JAKINKOV, NCT04366232 |
Phase 2 Clinical |
Not yet recruiting |
3 |
4 Months |
50 |
David DELARBRE, MD, Gilles HITTINGER, MD, Gilles KAPLANSKI, MD, Jean-Philippe Suppini, PhD |
2020-04-30 |
| A study to track coronavirus (COVID-19) in the general population |
Coronavirus disease 19 infection |
|
|
|
University of Oxford |
|
UK |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
300000 |
Department for Health and Social Care, Office for National Statistics |
2020-04-29 |
| ESCAPE: Study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome in adult severely ill patients with COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
standard of care treatment alone, vafidemstat alone |
Lysine specific histone demethylase 1 inhibitor, MAO B inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Oryzon Genomics SA |
|
Spain |
2020-04-24 |
|
2020-001618-39, CL08-ORY-2001_COVID-19, ESCAPE |
Phase 2 Clinical |
No longer recruiting |
1 |
|
40 |
Sonia Gutiérrez |
2020-04-30 |
| AUTONOMIC: Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic |
Anxiety disorder, Coronavirus disease 19 infection, Post traumatic stress disorder |
electrocardiography alone, electrodermal test alone, emotional stimulation test alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Direction Centrale du Service de Sante des Armees |
Institut de Recherche Biomedicale des Armees |
France |
2020-04-30 |
2020-06-30 |
2020-COVID19-11, AUTONOMIC, NCT04365335 |
Phase Not Applicable |
Recruiting |
2 |
2 Months |
60 |
Damien CLAVERIE, MD, PhD |
2020-05-04 |
| SINK COVID-19: Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 |
Coronavirus disease 19 infection |
Ketalar alone, naltrexone (once-monthly controlled-release, Medisorb), Alkermes alone, Ketalar plus naltrexone (once-monthly controlled-release, Medisorb), Alkermes |
Opioid receptor antagonist, Opioid receptor mu antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
William Beaumont Hospitals |
|
US |
2020-04-30 |
2020-08-31 |
2020-097, NCT04365985, SINK COVID-19 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
500 |
Matthew Sims, MD, Matthew Sims, MD PhD, Maureen Cooney, RN, BSN |
2020-04-30 |
| Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients |
Coronavirus disease 19 infection, Respiratory disease |
anti-SARS-CoV-2 convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Albert Einstein College of Medicine |
New York University |
US |
2020-04-17 |
2023-04-30 |
2020-11467, NCT04364737 |
Phase 2 Clinical |
Recruiting |
0 |
36 Months |
300 |
Hyunah Yoon, MD, Liise-anne Pirofski, MD, Mila Ortigoza, MD |
2020-04-30 |
| COVIDIOL: Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome |
Coronavirus disease 19 infection |
Hidroferol alone, best available therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundación Para La Investigación Biomédica De Córdoba, Maimonides Biomedical Research Institute of Cordoba |
Consejeria de Salud. Junta de Andalucia, Dynamic Solutions Inc, FAES Farma SA |
Spain |
2020-04-28 |
2020-08-28 |
2020-001717-20, COVIDIOL, COVIDIOL, NCT04366908 |
Phase 2 Clinical |
Not yet recruiting |
1 |
4 Months |
1008 |
Antonio Luque, Antonio Luque, MsC, José López Miranda, MD, José Manuel Quesada Gómez, MD |
2020-05-01 |
| MESCEL-COVID19: Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19 |
Coronavirus disease 19 infection |
umbilical cord tissue derived undifferentiated allogeneic mesenchymal cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Infantil Universitario Nino Jesus |
Apices Soluciones, S.L. |
Spain |
2020-04-24 |
2021-05-31 |
2020-001450-22, MESCEL-COVID19, MESCEL-COVID19, NCT04366271 |
Phase 2 Clinical |
Not yet recruiting |
6 |
13 Months |
106 |
Clara I Rodriguez, MD, Francisco García-Rio, MD, Jose A Lorente Balanza, MD, Julio Ancochea, MD, Luis Madero, MD, Luis Madero, PhD, Maria J del Cerro Marin, MD, Mrs. Laura Aranzasti, Sergio Serrano, MD, Teresa de Rojas, PhD |
2020-05-02 |
| REMDECO-19: Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections |
Coronavirus disease 19 infection |
remdesivir alone |
Coronavirus non structural protein 8 modulator, RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-05-31 |
APHP200522, NCT04365725, REMDECO-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
200 |
Jeremie ZERBIT, PharmaD, Jérémie ZERBIT, PharmaD |
2020-04-30 |
| RAMIC: Ramipril for the Treatment of COVID-19 |
Coronavirus disease 19 infection |
ramipril alone |
ACE inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of California San Diego |
Pfizer Inc |
US |
2020-04-30 |
2021-04-30 |
NCT04366050, RAMIC, RAMIC TRIAL |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
560 |
Archana Bhatt, Len Lazaro, Rohit Loomba |
2020-05-02 |
| Progesterone for the Treatment of COVID-19 in Hospitalized Men |
Coronavirus disease 19 infection |
progesterone (sc, in vitro fertlilization), Institut Biochimique alone, standard of care alone |
Progesterone receptor agonist |
Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cedars-Sinai Medical Center |
IBSA Institut Biochimique SA |
US |
2020-04-27 |
2021-04-17 |
NCT04365127, STUDY00000611 |
Phase 1 Clinical |
Recruiting |
0 |
11 Months |
40 |
Sara Ghandehari, MD, Vanessa Vasco |
2020-04-30 |
| COVIDMES: Efficacy and safety evaluation of umbilical cord mesenchymal stem cells for the treatment of patients with respiratory failure due to coronavirus (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
umbilical cord mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Banc De Sang I Teixits |
|
Spain |
2020-04-23 |
|
2020-001505-22, BST-COVID-01, COVIDMES |
Phase 1/Phase 2 Clinical |
No longer recruiting |
1 |
|
30 |
Banc de Sang i Teixits |
2020-04-30 |
| BIRCOV: ARB, ACEi, DRi in COVID-19 |
Coronavirus disease 19 infection, Hypertension |
angiotensin converting enzyme inhibitor (ACEi) therapy alone, angiotensin receptor blocker (ARB) therapy alone, dopamine reuptake inhibitor (DRI) therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical Practice Prof D. Ivanov |
|
Ukraine |
2020-04-01 |
2021-08-01 |
BIRCOV, COVID20, NCT04364984 |
Phase Not Applicable |
Recruiting |
1 |
16 Months |
10 |
Dmytro Ivanov, MD, Prof, Mariia Ivanova, MD, PhD |
2020-04-30 |
| DURO-SIN: COVID-19 in an academic teaching hospital in Konstanz/Germany - evaluation of the 'double rule out - single rule in' concept |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum Konstanz, II. Medizin |
|
Germany |
2020-04-27 |
|
81/2020, DRKS00021605, DURO-SIN, U1111-1251-0310 |
Phase Not Applicable |
Recruiting |
1 |
|
200 |
Stephan Walterspacher |
2020-04-30 |
| Factors Associated With Clinical Outcomes in Patients Hospitalized for COVID-19 in GHT-93 Est |
Coronavirus disease 19 infection, Viral pneumonia |
corticosteroid therapy alone, systematic antibiotic therapy alone, Variable regimens including azithromycin , baricitinib , hydroxychloroquine , lopinavir + ritonavir , sarilumab , tocilizumab |
HIV protease inhibitor, IL-6 receptor antagonist, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
|
Centre Hospitalier Intercommunal Robert Ballanger |
Groupe Hospitalier Pitie-Salpetriere |
France |
2020-03-14 |
2020-07-31 |
GHTRB-2020-01, NCT04366206 |
Phase Not Applicable |
Recruiting |
2 |
4 Months |
143 |
Benjamin Rossi, MD, Dr. Hélène GROS, Hélène Gros, MD, Lee S Nguyen, MD, PhDc |
2020-04-30 |
| Evaluating AVM-0703 for Treatment of COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
AVM-0703 plus hydrocortisone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
AVM Biotechnology LLC |
Medpace Inc |
|
2020-06-30 |
2023-06-30 |
AVM0703-101, NCT04366115 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
0 |
36 Months |
126 |
Brandon Franklin |
2020-04-30 |
| Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter, Cohort Study |
Coronavirus disease 19 infection, Viral pneumonia |
azithromycin alone, baricitinib alone, hydroxychloroquine alone, lopinavir + ritonavir alone, oseltamivir alone, remdesivir alone, sarilumab alone, tocilizumab alone |
Coronavirus non structural protein 8 modulator, Exo-alpha sialidase inhibitor, HIV protease inhibitor, IL-6 receptor antagonist, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, RNA polymerase modulator |
|
Groupe Hospitalier Pitie-Salpetriere |
CMC Ambroise Paré, Centre Hospitalier Intercommunal Montfermeil-Le Raincy, Centre Hospitalier Intercommunal Robert Ballanger |
France |
2020-03-14 |
2020-12-31 |
CIC1421-20-06, NCT04365764 |
Phase Not Applicable |
Recruiting |
2 |
9 Months |
400 |
Anis Saib, MD, Hélène Gros, MD, Joe-Elie Salem, MD, PhD, Lee S Nguyen |
2020-04-30 |
| COV-CREM: Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital of Besancon |
|
France |
2020-04-20 |
2025-04-20 |
2020/502, COV-CREM, NCT04365322 |
Phase Not Applicable |
Recruiting |
1 |
60 Months |
60 |
Kevin BOUILLER, MD, Marie KROEMER, PharmD PhD |
2020-04-30 |
| CBP-COVID: Impact of SARS-COV2 Infection and Confinement on Diagnostic and Therapeutic Management of Lung Cancer: Ambispective Study Extended Over Two Time Periods |
Coronavirus disease 19 infection, Lung tumor |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier le Mans |
ONCOPL (FR) |
|
2020-06-30 |
2022-08-28 |
CBP-COVID, CHM-2020/S15/03, NCT04366219 |
Phase Not Applicable |
Not yet recruiting |
0 |
25 Months |
2000 |
CHRISTELLE JADEAU, OLIVIER MOLINIER, MD |
2020-04-30 |
| A larger phase IIb/III trial of recombinant subunit-trimer vaccine (COVID-19), Clover Biopharmaceuticals for the potential prevention of coronavirus infection COVID-19 caused by SARS-CoV-2 (2019-nCoV) |
Coronavirus disease 19 infection |
recombinant subunit-trimer vaccine (COVID-19), Clover Biopharmaceuticals alone |
Angiotensin converting enzyme 2 modulator |
|
Linear Clinical Research Limited |
|
Australia |
|
|
|
Phase 2/Phase 3 Clinical |
Planned |
1 |
|
|
|
2020-04-30 |
| The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Hong Kong |
Queen Mary Hospital |
Hong Kong |
2020-04-27 |
2021-06-30 |
NCT04365348, UW20-300 |
Phase Not Applicable |
Not yet recruiting |
1 |
14 Months |
300 |
Agnes YK Lai, PhD, Mary SM Ip, MD |
2020-04-30 |
| A phase I clinical trial of recombinant subunit-trimer vaccine (COVID-19) in healthy adult and healthy elderly trial participants |
Coronavirus disease 19 infection |
recombinant subunit-trimer vaccine (COVID-19), Clover Biopharmaceuticals alone |
Angiotensin converting enzyme 2 modulator |
Healthy volunteers accepted |
Clover Biopharmaceuticals AUS Pty Ltd, Coalition for Epidemic Preparedness Innovations, Linear Clinical Research Limited |
|
Australia |
2020-06-30 |
|
|
Phase 1 Clinical |
Planned |
1 |
|
|
|
2020-05-04 |
| COVIPACT: Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers |
Acute stress disorder, Cognitive disorder, Coronavirus disease 19 infection, Hematological neoplasm, Post traumatic stress disorder, Sleep disorder, Solid tumor |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Francois Baclesse |
|
France |
2020-04-15 |
2020-12-31 |
2020-A00879-30, COVIPACT, NCT04366154 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
385 |
Audrey FAVEYRIAL, MD, Florence JOLY, PhD |
2020-05-01 |
| OUTCOV: Outpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome |
Bordetella pertussis infection, Coronavirus disease 19 infection, Dyspnea |
azithromycin alone, hydroxychlororquine alone, lopinavir + ritonavir alone |
HIV protease inhibitor |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Groupe Hospitalier Paris Saint-Joseph |
|
France |
2020-04-28 |
2021-01-28 |
NCT04365582, OUTCOV, OUTCOV |
Phase 3 Clinical |
Not yet recruiting |
5 |
9 Months |
640 |
Christos CHOUAID, MD, Helene Beaussier, MD PhD, Hilario Nunes, MD, Jean Marc NACCACHE, MD, Jean-Marc Naccache, MD, Pierre CHARLES, MD |
2020-04-30 |
| Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers |
Coronavirus disease 19 infection |
Lactobacillus coryniformis K8 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Puleva Biotech SA |
|
Spain |
2020-04-24 |
2020-10-31 |
NCT04366180, P054 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
314 |
Raquel Rodriguez Blanque |
2020-05-01 |
| COVIDGHPSJCite: Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City |
Coronavirus disease 19 infection |
|
|
|
Groupe Hospitalier Paris Saint-Joseph |
|
France |
2020-04-01 |
2022-12-31 |
COHORTE COVID GHPSJ CITEH, COVIDGHPSJCite, NCT04365530 |
Phase Not Applicable |
Recruiting |
5 |
33 Months |
2000 |
Benoit PILMIS, MD, Bernard DURAND GASSELIN, MD, Bernard Durand Gasselin, MD, Florence Bonte, MD, Helene BEAUSSIER, PharmD, pHD, Maxime TOUZOT, MD, Sebastien HASCOET, MD, Sebastien Hascoet, MD |
2020-05-03 |
| Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19 |
Coronavirus disease 19 infection, Heart injury, Inflammatory disease, Respiratory failure |
canakinumab alone |
Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cleveland Clinic Foundation |
|
US |
2020-04-24 |
2020-12-31 |
IND 149328, NCT04365153 |
Phase 2 Clinical |
Recruiting |
0 |
8 Months |
45 |
Calvin Sheng, M. D., Ossama Abou Hassan, M. D., Paul C Cremer, M. D., Sidhharth Dugar, M. D., Tom Wang, M. D., Venu Menon, M. D., Yuki Kuramochci, RN BSN, Yuki Kuramochi, RN BSN |
2020-05-04 |
| CardiacCovid: Patient Recovery From Heart Surgery During the Covid-19 Pandemic |
Cardiac surgical procedure, Coronavirus disease 19 infection, Depression |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Barts and The London NHS Trust |
Queen Mary University of London |
UK |
2020-04-18 |
2021-12-31 |
132127, CardiacCovid, NCT04366167 |
Phase Not Applicable |
Recruiting |
1 |
20 Months |
100 |
Aung Ye Oo, MD, Julie Sanders, PhD, Teofila Bueser, MSc |
2020-04-29 |
| A Novel Nomogram to Predict Severity of COVID-19 |
Coronavirus disease 19 infection |
RT-PCR test alone, computed tomography imaging alone, novel nomogram model prediction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xinqiao Hospital of Chongqing |
|
China |
2020-01-17 |
2021-12-31 |
NCT04366024, XQONC-016 |
Phase Not Applicable |
Recruiting |
1 |
23 Months |
1000 |
Jianguo Sun, Sun Jianguo |
2020-04-29 |
| A phase II, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
OT-101 alone |
Factor IX agonist |
|
Mateon Therapeutics Inc |
|
US |
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-29 |
| PRE-VENT: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of pacritinib plus standard of care versus placebo plus standard of care in hospitalized patients with severe COVID-19, including patients with and without cancer |
Coronavirus disease 19 infection |
pacritinib alone, standard of care alone |
CSF-1 antagonist, Cytochrome P450 reductase inhibitor, Flt3 tyrosine kinase inhibitor, IRAK-1 protein kinase inhibitor, Jak2 tyrosine kinase inhibitor |
|
CTI BioPharma Corp |
|
US |
2020-04-27 |
|
PRE-VENT |
Phase 3 Clinical |
Not yet recruiting |
0 |
|
358 |
John Mascarenhas |
2020-04-29 |
| REACOVIM: Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19) |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Direction Centrale du Service de Sante des Armees |
|
France |
2020-04-20 |
2022-04-20 |
2020-COVID19-05, NCT04365166, REACOVIM |
Phase Not Applicable |
Recruiting |
2 |
24 Months |
100 |
Clément DUBOST, MD, PhD, Nicolas LIBERT, MD, PhD |
2020-05-04 |
| Cardiovascular Effects of COVID-19 |
Cardiovascular disease, Coronavirus disease 19 infection |
fluoxetine (Zydis, tablet, autism), Autism Therapeutics alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
NYU Langone Health |
|
US |
2020-04-08 |
2020-12-31 |
20-00416, NCT04365699 |
Phase 2 Clinical |
Recruiting |
0 |
8 Months |
500 |
Stuart Katz, MD |
2020-05-04 |
| PIIPPI: COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients |
Coronavirus disease 19 infection |
Standard PPE alone, Standard care alone, povidone-iodine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Kentucky |
|
US |
2020-05-31 |
2021-05-31 |
58748, NCT04364802, PIIPPI |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
250 |
Alexandra E Kejner, MD, James Porterfield, MD, PhD, Melissa Thompson-Bastin, PharmD, Nikita Gupta, MD, Nikta Gupta, MD |
2020-05-04 |
| PEAC: Protective Effect of Aspirin on COVID-19 Patients |
Coronavirus disease 19 infection, Viral pneumonia |
aspirin alone, combined standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xijing Hospital |
|
China |
2020-02-10 |
2020-06-30 |
NCT04365309, PEAC, XI JINGH |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
4 Months |
128 |
Cai Yue |
2020-04-30 |
| The Psychological Impact of the COVID-19 on Students |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Hong Kong |
|
Hong Kong |
2020-04-26 |
2021-03-31 |
NCT04365361, UW20-298 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
300 |
Agnes YK Lai, PhD, Kelvin MP Wang, PhD, LAI YK Agnes, PhD |
2020-04-30 |
| A phase III trial to evaluate NT-300 for the early treatment of COVID-19 and other viral respiratory illnesses |
Coronavirus disease 19 infection, Viral respiratory tract infection |
nitazoxanide (controlled-release, viral infections), Romark alone |
|
|
Romark Laboratories LC |
|
|
|
|
|
Phase 3 Clinical |
Planned |
0 |
|
|
|
2020-04-29 |
| Validation of new detection methods for SARS CoV-2 in suspected COVID-19 |
Coronavirus disease 19 infection |
Naso-pharyngeal swab testing alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Constance |
Deutsche Forschungsgemeinschaft (DFG), German Federal Ministry of Education and Research |
Germany |
2020-04-24 |
|
DRKS00021578, Eilentscheid 05/2020, U0351-4483-4510 |
Phase 1 Clinical |
Recruiting |
1 |
|
300 |
Christof Hauck, Marcus Schuchmann |
2020-05-01 |
| A clinical study of POL-6014 in the treatment of patients with COVID-related acute respiratory distress syndrome |
Coronavirus disease 19 infection, Respiratory distress syndrome |
lonodelestat alone |
Leukocyte elastase inhibitor |
|
Santhera Pharmaceuticals AG |
Cold Spring Harbor Laboratory |
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-29 |
| PREVENT-COVID Trial: Prazosin to Prevent COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory tract infection |
once daily prazosin (OROS), ALZA alone |
Alpha 1A adrenoceptor antagonist, Cyclic nucleotide phosphodiesterase inhibitor |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
|
US |
2020-04-30 |
2020-12-31 |
COV2001, IRB00246659, NCT04365257, PREVENT-COVID Trial |
Phase 2 Clinical |
Not yet recruiting |
0 |
8 Months |
220 |
Chetan Bettegowda, MD/PhD |
2020-04-30 |
| Mon-Covid: Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino) |
Coronavirus disease 19 infection |
home care monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mario Negri Gynecologic Oncology group |
|
Italy |
2020-04-21 |
2020-12-31 |
MON-COVID, Mon-Covid, NCT04361916 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
425 |
Chiara Gerardi, PhD, Guido Bertolini, MD, Rita Banzi, PhD, Roberto Stura |
2020-04-30 |
| Use of Contemporary Live Tele-Video Conferencing for Continuing Surgical Training at the time of COVID-19 pandemic |
Coronavirus disease 19 infection |
|
|
|
Sultanah Aminah Hospital |
|
Malaysia |
2020-05-01 |
2020-05-31 |
NMRR-20-814-54742 |
Phase Not Applicable |
Status not specified |
1 |
1 Month |
|
dr henry tan chor lip |
2020-04-30 |
| Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
allogeneic and expanded adipose tissue-derived mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Andalusian Network for Design and Translation of Advanced Therapies |
Junta De Andalucia |
Spain |
2020-04-30 |
2021-10-31 |
2020-001364-29, ADIQURE/COVID-19, NCT04366323 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
18 Months |
26 |
Ana Cardesa Gil, Clinical Trial Unit |
2020-04-30 |
| Stress Level Among Healthcare Workers in Handling COVID-19 Patients in Sarawak General Hospital |
Coronavirus disease 19 infection |
|
|
|
Universiti Malaysia Sarawak |
|
Malaysia |
2020-05-04 |
2020-10-30 |
54744, NMRR-20-819-54744 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
|
Dr. Sim Sze Kiat |
2020-04-30 |
| CancerMCO: CancerMCO |
Coronavirus disease 19 infection |
|
|
|
Universiti Putra Malaysia |
|
Malaysia |
2020-05-01 |
2020-11-01 |
54786, CancerMCO, NMRR-20-825-54786 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
|
Dr Sri Ganesh Muthiah |
2020-04-30 |
| CT-COVID-AI: CT-COVID-AI |
Coronavirus disease 19 infection |
Chest CT Diagnosis alone |
|
|
Hospital Sungai Buloh |
|
Malaysia |
2020-05-01 |
2020-11-02 |
54784, CT-COVID-AI, NMRR-20-826-54784 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
|
Dr Mohan Dass Pathmanathan |
2020-04-30 |
| Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia |
Coronavirus disease 19 infection |
Standard treatment alone, hydroxychloroquine alone, Variable regimens including azithromycin , hydroxychloroquine , lopinavir + ritonavir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National University of Colombia |
Fundación Cardioinfantil-Instituto De Cardiología, Hospital Universitario Reina Sofia, Hospital Universitario San Ignacio, Hospital Universitario de Neiva, Javeriana University |
Colombia |
2020-05-11 |
2020-10-31 |
76968, NCT04359095 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
6 |
5 Months |
1600 |
Angel García-Peña, MD, Carlos A Alvarez-Moreno, MD, MSc, PhD, Dagoberto Santofimio-Sierra, MD, Hernando G Gaitán-Duarte, MD, MSc, Hernando Gaitán, MD, Jose G Ruiz-Rodriguez, MD, Juan Villar-Centeno, Nancy Yomayusa-Gonzalez, MD |
2020-05-01 |
| Needle Stick Injuries in Emergency Medical Service Practice |
Coronavirus disease 19 infection |
Cardiopulmonary resuscitation alone, double gloves alone |
|
|
Lazarski University |
Medical University of Bialystok, Poznan University of Medical Sciences |
Poland |
2020-02-28 |
2020-04-24 |
NCT04363788, OH_PPE_1 |
Phase Not Applicable |
Completed |
1 |
1 Month |
300 |
|
2020-04-30 |
| DISTANSE COVID: Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized, Controlled Trial |
Coronavirus disease 19 infection |
Cash transfer alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Michaels Hospital |
|
Canada |
2020-04-20 |
2021-06-30 |
20-081, DISTANSE COVID, NCT04359264 |
Phase Not Applicable |
Not yet recruiting |
2 |
14 Months |
392 |
Mike Bedard, Mike Bedard, MD, Nav Persaud, Nav Persaud, MD, MSc |
2020-04-30 |
| Adapting the Decathlon Group Easybreathe snorkelling face mask for the safer administration of oxygen and/or continuous positive airway pressure and in the intra/interhospital transportation of patients with proven or suspected COVID 19 infection |
Coronavirus disease 19 infection |
Easybreathe snorkelling face mask alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Monash Health |
|
Australia |
2020-04-27 |
2020-10-27 |
ACTRN12620000472976p |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
100 |
Dr Simon Joosten |
2020-05-01 |
| COVID-19 Recovered Volunteer Research Participant Pool Registry |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of California Los Angeles |
|
US |
2020-04-08 |
2042-04-20 |
20-000625, NCT04359602 |
Phase Not Applicable |
Recruiting |
0 |
264 Months |
10000 |
Antonia Petruse, MBA, Arash Naeim, MD, PhD |
2020-04-30 |
| Different PEEP Settings of COVID-19 Induced ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
ARDSnet table PEEP setting alone, Optimizing compliance alone, Optimizing oxygenation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Southeast University |
|
China |
2020-03-05 |
2020-03-25 |
COVID-19 PEEP TITRATION, NCT04359251 |
Phase Not Applicable |
Completed |
1 |
|
20 |
Chun C Pan, Chun Pan |
2020-04-30 |
| STRIPE-3: Study for Testing and Reviewing Improvised PPE Effectiveness 3 |
Coronavirus disease 19 infection |
Anesthetic facemask based improvised personal protective equipment alone, Snorkel-based improvised personal protective equipment alone, light exercise alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guy's & St Thomas' Hospital NHS Trust |
|
UK |
2020-04-28 |
2020-10-28 |
NCT04362163, STRIPE-3, TAP_PRG_21_04_2020_2 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
10 |
Paul R Greig, MBChB |
2020-05-01 |
| REST: Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic |
Acute stress disorder, Coronavirus disease 19 infection |
Online cognitive behavioral therapy (CBT) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University Hospital of Strasbourg |
|
|
2020-05-01 |
2021-10-01 |
7799, NCT04362358, REST |
Phase Not Applicable |
Not yet recruiting |
0 |
17 Months |
120 |
Luisa Weiner, MD |
2020-04-30 |
| TVP-COVID-RIV: Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sociedad Espanola de Angiologia y Cirugia Vascular |
|
Spain |
2020-04-30 |
2020-12-31 |
NCT04361981, RIV-R3, TVP-COVID-RIV |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
50 |
Joaquin De Haro, MD |
2020-04-30 |
| Liver Injury in Patients With COVID-19 |
Coronavirus disease 19 infection, Liver injury |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad Austral De Argentina |
|
Argentina |
2020-04-15 |
2020-12-31 |
CIE N° P 20-011, NCT04358380 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
34 |
Marcelo O Silva, MD |
2020-04-30 |
| DAWN AZITHRO: COVID-19: A randomized, open-label, adaptive, proof-of-concept clinical trial of new antiviral drug candidates against SARS-CoV-2 |
Coronavirus disease 19 infection |
azithromycin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
UZ Leuven-University Hospitals |
|
Belgium |
2020-04-22 |
|
2020-001614-38, DAWN AZITHRO, S63935 |
Phase 2 Clinical |
Recruiting |
1 |
|
240 |
Clinical trial center UZ Leuven, clinical trial center UZ Leuven |
2020-04-30 |
| COVID19 HTAA: COVID19 HTAA |
Coronavirus disease 19 infection |
|
|
|
Hospital Tengku Ampuan Afzan |
|
Malaysia |
2020-04-25 |
2020-07-31 |
54513, COVID19 HTAA, NMRR-20-811-54513 |
Phase Not Applicable |
Status not specified |
1 |
3 Months |
90 |
Dr SOH TZE VEE |
2020-04-30 |
| The epidemiology of COVID-19 cases and disease surveillance system in Hulu Langat district, Selangor |
Coronavirus disease 19 infection |
|
|
|
Pejabat Kesihatan Daerah Hulu Langat |
|
Malaysia |
2020-04-24 |
2021-04-23 |
54757, NMRR-20-809-54757 |
Phase Not Applicable |
Status not specified |
1 |
12 Months |
|
Dr WAN MING KEONG |
2020-04-30 |
| MLCOVID: MLCOVID |
Coronavirus disease 19 infection |
Machine Learning alone |
|
|
Institute For Medical Research (Inc In Malaysia) |
|
Malaysia |
2020-04-24 |
2021-04-23 |
54483, COVID19-HSB/2, MLCOVID, NMRR-20-807-54483 |
Phase Not Applicable |
Status not specified |
1 |
12 Months |
|
Dr Suresh Kumar, Dr WONG XIN CI |
2020-04-30 |
| QTc COVID: QTc COVID |
Coronavirus disease 19 infection |
|
|
|
Hospital Sungai Buloh |
|
Malaysia |
2020-04-30 |
2020-05-30 |
54728, NMRR-20-798-54728, QTc COVID |
Phase Not Applicable |
Status not specified |
1 |
1 Month |
|
Ms KOH HUI MOON |
2020-04-30 |
| IP COVID-19: IP COVID-19 |
Coronavirus disease 19 infection |
|
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-30 |
2020-09-30 |
54770, IP COVID-19, NMRR-20-793-54770 |
Phase Not Applicable |
Status not specified |
1 |
5 Months |
|
Dr. Ainul Nadziha bt. Mohd. Hanafiah, Roslinda binti Abu Sapian |
2020-04-30 |
| Study of FT-516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia |
Coronavirus disease 19 infection, Hypoxia |
FT-516 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Masonic Cancer Center |
|
US |
2020-05-04 |
2022-01-31 |
IDIM-2020-28708, NCT04363346 |
Phase 1 Clinical |
Not yet recruiting |
0 |
20 Months |
12 |
Dr.Joshua Rhein, MD, Mahsa Abassi, DO,MPH, Meghan Rothenberger, MD, Timothy Schacker, MD |
2020-05-01 |
| COVID AMBU 60: Multicenter, Observational Study on Management COVID-19 Positive Outpatients in a French Cluster |
Coronavirus disease 19 infection |
observational management alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Maison de Sante Pluridisciplinaire de Creil |
|
France |
2020-03-01 |
2020-12-31 |
2020-A01059-30, COVID AMBU 60, NCT04363099 |
Phase Not Applicable |
Recruiting |
1 |
10 Months |
1000 |
DIMI Svetlane, Svetlane DIMI, Svetlane DIMI, M.D |
2020-04-30 |
| COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador |
Coronavirus disease 19 infection, Respiratory tract infection |
azithromycin alone, chloroquine alone, corticosteroids alone, enoxaparin alone, heparin alone, hydroxychloroquine alone, ivermectin alone, lopinavir + ritonavir alone, nitazoxanide alone, oseltamivir alone, tocilizumab alone |
Chloride channel modulator, Exo-alpha sialidase inhibitor, HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Clinico San Carlos |
Universidad Catolica Santiago de Guayaquil |
Spain |
2020-04-30 |
2020-05-31 |
001, COVID-EC Study, NCT04362969 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
300 |
Jorge Carriel M. |
2020-05-01 |
| Collection of Biological Samples With Clinical Characterization of Covid-19 Patients |
Coronavirus disease 19 infection |
blood sampling alone |
|
|
Centre Hospitalier Intercommunal Creteil |
|
France |
2020-05-01 |
2020-12-01 |
COVIGENET, NCT04363385 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
500 |
Bernard MAITRE, Ph D, Bernard Maitre, Ph D, Isabelle HAU, MD |
2020-04-29 |
| Rhu-pGSN for Severe Covid-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
gelsolin, BioAegis Therapeutics alone |
Actin antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
BioAegis Therapeutics Inc |
|
|
2020-06-30 |
2020-09-30 |
BTI-202, NCT04358406 |
Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
60 |
Mark J DiNubile, MD, Susan L Levinson, PhD |
2020-05-01 |
| CEDiD: COVID-19 Early Diagnosis in Doctors |
Coronavirus disease 19 infection |
Empatica E4 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
King's College London |
Empatica Srl |
UK |
2020-04-27 |
2020-05-27 |
CEDID STUDY STH, CEDiD, NCT04363489 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
30 |
Alexander Zargaran, Anne Greenough, Dina Radenkovic, Dina Radenkovic, MBBS, BSc, Dr Alexander Zargaran |
2020-04-29 |
| Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19 |
Coronavirus disease 19 infection |
isoprinosine alone, levamisole alone, isoprinosine plus levamisole |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
FMASU P20A/ 2020, NCT04360122 |
Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
100 |
Fatma Soliman E Ebeid |
2020-04-30 |
| The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
pulmonary physiotherapy techniques alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-20 |
2020-08-01 |
99-1-103-47429, NCT04357340 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
40 |
Behrouz Attarbashi Moghaddam, Ph.D., Mohammad Javaherian, Ph.D. cand., Seyyed Reza Raees Karami, MD., Zahra Ahmadinejad, MD. |
2020-04-30 |
| CovImmune: Study of Immune Response During SARS-CoV-2 Infection - (COVID-19) |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Nice |
|
France |
2020-04-22 |
2020-10-22 |
20-PP-05, CovImmune, NCT04355351 |
Phase Not Applicable |
Not yet recruiting |
3 |
6 Months |
400 |
Barbara SEITZ-POLSKI, MCUPH, Jean DELLAMONICA, PUPH, Matteo VASSALLO, PH, elisa DEMONCHY, PH, johanna PLANCHARD, PH, sonia BOYER-SUAVET, PH |
2020-04-30 |
| Convalescent Plasma Trial in COVID-19 Patients |
Coronavirus disease 19 infection, Hypoxia, Viral pneumonia |
convalescent plasma alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Royal College of Surgeons in Ireland - Medical University of Bahrain |
Bahrain Defence Force Royal Medical Services, Military Hospital, Salmaniya Medical Complex |
Bahrain |
2020-04-19 |
2020-06-30 |
BDF/R&REC/2020-423, NCT04356534 |
Phase 2 Clinical |
Not yet recruiting |
1 |
2 Months |
40 |
Abdulkarim Abdulrahman, Dr., Abdulrahman Almadani, Dr., Amal Hejab, Dr., Manaf Al Qahtani, Dr., Manal Al Sayed, Dr., Pearl Wasif, MSc., Salman Yousif Alali, Dr., Sameer Otoom, Prof., Stephen Atkin, Prof. |
2020-04-30 |
| Nancy-CovH-AKI: Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe COVID-19 Infection |
Coronavirus disease 19 infection, Heart injury, Renal injury |
clinical examination alone, telephone follow-up alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Central Hospital, Nancy, France |
|
France |
2020-04-27 |
2020-10-18 |
2020PI072, NCT04354610, Nancy-CovH-AKI |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
57 |
Antoine KIMMOUN, MD, PhD, Patrick ROSSIGNOL, MD, PhD |
2020-05-04 |
| FatCovid-19: Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability |
Chronic fatigue syndrome, Coronavirus disease 19 infection |
actigraphy alone, blood test alone, electromyography alone, ergometer alone, magnetic resonance imaging alone, maximal effort test alone, neuromuscular evaluation alone, peripheral nerve stimulation alone, transcranial magnetic stimulation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Centre Hospitalier Universitaire de Saint Etienne |
Universite Jean Monnet |
France |
2020-04-30 |
2021-12-31 |
2020-A00982-37, 20CH085, FatCovid-19, NCT04363606 |
Phase Not Applicable |
Not yet recruiting |
3 |
20 Months |
52 |
Guillaume THIERY, MD PhD, Jérome MOREL, MD PhD, Jérôme MOREL, MD PhD, Laurent GERGELE, MD, Lydia OUJAMAA, MD, Léonard FEASSON, MD PhD, Pascal GIRAUX, MD, Pierre CROISILLE, MD PhD |
2020-04-29 |
| MARIPOSA: A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
standard of care alone, tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Roche Holding AG |
|
|
2020-05-04 |
2020-08-03 |
CA42481, MARIPOSA, NCT04363736 |
Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
100 |
Clinical Trials |
2020-04-29 |
| COVIDeF: Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being |
Coronavirus disease 19 infection |
Variable regimens including blood sampling |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-03-31 |
2022-03-31 |
2020-A00754-35, APHP200382, COVIDeF, NCT04352348 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
2000 |
Linda Gimeno, Pierre HAUSFATER, MD, Pierre Hausfater, MD |
2020-04-30 |
| COMBAT-COVID19: Colchicine in Moderate Severity Hospitalized Patients Before ARDS to Treat COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
colchicine alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Maimonides Medical Center |
|
US |
2020-04-26 |
2021-06-30 |
2020-04-12, COMBAT-COVID19, NCT04363437 |
Phase 2 Clinical |
Recruiting |
0 |
14 Months |
70 |
Antonios Likourezos, MA, MPH, Antonios Likourezos, MPH, Felix Yang, MD |
2020-05-01 |
| Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19 |
Coronavirus disease 19 infection, Respiratory failure |
anakinra alone |
Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Alabama at Birmingham |
|
US |
2020-05-31 |
2020-12-31 |
CHATHAM-CYTOKINE COVID-19, NCT04362111 |
Phase 3 Clinical |
Not yet recruiting |
0 |
7 Months |
20 |
Angela Kendrach, Walter W Chatham, MD |
2020-04-29 |
| GETAFE: Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial |
Coronavirus disease 19 infection |
lenalidomide plus low molecular weight heparin (LMWH) |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Universitario de Getafe |
|
Spain |
2020-04-27 |
2020-12-31 |
COVID19-EC01, GETAFE, NCT04361643 |
Phase 4 Clinical |
Not yet recruiting |
2 |
8 Months |
120 |
Joaquin De Haro, MD, Joaquin De Haro, MD, PhD, Joaquin De Haro, MD,PhD |
2020-05-04 |
| Tocilizumab Treatment in Patients With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto Nacional de Cancerologia de Mexico |
Roche Pharma (Schweiz) AG |
Mexico |
2020-04-01 |
2020-08-01 |
INF-3343-20-22-1, NCT04363853 |
Phase 2 Clinical |
Recruiting |
1 |
4 Months |
200 |
Diana Flores Estrada, Oscar G Arrieta, MD M Sc., Oscar G Arrieta, Oncologist, Oscar Gerardo Arrieta Rodríguez |
2020-05-04 |
| The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , ceftriaxone , colchicine , lopinavir + ritonavir , omega-3 , selenium , tiamine , vitamin A , vitamin C , vitamin D |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-03-20 |
2020-05-30 |
NCT04360980, SBMU.IR.REC.165423 |
Phase 2 Clinical |
Recruiting |
2 |
2 Months |
80 |
CKDRC,SBMU, MD, Nooshin Dalili, Dr, Nooshin Dalili, MD, SBMU, nooshin dalili |
2020-05-04 |
| COVID 19 Biomarkers |
Coronavirus disease 19 infection, Respiratory distress syndrome |
|
|
|
University of British Columbia |
|
Canada |
2020-03-30 |
2021-09-30 |
H20-00971, NCT04363008 |
Phase Not Applicable |
Recruiting |
4 |
18 Months |
150 |
Cheryl Wellington, PhD, Mypinder Sekhon, Mypinder Sekhon, MD |
2020-05-04 |
| The Impact of COVID-19 Pandemic on the Smoking Behavior of Young Smokers and the Youth Quitline Service in Hong Kong |
Coronavirus disease 19 infection, Nicotine dependence |
Telephone survey alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
The University of Hong Kong |
|
Hong Kong |
2020-04-24 |
2020-06-30 |
NCT02758028_1, NCT04360863 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
150 |
Ho Cheung William Li, PhD, Long Kwan Ho, MPhil |
2020-05-04 |
| Psychological Impact of Corona Virus Among Doctors in Assiut University Hospitals |
Acute stress disorder, Coronavirus disease 19 infection, Psychiatric disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assiut University |
|
Egypt |
2020-05-31 |
2021-06-30 |
NCT04363229, PSHYCOLOGICAL IMPACT OF CORONA |
Phase Not Applicable |
Not yet recruiting |
1 |
13 Months |
250 |
Mariam Roshdy Elkhayat, mariam elkhayat, MD, shimaa abdelsameaa, MD |
2020-04-29 |
| Clinical Impact of Bactek-R in Subject With Mild Pneumonia Due to COVID-19 Infection |
Coronavirus disease 19 infection, Viral pneumonia |
MV-130 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Inmunotek SL |
BioClever 2005 SL |
|
2020-05-10 |
2020-07-31 |
MV130-SLG-35, NCT04363814 |
Phase 3 Clinical |
Not yet recruiting |
0 |
2 Months |
100 |
Guillermo Ángeles, Guillermo Ángeles, MD, M. Polanco, Martín Martín, MD, Miguel Casanovas, PhD, MD, Natalia García, Nicolas Batlle, MD, Raymundo Hernández |
2020-05-04 |
| ANACONDA: Anakinra for COVID-19 Respiratory Symptoms |
Coronavirus disease 19 infection, Respiratory disease |
anakinra alone, optimized standard of care alone |
Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Tours |
INSERM CIC-P 1415, Swedish Orphan Biovitrum AB |
|
2020-04-27 |
2020-09-24 |
2020-001734-36, ANACONDA, ANACONDA-COVID-19, DR200111, NCT04364009 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
240 |
Alexandra AUDEMARD-VERGER, MD-PhD, Elodie MOUSSET |
2020-04-29 |
| A multicenter, randomized, double-blind, placebo-controlled, proof-of-concept, phase II trial of Metablok for lung and kidney inflammation in patients with COVID-19 |
Coronavirus disease 19 infection, Lung inflammation, Nephritis |
Metablok alone |
Dehydropeptidase-1 modulator |
|
Arch Biopartners Inc |
|
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-28 |
| LEAD COVID-19: The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations |
Blood clotting disorder, Coronavirus disease 19 infection, Vitamin D deficiency |
aspirin alone, aspirin plus vitamin D |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Louisiana State University Health Sciences Center New Orleans |
|
US |
2020-05-31 |
2020-12-31 |
20-063, LEAD COVID-19, NCT04363840 |
Phase 2 Clinical |
Not yet recruiting |
0 |
7 Months |
1080 |
Frank H Lau, MD |
2020-04-29 |
| Alterations in inflammatory and coagulation variables in COVID-19 patients |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Munich |
|
Germany |
2020-04-27 |
|
20-296, DRKS00021581 |
Phase Not Applicable |
Recruiting |
1 |
|
100 |
Tobias Nitschke |
2020-04-29 |
| AziA: Azithromycin + Amoxicillin/clavulanate versus Amoxicillin/clavulanate in COVID-19 Patients With Pneumonia in Non-intensive Unit |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including amoxicillin + clavulanate , azithromycin , cephalosporin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CHU De Nantes |
|
France |
2020-04-30 |
2020-07-30 |
AziA, NCT04363060, RC20_0168 |
Phase 3 Clinical |
Not yet recruiting |
3 |
3 Months |
104 |
Blandine RAMMAERT, MD, PhD, Emmanuel MONTASSIER, Romain DECOURS, MD, PhD, Vincent DUBEE, MD, PhD |
2020-05-04 |
| Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , remdesivir , sarilumab |
IL-6 receptor antagonist, RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
VA Boston Healthcare System |
|
US |
2020-04-10 |
2023-04-10 |
IRB 3305, NCT04359901 |
Phase 2 Clinical |
Recruiting |
0 |
36 Months |
120 |
Colleen Shannon, MPH, Patricia Woods, RN, MSN, Paul Monach, MD, Sara Schiller, MPH, Westyn Branch-Elliman, MD |
2020-04-30 |
| Identification of predictive biomarkers for severe progression of COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bundeswehrkrankenhaus Berlin |
|
Germany |
2020-05-03 |
|
DRKS00021591, Eth-10/20 |
Phase Not Applicable |
Not yet recruiting |
4 |
|
100 |
Christian Zobel, Maximilian Schreiner |
2020-05-03 |
| CytoResc: CytoSorb Rescue for COVID-19 Cytokine Storm |
Coronavirus disease 19 infection |
CytoSorb therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Charité Campus Virchow-Klinikum |
|
Germany |
2020-05-01 |
|
CytoResc, DRKS00021447, EA1/069/20, U1111-1250-8875 |
Phase 2b Clinical |
Not yet recruiting |
4 |
|
100 |
Philipp Enghardt, Torsten Slowinski |
2020-04-30 |
| Local Thermotherapy for Patients With Moderate Symptoms of COVID-19 |
Coronavirus disease 19 infection |
electric chest pad alone, electric cushion therapy alone, thermotherapy alone |
|
|
National Institute of Perinatology |
Directorate for Quality and Health Education, Juarez de Mexico Hospital, Laboratorios Silanes SA De CV |
Mexico |
2020-04-30 |
2020-11-30 |
CONACYTF0005-2020-01S311971, NCT04363541, U1111-1250-7416 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
298 |
Gabriela Ibañez Cervantes, PhD, Norma del Carmen Galindo Sevilla, PhD, Norma del Carmen Galindo-Sevilla |
2020-04-30 |
| ESCAPE: Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma therapy |
Coronavirus disease 19 infection |
High-Titer COVID-19 Convalescent Plasma (HT-CCP) alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Brigham & Women's Hospital |
|
US |
2020-04-30 |
2021-12-31 |
2020P001215, ESCAPE, NCT04361253 |
Phase 3 Clinical |
Not yet recruiting |
0 |
20 Months |
220 |
Karina Oganezova, Richard Kaufman, MD |
2020-04-30 |
| COVID.PPI: The influence of proton pump inhibitor therapy on the clinical course of COVID-19 |
Coronavirus disease 19 infection |
proton pump inhibitors therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum der Albert-Ludwigs Universitaet Freiburg |
|
Germany |
2020-04-28 |
|
254/20, COVID.PPI, DRKS00021523 |
Phase Not Applicable |
Recruiting |
1 |
|
200 |
Dominik Bettinger |
2020-04-30 |
| Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19) |
Autism, Coronavirus disease 19 infection |
WeChat-based parenting education alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs) |
Fujian Maternity and Child Health Care Hospital |
|
China |
2020-02-01 |
2020-10-31 |
ChiCTR2000031772 |
Phase 0 Clinical |
Recruiting |
1 |
9 Months |
105 |
Guihua Liu |
2020-04-30 |
| COVID-AGE: Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults |
Coronavirus disease 19 infection |
glucocorticoids alone, Variable regimens including anakinra , azithromycin , baricitinib , ceftriaxone , emtricitabine + tenofovir , hydroxychloroquine , lopinavir + ritonavir |
HIV protease inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Type I IL-1 receptor antagonist |
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Complejo Hospitalario Universitario de Albacete |
|
Spain |
2020-04-20 |
2020-07-31 |
COVID-AGE, NCT04362943, PAS-BAR-2020-04 |
Phase 4 Clinical |
Recruiting |
2 |
3 Months |
576 |
Almudena Avendaño Céspedes, RN, PhD, Pedro Abizanda Soler, MD,PhD |
2020-04-30 |
| Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure |
clazakizumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
|
US |
2020-04-30 |
2020-07-31 |
IRB00247932, NCT04363502 |
Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
30 |
Nada Alachkar, MD, Russell Wesson, MD |
2020-04-30 |
| PROTECT: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19) |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL |
Universita di Bologna |
Italy |
2020-05-31 |
2021-03-31 |
IRST100.47, NCT04363827, PROTECT |
Phase 2 Clinical |
Not yet recruiting |
1 |
10 Months |
2300 |
Giovanni Martinelli, Prof., Oriana Nanni, Pierluigi Viale, Prof. |
2020-04-30 |
| Study for Healthy Behavior, Psychological Analysis and Psychological Reconstruction Strategies of Students Population Keeping in Home Under the Pandemic of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Psychiatric disorder |
Face-to-face consultation alone, Phone consultation alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Sun Yat-Sen University |
National Natural Science Foundation of China |
China |
2020-03-18 |
2021-03-18 |
ChiCTR2000032095 |
Phase 0 Clinical |
Recruiting |
1 |
12 Months |
130 |
Peijia Liu |
2020-04-30 |
| The Danish Pre-HCQ COVID19 Dialysis Study: Hydroxychloroquine for prevention of COVID-19 in patients on chronic dialysis |
Coronavirus disease 19 infection |
Plaquenil alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rigshospitalet, Denmark |
|
Denmark |
2020-04-15 |
|
2020-001257-51, The Danish Pre-HCQ COVID19 Dialysis Study |
Phase 3 Clinical |
Recruiting |
1 |
|
568 |
Department of Nephrology 2132 |
2020-04-29 |
| A pilot study in patients with SARS-CoV-2 infection |
Coronavirus disease 19 infection |
|
|
|
Hemogenyx Pharmaceuticals Ltd |
|
|
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-29 |
| A Study for Efficacy and Safety of Live Biotherapeutic MRx-4DP0004 to Treat COVID-19 |
Coronavirus disease 19 infection |
MRx-0004 alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
4D pharma plc |
|
UK |
2020-05-31 |
2020-09-30 |
MRX-4DP0004-II-001, NCT04363372 |
Phase 2 Clinical |
Not yet recruiting |
1 |
4 Months |
90 |
Clinical Operations, Dinesh Saralaya, MBBS, MD, MRCP, FRCP |
2020-04-30 |
| Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill |
Coronavirus disease 19 infection |
Mycobacterium w alone, standard care therapy alone |
Interferon gamma receptor agonist, MAPK gene modulator, TLR-2 agonist, TLR-4 agonist, TLR-9 agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cadila Pharmaceuticals Ltd |
Council of Scientific and Industrial Research (India) |
|
2020-04-30 |
2021-04-30 |
CRSC20006, NCT04358809 |
Phase 3 Clinical |
Not yet recruiting |
0 |
12 Months |
480 |
Anil Avhad, MBBS, Sanjay Patel, MBBS |
2020-04-29 |
| Pharmacological Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment |
Coronavirus disease 19 infection |
Ascor (McGuff Pharmaceuticals, Ltd) plus magnesium chloride |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Thomas Jefferson University |
|
US |
2020-04-30 |
2021-04-30 |
JT#15681, NCT04363216 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
66 |
Dagan Coppock, M.D., Daniel Monti, M.D., Melissa McCarey, Michael W Foster, M.D. |
2020-05-02 |
| COroFet: Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic |
Coronavirus disease 19 infection |
RT-PCR alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Toulouse |
|
France |
2020-04-17 |
2022-04-30 |
COroFet, NCT04360811, RC31/20/0123 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
3600 |
Charlotte Dubucs, MD, Marion Groussolles, MD |
2020-04-30 |
| HCQPreP: Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Louisiana State University Health Sciences Center New Orleans |
Lafayette General Medical Center, University Of Louisiana At Lafayette |
US |
2020-04-27 |
2020-08-03 |
HCQPreP, LSU NO HSC IRB 20-050, NCT04363450 |
Phase 3 Clinical |
Recruiting |
0 |
3 Months |
1700 |
Ann Chauffe, Ann D Chauffe, DO, MPH, Ann D. Chauffe, DO, MPH, Carl Sabottke, MD, Daniel Stout, MD, Daniel Stouts, MD, James B Falterman, MD, Nicholas Sells, MD, Rebecca B Lee, DO, MS, Rebecca B. Lee, DO, MS |
2020-05-01 |
| Comparison of VieScope versus Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions |
Coronavirus disease 19 infection, Edema |
Vie Scope laryngoscope alone, intubation alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lazarski University |
Medical University of Bialystok, Poznan University of Medical Sciences, Wroclaw Medical University |
Poland |
2020-01-20 |
2020-02-25 |
INT_PPE_2020_1, NCT04363775 |
Phase Not Applicable |
Completed |
1 |
1 Month |
35 |
Łukasz Szarpak |
2020-04-29 |
| ACCESS: ACCESS A Master Digital Surveillance Protocol for COVID-19 |
Coronavirus disease 19 infection |
mobile app (Medable Inc) alone, wearable sensor alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medable Inc |
American Heart Association, Biointellisense Inc, Datavant, PWNHealth LLC |
US |
2020-04-20 |
2031-10-01 |
ACCESS, NCT04363268, PRO00041635 |
Phase Not Applicable |
Recruiting |
0 |
137 Months |
1000000 |
Ingrid Oakley-Girvan, Ph.D., Ingrid Oakley-Girvan, PhD, Jena Daniels, B.S., Jena Daniels, BS, Michelle Longmire, M.D., Reem Yunis, Ph.D., Reem Yunis, PhD |
2020-04-30 |
| Effect of plasma of patients recovered from Covid-19 versus control group on treatment of Covid-19 |
Coronavirus disease 19 infection |
Variable regimens including chloroquine , lopinavir , plasma , ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hamadan University of Medical Sciences |
|
Iran |
2020-05-14 |
|
IR.UMSHA.REC.1399.037, IRCT20120215009014N353 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
100 |
Dr. Ebrahim Jalili, Dr. Jalal Poorolajal, Dr. Saeid Bashirian, Samereh Ghelichkhani |
2020-04-29 |
| CAN-COVID: Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
canakinumab alone, standard of care alone |
Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Novartis AG, Novartis Farmaceutica SA |
|
Spain |
2020-04-30 |
2020-10-05 |
2020-001370-30, CACZ885D2310, CAN-COVID, NCT04362813 |
Phase 3 Clinical |
Recruiting |
1 |
5 Months |
450 |
Novartis Pharmaceuticals, Trial Monitoring Organization (TMo) |
2020-04-29 |
| Dose-Finding Study of Ivermectin in the Treatment of COVID-19 |
Coronavirus disease 19 infection |
ivermectin alone, standard regimen therapy alone |
Chloride channel modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Qazvin University Of Medical Sciences |
|
Iran |
2020-05-04 |
|
IR.QUMS.REC.1399.017, IRCT20200408046987N1 |
Phase 3 Clinical |
Recruiting |
2 |
|
100 |
Dr Abbas Allami, Dr. Aliakbar Karami, Nematollah Gheibi, dr. morteza shakhs niaee |
2020-05-04 |
| VA-REACH: VA Remote and Equitable Access to COVID-19 Healthcare Delivery |
Coronavirus disease 19 infection |
azithromycin alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
San Francisco VA Health Care System |
|
US |
2020-04-30 |
2021-08-31 |
20-30517, NCT04363203, VA-REACH |
Phase 4 Clinical |
Not yet recruiting |
0 |
16 Months |
600 |
Salomeh Keyhani, MD MPH, Staff Physician |
2020-04-30 |
| COVIDAM: An open-label, single-center, randomized, controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Institute of Tropical Medicine |
|
Belgium |
2020-04-12 |
|
2020-001417-21, COVIDAM, ITM202004 |
Phase 2 Clinical |
Recruiting |
1 |
|
206 |
Yven Van Herrewege |
2020-04-29 |
| A first-in-human trial of recombinant adenoviral vector vaccine targeting SARS-CoV-2 spike protein for the treatment in patients with COVID-19 infection |
Coronavirus disease 19 infection |
recombinant adenoviral vector vaccine targeting SARS-CoV-2 spike protein (liquid formulation, COVID-19), ReiThera alone |
COVID19 Spike glycoprotein modulator |
|
ReiThera Srl |
|
Italy |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-29 |
| ONCOVID-19: Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection |
Coronavirus disease 19 infection, Hematological neoplasm, Solid tumor |
medical treatment alone |
|
|
Centre Leon Berard |
|
France |
2020-04-02 |
2020-06-30 |
ET20-069, NCT04363632, ONCOVID-19 |
Phase Not Applicable |
Recruiting |
18 |
2 Months |
150 |
Anne-Laure Anne-Laure, Dr., Blaha BELGADI, Dr., Charlotte FAUCHER, Dr., Dominique DRAMAIS, Dr., Guillaume Carbonnelle, Dr., Jean-Pierre DELORD, Pr., Jocelyne PROVENCAL, Dr., Julien GAUTIER, Julien PERON, Dr., Laetitia STEFANI, Dr., Magali BRIERE, Dr., Marianne HAMON, Dr., Nicolas MARTIN, Dr, Roland SCHOTT, Dr., Simon PERNOT, Dr., Souad ASSAAD, Dr, Stéphane LEPRETRE, Dr., Xavier DURANDO, Pr., Yacine MERROUCHE, Dr. |
2020-04-30 |
| PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients |
Coronavirus disease 19 infection |
Electric Impedance Tomography (EIT) alone, positive end-expiratory pressure (PEEP) decremental alveolar recruitment alone, positive end-expiratory pressure (PEEP) incremental alveolar recruitment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Szeged |
Budapesti Müszaki És Gazdaságtudományi Egyetem, Hochschule Furtwangen, Germany |
Hungary |
2020-05-01 |
2021-04-19 |
COVID-19EIT, NCT04360837 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
10 |
András Lovas, MD PhD |
2020-05-01 |
| ROCOCO: Serology COVID-19 From the Cornwall Hospital Union |
Coronavirus disease 19 infection |
immunoglobulin (IgG) Dia-Pro serological test alone, serum test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier de Cornouaille |
Centre Hospitalier Regional Universitaire de Brest |
France |
2020-05-04 |
2020-11-04 |
29BRC20.0122, NCT04363593, ROCOCO |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
3200 |
Marie-Sarah FANGOUS, PH |
2020-04-29 |
| RESPIRE: Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
ruxolitinib alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
L'Azienda USL Nord Ovest |
Azienda Ospedaliera Universitaria Senese, Azienda Ospedaliero, Universitaria Pisana, Fondazione Toscana Gabriele Monasterio |
Italy |
2020-04-25 |
2020-05-31 |
2020.COVID-19.RUXO106, NCT04361903, RESPIRE |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
13 |
Barbara Dr Meini, Pharmacist, Enrico Dr Capochiani, hematologist |
2020-04-29 |
| SJTRC: St. Jude Tracking of Viral and Host Factors Associated With COVID-19 |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Jude Children's Research Hospital |
|
US |
2020-04-23 |
2025-03-20 |
NCT04362995, SJTRC, SJTRC |
Phase Not Applicable |
Recruiting |
0 |
58 Months |
1517 |
Aditya H. Gaur, MD, Jeremie H. Estepp, MD, Joshua Wolf, MBBS, PhD, FRACP, Paul G. Thomas, PhD |
2020-04-29 |
| COPEP: Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland |
Coronavirus disease 19 infection |
Plaquenil alone, lopinavir + ritonavir alone |
HIV protease inhibitor |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires De Geneve |
|
Switzerland |
2020-04-30 |
2020-10-31 |
CCER 2020-00864, COPEP, NCT04364022 |
Phase 3 Clinical |
Recruiting |
2 |
6 Months |
420 |
Alexandra Calmy, Prof, Niklaus Labhardt, Prof |
2020-04-29 |
| OSACOVID-19: Obstructive Sleep Apnea and Covid-19 Outcomes |
Coronavirus disease 19 infection, Obstructive sleep apnea, Viral pneumonia |
polysomnography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Koc University |
|
Turkey |
2020-04-27 |
2020-12-31 |
2020.140.IRB1.030, NCT04363333, OSACOVID-19 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
275 |
The OSACOVID-19 Study Group, Yeliz Celik, MSc, Yuksel Peker, MD, PhD |
2020-04-30 |
| Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program |
Coronavirus disease 19 infection |
convalescent plasma alone, acetaminophen plus diphenhydramine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Arkansas |
|
|
|
|
260944, NCT04363034 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Danielle Evans, David Avery |
2020-04-30 |
| PLACID: Study to assess the efficacy and safety of convalescent plasma in moderate COVID-19 disease |
Coronavirus disease 19 infection |
Usual care alone, convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Indian Council of Medical Research |
|
India |
2020-04-22 |
|
CTRI/2020/04/024775, PLACID, Protocol v 1.1 |
Phase 2 Clinical |
Not yet recruiting |
2 |
|
452 |
DR Sunita Bundas, Dr Anup Agarwal, Dr Aparna Mukherjee, Dr J R Khambolja |
2020-05-04 |
| A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Oregon Health Sciences University |
OHSU Knight Cancer Institute |
US |
2020-05-31 |
2021-06-30 |
NCT04363866, STUDY00021303 |
Phase 4 Clinical |
Not yet recruiting |
0 |
13 Months |
40 |
Brett Rodgers, Marcel Curlin, MD |
2020-04-29 |
| Novel Artificial Intelligence Algorithm to screen COVID-19 Patients from X-Ray , CT-Scan of Thorax and Voice Sampling through Android App and storage through Cloud |
Coronavirus disease 19 infection |
Android App alone, Chest X-Ray Artificial Intelligence Module alone, THORAX CT-Scan Artificial Intelligence Module alone, Voice Sampling Artificial Intelligence Module alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rabindranath Tagore Medical College |
|
India |
2020-04-23 |
|
CTRI/2020/04/024776 |
Phase Not Applicable |
Recruiting |
2 |
|
1650 |
Dr Arvind Kumar Morya, Dr Mahesh Mahich |
2020-05-04 |
| Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19 |
Coronavirus disease 19 infection, Rheumatoid arthritis |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Manchester |
|
UK |
2020-05-01 |
2021-05-01 |
282566, NCT04363047 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
125 |
Anne C Barton, Dr. Sebastien Viatte, Lynne Macrae |
2020-04-29 |
| AdoPro-Cov19: Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine |
Coronavirus disease 19 infection |
|
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Hôpital Cochin |
INSERM |
France |
2020-05-31 |
2020-12-31 |
AdoPro-Cov19, NCT04363671, P20-670 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
30 |
Carretier Emilie, Emilie Carretier, MD, Jonathan Lachal, PhD |
2020-04-28 |
| Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection |
Coronavirus disease 19 infection, Cough, Fever, Viral pneumonia |
|
|
Female |
Fundacion Infant |
|
Argentina |
2020-05-01 |
2020-09-30 |
NCT04362956, PERINATAL COVID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
200 |
Gaston Ofman, Head of Perinatal Research, Gaston Ofman, MD |
2020-04-29 |
| RuXoCoil: Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS |
Coronavirus disease 19 infection, Viral pneumonia |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Philipps-Universitat Marburg |
|
Germany |
2020-05-31 |
2020-11-30 |
KKS-278, NCT04359290, RuXoCoil |
Phase 2 Clinical |
Not yet recruiting |
1 |
6 Months |
15 |
Andreas Burchert, Prof Dr., Andreas Neubauer, Prof Dr. |
2020-04-30 |
| A medical records based study for epidemiological characteristics of 88 patients with new coronavirus pneumonia (COVID-19) and its impact on severe disease |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital) |
|
China |
2020-01-29 |
2020-03-16 |
ChiCTR2000032239 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
88 |
Gu Xue |
2020-04-29 |
| COVIDITY: A Phase I Study of Vaccine SCIB-1 For the Treatment of COVID-19 |
Coronavirus disease 19 infection |
SCIB-1 alone |
Immunoglobulin Fc receptor modulator |
|
Scancell Ltd |
Nottingham Trent University, University of Nottingham |
UK |
2021-03-31 |
|
COVIDITY |
Phase 1 Clinical |
Planned |
1 |
|
|
Christopher Coleman, Dr. Sally Adams, Graham Pockley, James Dixon, Janet Daly, Jonathan Ball, Lindy Durrant |
2020-04-29 |
| CoCo-Neuro: Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders |
Coronavirus disease 19 infection, Neurological disease, Psychiatric disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
|
2020-04-24 |
2022-04-24 |
APHP200525, CoCo-Neuro, NCT04362930 |
Phase Not Applicable |
Not yet recruiting |
0 |
24 Months |
2000 |
CECILE DELORME, MD, Jean-Christophe CORVOL, MD,PHD |
2020-04-29 |
| Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Cancer Institute |
National Institutes of Health Clinical Center |
US |
2020-04-27 |
2024-12-01 |
20-C-0103, 200103, NCT04362865 |
Phase Not Applicable |
Recruiting |
0 |
55 Months |
150 |
Leah E Hoffman, R.N., Robert J Kreitman, M.D. |
2020-05-04 |
| A trial to evaluate plasma therapy for the treatment of COVID-19 patients |
Coronavirus disease 19 infection |
plasma therapy alone |
|
|
Korea Center for Disease Control & Prevention |
|
South Korea |
|
|
|
Phase 2 Clinical |
Recruiting |
1 |
|
2 |
|
2020-04-28 |
| A clinical trial of a plasma therapy for the treatment of patients with Covid-19 |
Coronavirus disease 19 infection |
plasma therapy alone |
|
|
Korea Center for Disease Control & Prevention |
|
South Korea |
2020-07-31 |
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-28 |
| Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19 |
Coronavirus disease 19 infection |
Hydroxychloroquine plus nitazoxanide |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tanta University |
|
Egypt |
2020-05-31 |
2020-12-31 |
HCQ/NTZ, NCT04361318 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
100 |
Kamal Okasha, MD, PhD |
2020-04-30 |
| Comparison of suspected or negative cases with confirmed cases of COVID-19 at Max Hospital |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Max Healthcare Institute Ltd, India |
|
India |
2020-04-28 |
|
CTRI/2020/04/024772 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
90 |
Samreen Siddiqui, Sujeet Jha |
2020-04-29 |
| A trial to remotely monitor the cardiac safety of patients with COVID-19 via data gathered from Withings Move ECG Watch |
Cardiotoxicity drug-induced, Coronavirus disease 19 infection |
Withings Move ECG Watch alone |
|
|
Cardiologs Technologies |
|
France |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
|
Jean-Claude Deharo |
2020-04-28 |
| Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subjects |
Coronavirus disease 19 infection |
VPM-1002 alone |
Listeriolysin stimulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Serum Institute of India Privated Ltd |
|
India |
2020-04-21 |
|
CTRI/2020/04/024749, SII-rBCG/COVID-19/IN-01 |
Phase 3 Clinical |
Not yet recruiting |
5 |
|
5946 |
Dr Hitt Sharma, Dr Pradeep Dcosta, Dr Sanjay Lalwani, Dr Savita Verma, Dr Umesh Shaligram, Dr Vasudev Rajapantula, Dr Venkat Rao |
2020-04-29 |
| A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence |
Coronavirus disease 19 infection, Dyspepsia, Viral pneumonia |
Xiang-Sha-Liu-Jun pill alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Ezhou Hospital of traditional Chinese Medicine in Hubei Province |
State Administration of Traditional Chinese Medicine People's Republic of China |
China |
2020-04-01 |
2020-06-30 |
ChiCTR2000032237, ChiMCTR2000003234 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
200 |
Hong Ying, Shao Xianzhi |
2020-04-29 |
| Clinical study for the potential impact of novel coronavirus pneumonia (COVID-19) on endocrine system |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Jiao Tong University |
|
China |
2020-04-23 |
2020-05-06 |
ChiCTR2000032233 |
Phase Not Applicable |
No longer recruiting |
2 |
|
28 |
Jiang Lai, Mao Yanfei |
2020-04-29 |
| COVID-19 Patient Positioning Pragmatic Trial |
Coronavirus disease 19 infection |
Prone position alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanderbilt University Medical Center, US |
|
US |
2020-04-27 |
2021-06-30 |
200727, NCT04359797 |
Phase Not Applicable |
Recruiting |
0 |
14 Months |
300 |
Todd W Rice, MD, MSc |
2020-04-30 |
| COVAPID: Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections |
Coronavirus disease 19 infection, Influenza virus infection, Lower respiratory tract infection, Viral pneumonia |
mechanical ventilation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-07-31 |
2020-A00995-34, 2020_27, COVAPID, NCT04359693 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
1071 |
Saad Nseir, MD,PhD |
2020-04-30 |
| Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- or Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers |
Coronavirus disease 19 infection, Viral respiratory tract infection |
nitazoxanide (controlled-release, viral infections), Romark alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Romark Laboratories LC |
|
|
2020-04-27 |
2020-08-31 |
NCT04359680, RM08-3007 |
Phase 3 Clinical |
Recruiting |
0 |
4 Months |
800 |
Matthew Bardin, PharmD, BCPS |
2020-04-30 |
| COVASE: Nebulized Dornase Alfa for Treatment of COVID-19 |
Coronavirus disease 19 infection, Inflammatory disease |
dornase alfa alone, standard of care alone |
Deoxyribonuclease I stimulator, Deoxyribonuclease stimulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of London |
|
UK |
2020-05-01 |
2020-11-01 |
132333, COVASE, NCT04359654 |
Phase 2 Clinical |
Not yet recruiting |
1 |
6 Months |
50 |
Donna Basire, Joanna Porter, MD PhD, Misha Ladva, Novin Fard |
2020-05-01 |
| BCG-Denmark versus no-BCG for COVID 19 prevention |
Coronavirus disease 19 infection |
BCG-Denmark alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Jawaharlal Institute of Postgraduate Medical Education Research |
|
India |
2020-05-01 |
|
CTRI/2020/04/024833 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
1826 |
Narayanan Parameswaran |
2020-04-29 |
| Imatinib in COVID-19 infection |
Coronavirus disease 19 infection |
imatinib alone |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
All India Institute of Medical Sciences |
|
India |
2020-04-26 |
|
CTRI/2020/04/024806 |
Phase 2 Clinical |
Recruiting |
1 |
|
100 |
Akash Kumar |
2020-04-29 |
| Impact of Covid-19 pandemic on practice pattern of Indian urologists |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry |
Sanjay Gandhi Postgraduate Institute of Medical Sciences |
|
India |
2020-04-24 |
|
CTRI/2020/04/024805 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
160 |
Sanjoy Kumar Sureka |
2020-04-28 |
| Screening of proprietary Chinese medicines in convalescent rehabilitation of novel coronavirus pneumonia (COVID-19) convalescent patients |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Insomnia, Viral pneumonia |
shumian capsule alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hubei province hospital of Traditional Chinese Medicine |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-04-01 |
2020-07-10 |
ChiCTR2000032214, ChiMCTR2000003233 |
Phase Not Applicable |
Not yet recruiting |
3 |
3 Months |
200 |
Ba Yuanming, Li Li |
2020-04-29 |
| Evaluation of safety and efficacy of convalescent plasma in COVID-19 patients |
Coronavirus disease 19 infection |
convalesecent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
International Stemcell Services Limited |
|
India |
2020-04-30 |
|
CTRI/2020/04/024804, F. No. X. 11026/71/2020-BD, IMD/CoV/003/2020 |
Phase 2 Clinical |
Recruiting |
1 |
|
|
Dr Jyothnsa Rao, Dr Vishal Rao, Meena Dalal |
2020-04-29 |
| A medical records based study for the impact of wearing medical masks on oxygen saturation in adult surgical patients after general anesthesia during novel coronavirus pneumonia (COVID-19) pandemic |
Coronavirus disease 19 infection |
medical masks alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First Affiliated Hospital of Chongqing Medical University |
|
China |
2020-04-23 |
2020-05-23 |
ChiCTR2000032213 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
151 |
Feng Lv, Su Min |
2020-04-28 |
| Effectiveness to Manage Covid 19 Pandemic by Teaching Ventilatory Management to Non-anesthesiology Residents |
Coronavirus disease 19 infection |
ventilatory management teaching alone |
|
Young Adults (18-44 yrs) |
GSL Medical College |
|
India |
2020-01-01 |
|
CTRI/2020/04/024747 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
26 |
TATIKONDA CHANDRA MOULI |
2020-04-29 |
| A medical records based retrospective study for the effectiveness and safety of Xi-Yan-Ping injection combined with conventional protocol in the treatment of common type novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Xiyanping alone, conventional treatment alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Public Health Clinical Center |
|
China |
2020-05-15 |
2020-08-22 |
ChiCTR2000032412 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
426 |
Hongzhou Lu, Lin Wenjun |
2020-04-29 |
| The efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomized, controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
Vitamin C alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rui Jin Hospital |
Science and Technology Commission of Shanghai Municipality |
China |
2020-01-01 |
2020-06-01 |
ChiCTR2000032400 |
Phase 2 Clinical |
Recruiting |
1 |
5 Months |
120 |
Bing Zhao, Enqiang Mao |
2020-04-29 |
| A multicenter, randomized, double-blind, placebo-controlled trial for Xiaoyao capsule in the improvement of sleep mood disorder of convalescence patients of novel coronavirus pneumonia (COVID-19) |
Anxiety disorder, Coronavirus disease 19 infection, Viral pneumonia |
xiaoyao capsule alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Xiaogan Traditional Chinese Medicine Hospital |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-04-01 |
2020-07-01 |
ChiCTR2000032399, ChiMCTR2000003249 |
Phase Not Applicable |
Recruiting |
3 |
3 Months |
200 |
Yang Guiping, Zhou Jing |
2020-05-03 |
| TRONCHER: Assessment of Efficacy and Safety of Tocilizumab Compared to Deferoxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia |
Coronavirus disease 19 infection |
usual standard treatment alone, enoxaparin sodium plus tocilizumab |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Abderrahmane Mami Hospital |
Datametrix AG, Eshmoun Clinical Research Centre |
Tunisia |
2020-05-04 |
2020-10-04 |
ECC2020-06, NCT04361032, TRONCHER |
Phase 3 Clinical |
Not yet recruiting |
1 |
5 Months |
260 |
Chokri Jeribi, Dr, Dr Jalila Ben Khelil, Eshmoun Clinical Research Centre |
2020-04-29 |
| Physical Activity in University Students Around COVID-19 Confinement |
Coronavirus disease 19 infection, Pain |
online survey alone |
|
Healthy volunteers accepted |
Universidad del Pais Vasco |
Universidad De Cantabria, Universidad De Castilla-La Mancha, Universidad De Las Palmas De Gran Canaria, Universidad Miguel Hernandez de Elche, Universidad Politecnica de Madrid, Universidad Publica De Navarra, Universidad de Extremadura, Universidad de Sevilla, Universidad de Zaragoza, Universitat Jaume I de Castelló, Universitat de les Illes Balears, University of Cadiz, University of Granada, University of León, University of Valencia |
Spain |
2020-04-16 |
2020-10-20 |
COVID_PA2020, NCT04361019 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
25000 |
Ana Rodriguez, PhD, Ander Espin, MSc, Ander Espin, Ph D, Diego Jimenez, PhD, Diego Moliner, PhD, Domingo Gonzalez, PhD, Francisco B Ortega, PhD, Francisco J Vera, PhD, Idoia Labayen, PhD, Ignacio Ara, PhD, Jon Irazusta, PhD, Jonatan Ruiz, PhD, Jose Antonio Casajus, PhD, Jose Antonio Serrano, PhD, Jose Castro, PhD, Josep Tur, PhD, Luis Carrasco, PhD, Marcela Gonzalez, PhD, Mari Carmen Gomez, PhD, Maria Jose Cuevas, PhD, Maria Jose Noriega, PhD, Narcis Gusi, PhD, Pedro J Benito, PhD, Susana Aznar, PhD |
2020-04-28 |
| PSY-CO-CHU: Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: an Online Survey |
Anxiety disorder, Coronavirus disease 19 infection, Insomnia, Pain |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
|
France |
2020-04-09 |
2020-04-22 |
LOCAL COVID 2019/JYL-01), NCT04358640, PSY-CO-CHU |
Phase Not Applicable |
Recruiting |
1 |
|
2000 |
Jean-Yves LEFRANT, Jean-Yves LEFRANT, MD,PhD, Jean-Yves Lefrant, MD,PhD |
2020-04-29 |
| COVID-19 Mortality Prediction Model |
Coronavirus disease 19 infection, Viral pneumonia |
COViage alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Dascena |
|
US |
2020-04-01 |
2020-04-17 |
04202001, NCT04358510 |
Phase Not Applicable |
Completed |
0 |
|
114 |
|
2020-04-30 |
| COSA: Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter |
Coronavirus disease 19 infection, Respiratory failure |
Seraph 100 Microbind affinity blood filter alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hannover Medical School |
|
Germany |
2020-04-15 |
2021-10-01 |
COSA, COSA-8998, NCT04361500 |
Phase Not Applicable |
Recruiting |
2 |
17 Months |
100 |
Bernhard MW Schmidt, Jan T Kielstein, Prof, Julius J Schmidt, Julius J Schmidt, Dr |
2020-04-28 |
| KICC-COVID19: Keto-diet for Intubated Critical Care COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
Ketogenic diet alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
|
US |
2020-04-20 |
2020-08-01 |
IRB00247383, KICC-COVID19, NCT04358835 |
Phase Not Applicable |
Not yet recruiting |
0 |
3 Months |
15 |
Mackenzie Cervenka, MD, Tanya McDonald, MD PhD |
2020-04-29 |
| Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for COVID-19 Pneumonia |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
2020-04-09 |
2020-05-17 |
7773, NCT04362345 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
100 |
Antonin HUGEROT, MD, Charlotte KAEUFFER, MD, Coralie LE HYARIC, MD, François DANION, MD, Joy MOOTIEN, MD, Nicolas LEFEBVRE, MD, Nicolas MEYER, MD, PhD, Olivier HINSCHBERGER, MD, Saïd CHAYER, PhD, HDR, Yves HANSMANN, MD, PhD, Yvon RUCH, MD |
2020-05-01 |
| MARNEVO-Covid: Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection |
Coronavirus disease 19 infection, Epilepsy, Viral encephalitis |
blood sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier de PAU |
|
|
2020-05-05 |
2021-01-05 |
CHPAU2020/02, MARNEVO-Covid, NCT04361344 |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
30 |
|
2020-04-28 |
| START: START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19) |
Coronavirus disease 19 infection |
standard care alone, Brammanandha bairavam plus Kabasura kudineer |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Eminentlabs GmbH |
|
India |
2020-04-17 |
2020-06-26 |
ISRCTN13311119, NV-05-943-2020, START |
Phase 2 Clinical |
Recruiting |
1 |
2 Months |
116 |
Mr Thanicakachalam |
2020-04-29 |
| RAPID COVID COAG: Coagulopathy of COVID-19: A Pragmatic, Randomized, Controlled Trial of Therapeutic Anticoagulation Versus Standard Care |
Blood clotting disorder, Coronavirus disease 19 infection |
dalteparin sodium alone, enoxaparin sodium alone, tinzaparin sodium alone, unfractionated heparin alone |
Antithrombin III, Factor IIa antagonist, Factor Xa antagonist, Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Michaels Hospital |
University of Vermont Medical Center |
Canada, US |
2020-04-30 |
2020-12-31 |
NCT04362085, RAPID COVID COAG, RAPID COVID-COAG |
Phase 3 Clinical |
Not yet recruiting |
1 |
8 Months |
462 |
Mary Cushman, MD, Michelle Sholzberg, MD, FRCPC, Peter Jüni, MD, FESC |
2020-04-28 |
| A phase IIb/III, multinational, adaptive pilot to pivotal trial design of NP-120 in COVID-19 infected patients from progressing to mechanical ventilation with intubation and death |
Coronavirus disease 19 infection |
ifenprodil (injectable/intravenous, COVID-19/acute lung injury), Nash Pharmaceuticals alone, standard of care alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals |
|
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
100 |
|
2020-04-27 |
| COVSurf: A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19 |
Coronavirus disease 19 infection |
COVSurf drug delivery system alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Southampton NHS Foundation Trust |
Bill & Melinda Gates Foundation, University College London |
UK |
2020-04-27 |
2020-11-02 |
COVSurf, NCT04362059, RHM CRI0399 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
24 |
Danny B Pratt, Michael P Grocott, MD |
2020-04-29 |
| Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
anti-SARS-CoV-2 convalescent plasma cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tulane University School of Medicine |
|
US |
|
|
2020-595, NCT04358211 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Nakhle Saba, MD |
2020-04-28 |
| Evaluation of Antibody Tests for COVID-19 |
Coronavirus disease 19 infection |
rapid-format, point-of-care antibody test kit alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Washington University School of Medicine, US |
|
US |
2020-04-27 |
2020-10-27 |
202004088, NCT04360954 |
Phase Not Applicable |
Recruiting |
0 |
6 Months |
1000 |
Gary Weil, MD, Peter Fischer, PhD, Teresa Tufte, MPH |
2020-04-29 |
| STOP COVID 19: Sequencing and Tracking of Phylogeny in COVID-19 Study |
Coronavirus disease 19 infection |
Nanopore-based whole genome sequencing alone, phylogenetic analysis alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Portsmouth Hospitals |
University of Portsmouth |
UK |
2020-05-31 |
2022-09-30 |
NCT04359849, PHT/2020/34, STOP COVID 19 |
Phase Not Applicable |
Recruiting |
1 |
28 Months |
500 |
Alice Mortlock, Samuel Robson |
2020-04-28 |
| A clinical study of atexakin alfa for the treatment in patients with COVID-19-induced ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
atexakin alfa alone |
IL-6 receptor agonist |
|
Real Relief Holding ApS |
NeuroRx Inc |
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
|
2020-04-27 |
| Plasma Therapy of COVID-19 in Critically Ill Patients |
Coronavirus disease 19 infection |
anti-SARS-CoV-2 convalescent plasma cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Columbia University |
New York Blood Center |
US |
2020-04-21 |
2021-04-30 |
AAAS9924, NCT04359810 |
Phase 2 Clinical |
Recruiting |
0 |
12 Months |
105 |
Andrew Eisenberger, MD, Max O'Donnell, MD, Walter I. Lipkin, MD |
2020-05-01 |
| CHEER: Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Shaheed Zulfiqar Ali Bhutto Medical University Islamabad |
|
Pakistan |
2020-04-25 |
2020-09-25 |
CHEER, F.1-1/2015/ERB/SZABMU/549, NCT04359537 |
Phase 2 Clinical |
Not yet recruiting |
1 |
5 Months |
200 |
Fibhaa Syed, FRCP, Mohammed Ali Arif, FRCP, Rauf Niazi, FRCP |
2020-04-29 |
| Treatment Of Coronavirus Disease 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) |
Coronavirus disease 19 infection |
Anti-Sars-CoV-2 convalescent plasma alone |
|
|
US Army Medical Research and Development Command |
|
|
|
|
NCT04360486, S-20-02 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Andrew P Cap, MS, MD, PhD, FACP |
2020-04-29 |
| Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) |
Coronavirus disease 19 infection, Systemic inflammatory response syndrome |
standard of care alone, tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Emory University |
National Cancer Institute |
US |
2020-05-30 |
2022-05-30 |
NCI-2020-02314, NCT04361552, P30CA138292, STUDY00000419, WINSHIP4998-20 |
Phase 3 Clinical |
Recruiting |
0 |
24 Months |
180 |
Ajay K Nooka, Ajay K. Nooka, Shondolyn D. Richburg |
2020-04-29 |
| COVID19 LTFU: Long-Term Outcomes of Patients With COVID-19 |
Coronavirus disease 19 infection |
physical disability assessment tool alone, psychological Sequelae assessment tool alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-08 |
2021-12-30 |
20-0538, COVID19 LTFU, NCT04360538 |
Phase Not Applicable |
Recruiting |
0 |
20 Months |
500 |
Anne Pohlman, MSN, Bhakti Patel, MD, John Kress, MD, Krysta Wolfe, MD |
2020-04-29 |
| Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19 |
Coronavirus disease 19 infection |
nitric oxide (inhaled, INOpulse), Bellerophon alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bellerophon Therapeutics LLC |
|
|
|
|
NCT04358588, PULSE-EAP-001 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Hunter Gilles, MD, Michelle Alamo, Valerie Parker |
2020-04-29 |
| THROMBOVID: Study of Hemostasis in Case of Severe COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
|
2020-04-17 |
2021-05-01 |
7774, NCT04359992, THROMBOVID |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
50 |
Charles TACQUARD |
2020-04-29 |
| LIINC: Long-term Impact of Infection With Novel Coronavirus (COVID-19) |
Coronavirus disease 19 infection |
biological sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of California San Francisco |
|
US |
2020-04-21 |
2024-12-21 |
20-30479, LIINC, NCT04362150 |
Phase Not Applicable |
Recruiting |
0 |
56 Months |
800 |
Michael J Peluso, MD, Rebecca Hoh, Rebecca Hoh, MS, RD, Steven Deeks, MD, Steven G Deeks, MD |
2020-04-30 |
| Efficacy of tenofovir in covid-19 |
Coronavirus disease 19 infection |
hydroxychloroquine plus tenofovir disoproxil fumarate |
DNA polymerase inhibitor, HIV-1 reverse transcriptase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ardabil University of Medical Sciences |
|
Iran |
2020-04-29 |
|
IR.AUMS.REC.1399.051, IRCT20200421047155N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
86 |
Shahab Bohlooli, Shahram Habibzadeh, Sina Parsay |
2020-04-30 |
| A 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells for the treatment of COVID-19 associated with lung inflammation |
Coronavirus disease 19 infection, Lung inflammation |
umbilical cord-derived mesenchymal stem cells (intravenous, COVID-19/lung inflammation/acute lung injury/acute respiratory distress syndrome), University of Miami alone |
|
|
KCNQ2 Cure Alliance Foundation, University of Miami Miller School of Medicine |
|
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
24 |
Camillo Ricordi, M.D |
2020-04-29 |
| CV-COVID-19: Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System |
Cardiac failure, Coronavirus disease 19 infection, Heart arrhythmia, Myocardial infarction, Stroke, Sudden cardiac death |
real-time reverse transcriptase-polymerase chain reaction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Clinic of Barcelona |
|
Spain |
2020-04-20 |
2025-08-31 |
CV-COVID-19, HCB/2020/0457, NCT04359927 |
Phase Not Applicable |
Recruiting |
1 |
64 Months |
10000 |
Luis Ortega Paz, MD, PhD, Luis Ortega, MD, PhD, Manel Sabaté, MD, PhD, Salvatore Brugaletta, MD, PhD |
2020-04-30 |
| FIC: Favipiravir in Hospitalized COVID-19 Patients |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-04-20 |
2020-05-05 |
FAVIPIRAVIR IN COVID-19, FIC, NCT04359615 |
Phase 4 Clinical |
Not yet recruiting |
1 |
|
40 |
Mehran Lack, MD, Mohammad Fathi, MD, Nader Markazi, MD, Nasser Malekpour Alamdari, MD, Sanaz Zargar Balaye Jam, MD, Sasan Tavana, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA |
2020-04-30 |
| Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19 |
Coronavirus disease 19 infection |
convalescent immune plasma alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Institutes of Health Clinical Center |
|
US |
2020-04-21 |
2030-04-14 |
20-CC-0092, 200092, NCT04360278 |
Phase Not Applicable |
Recruiting |
0 |
119 Months |
1500 |
Kamille A West, M.D. |
2020-05-01 |
| Ivermectin and Nitazoxanide Combination Therapy for COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure |
ivermectin plus nitazoxanide |
Chloride channel modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tanta University |
|
Egypt |
2020-05-31 |
2020-12-31 |
IVR/NTZ, NCT04360356 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
100 |
Kamal Okasha, Md, PhD, Nahla Elashmawy, Md, PhD |
2020-04-30 |
| VTE COVID: Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19 |
Coronavirus disease 19 infection, Thromboembolism |
fondaparinux sodium alone, low-molecular-weight heparin alone |
Factor Xa antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Quovadis Associazione |
Azienda Ospedaliera di Padova |
Italy |
2020-05-31 |
2020-06-30 |
NCT04359212, VTE COVID, VTE COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
80 |
Giuseppe Camporese, MD, Paolo Simioni, MD |
2020-04-29 |
| Evaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19 |
Coronavirus disease 19 infection |
herbal extract (Glycyrrhiza glabra, Mentha pulegium and Urtica) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Baqiyatallah University of Medical Sciences |
|
Iran |
2020-03-30 |
2020-05-31 |
IR.BMSU.REC.1399.054, IRCT20080901001165N49 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
80 |
Ali Ghazivini, Dr. Rezaeiyan, Hossein Biganeh, Parisa Kianpour, Siamak Mohammadi, Yunes Panahi |
2020-04-27 |
| The effect of Naproxen in recovery and reducing mortality in patients with COVID-19 |
Coronavirus disease 19 infection |
naproxen alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Iran University of Medical Sciences |
|
Iran |
2020-04-13 |
|
IR.IUMS.REC.1399.001, IRCT20200410047009N1 |
Phase 4 Clinical |
Recruiting |
1 |
|
101 |
Maryam Esghaei |
2020-04-29 |
| effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections |
Coronavirus disease 19 infection |
Arbidol plus hydroxychloroquine, Amin Pharmaceutical Company |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-22 |
|
IR.MUMS.REC.1399.103, IRCT20200325046859N2 |
Phase 2/Phase 3 Clinical |
No longer recruiting |
1 |
|
40 |
Rozita Khodashahi |
2020-04-28 |
| Evaluation of the colchicine tablet efficacy as an adjuvant therapy for patients with mild to moderate COVID-19 |
Coronavirus disease 19 infection |
colchicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-29 |
|
IR.MUMS.REC.1399.096, IRCT20200408046990N2 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Sepideh Elyasi |
2020-04-30 |
| Atrium COVID-19 Syndromic and Serological Surveillance |
Coronavirus disease 19 infection |
daily syndromic surveillance alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Atrium Health |
|
US |
2020-04-30 |
2021-12-31 |
04-20-11A, NCT04361123 |
Phase Not Applicable |
Recruiting |
0 |
20 Months |
450000 |
Michael Runyon, MD, MPH |
2020-05-01 |
| Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19) |
Coronavirus disease 19 infection, Lung disease, Sepsis, Viral pneumonia |
Reuquinol alone, Reuquinol plus azithromycin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Apsen Farmaceutica SA |
Universidade Federal de Sao Paulo - UNIFESP |
Brazil |
2020-05-04 |
2020-11-04 |
APS001/2020, NCT04361461 |
Phase 3 Clinical |
Not yet recruiting |
1 |
6 Months |
500 |
Dr. Eduardo Alexandrino Servolo de Medeiros, M.D, Fernanda Martinez, B.Sc. |
2020-04-28 |
| Precision Immunology to Determine the Immune Response in Patients With COVID-19 |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Bonn |
|
Germany |
2020-04-20 |
2022-09-30 |
BOST-03, NCT04360733 |
Phase Not Applicable |
Recruiting |
1 |
29 Months |
200 |
Chrisitan Bode, MD, Christian Bode, MD, Dr. Christian Bode, Folkert Steinhagen, MD |
2020-04-29 |
| Effect of lithium carbonate on COVID-19 |
Coronavirus disease 19 infection |
lithium carbonate alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-05-02 |
|
IR.MUMS.REC.1399.145, IRCT20081019001369N5 |
Phase 2 Clinical |
Recruiting |
1 |
|
40 |
Hossein Hosseinzadeh, Javad Dehghan Nayyeri |
2020-05-04 |
| Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients |
Coronavirus disease 19 infection |
telmisartan alone |
Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Hawaii |
|
US |
2020-07-01 |
2021-06-30 |
H051, NCT04360551 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
40 |
Cecilia M Shikuma, MD, Debra Ogata-Arakaki, RN |
2020-04-27 |
| COVIDORL: Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity |
Coronavirus disease 19 infection, Olfaction disorder |
budesonide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fondation Ophtalmologique Adolf De Rothschild |
Assistance Publique Hopitaux de Paris |
France |
2020-04-25 |
2021-05-25 |
COVIDORL, MDL_2020_10, NCT04361474 |
Phase 3 Clinical |
Not yet recruiting |
1 |
13 Months |
120 |
Amélie Yavchitz, Mary DAVAL, Mary Daval |
2020-04-29 |
| NCoV: Neurocognitive Impairment in Patients With COVID-19 |
Cognitive disorder, Coronavirus disease 19 infection, Delirium |
|
|
|
University of Rostock |
Ludwig-Maximilians University of Munich, University College London |
Germany |
2020-04-15 |
2021-04-01 |
COVID-BRAIN, NCT04359914, NCoV |
Phase Not Applicable |
Recruiting |
1 |
11 Months |
80 |
Gerd Klinkmann, MD, Johannes Ehler, MD |
2020-04-29 |
| STOP-COVID19: A multicenter, investigator-initiated, prospective, randomized, double-blind, placebo-controlled trial of brensocatib in patients with severe COVID-19 |
Coronavirus disease 19 infection |
brensocatib alone |
Dipeptidyl peptidase I inhibitor |
|
University of Dundee |
Insmed Inc |
UK |
|
|
STOP-COVID19 |
Phase 2 Clinical |
Status not specified |
1 |
|
300 |
Professor James Chalmers |
2020-04-27 |
| AVINALI: Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19 |
Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome |
aviptadil alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
NeuroRx Inc |
|
|
2020-06-01 |
2020-10-01 |
AVINALI, NCT04360096, RLF-100-002 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
144 |
Jonathan C Javitt, MD, MPH, Robert E Besthof, MIM |
2020-04-28 |
| Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study |
Coronavirus disease 19 infection |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zealand University Hospital |
|
Denmark |
2020-04-22 |
|
2020-001459-42, 26223678Hans |
Phase 2 Clinical |
No longer recruiting |
1 |
|
40 |
Hans Hasselbalch |
2020-04-29 |
| Isotretinoin in Treatment of COVID-19 (Randomized) |
Coronavirus disease 19 infection |
isotretinoin alone, Variable regimens including ascorbic acid , azithromycin , clarithromycin , cyanocobalamin , hydroxychloroquine , isotretinoin , lopinavir + ritonavir , oseltamivir , paracetamol |
Exo-alpha sialidase inhibitor, HIV protease inhibitor, Retinoic acid receptor agonist |
Young Adults (18-44 yrs) |
Tanta University |
|
Egypt |
2020-04-21 |
2020-09-30 |
9469305C, NCT04361422 |
Phase 3 Clinical |
Not yet recruiting |
1 |
5 Months |
300 |
Lamia Elgarhy |
2020-04-29 |
| UHID-COVID19: Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital for Infectious Diseases |
|
Croatia |
2020-04-16 |
2021-04-15 |
NCT04359667, UHID-04, UHID-COVID19 |
Phase 2 Clinical |
Recruiting |
1 |
12 Months |
30 |
Arijana Pavelic, BA, Marko Kutlesa, MD, PhD, Miroslav Mayer, MD, PhD, Rok Civljak, MD, PhD |
2020-04-29 |
| COVID-19 PREVENTION: Medication for prevention of Corona-virus for Danish nursing home residents |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , vitamin D , zinc |
|
Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Odense University Hospital |
|
Denmark |
2020-04-23 |
|
2020-001363-85, 60152610, COVID-19 PREVENTION |
Phase 3 Clinical |
No longer recruiting |
1 |
|
206 |
Clinical Trial Information |
2020-04-29 |
| CQOTE: Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19 |
Coronavirus disease 19 infection, HIV infection |
chloroquine alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Cape Town |
|
South Africa |
2020-05-01 |
2021-07-31 |
CQOTE, HIV-COVID-19 CQOTE, NCT04360759 |
Phase 3 Clinical |
Not yet recruiting |
2 |
15 Months |
560 |
Amy Ward, MBBCh, Bianca Sossen, MBChB, Bianca Sossen, MBChB, MSc, Bianca Sossen, MBChB, MSc), Graeme Meintjes, PhD, Jacob Standler, MBChB, Mpumi Maxebengula, BCom, Nompumelelo Maxebengula, Sean Wasserman, MBChB, Trevor Ayanda Mnguni, MBChB, FCP(SA) |
2020-04-29 |
| A Study to Explore the Role of Gut Flora in COVID-19 Infection |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
ProgenaBiome |
|
US |
2020-04-16 |
2021-07-31 |
NCT04359836, PRG-041 |
Phase Not Applicable |
Recruiting |
0 |
15 Months |
250 |
Jordan Daniels, MS, Sabine Hazan, MD |
2020-04-28 |
| Leflunomide in Mild COVID-19 Patients |
Coronavirus disease 19 infection |
leflunomide alone |
Dihydroorotate dehydrogenase inhibitor, Protein tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-30 |
2020-07-31 |
IRB20-0622, NCT04361214 |
Phase 1 Clinical |
Not yet recruiting |
0 |
3 Months |
20 |
Laurencia Perea, Michael Millis, Michael Millis, MD |
2020-05-02 |
| Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 |
Coronavirus disease 19 infection |
favipiravir alone, standard of care alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fujifilm Pharmaceuticals USA, Inc |
|
US |
2020-04-17 |
2020-12-31 |
FAVI-COV-US201, NCT04358549 |
Phase 2 Clinical |
Recruiting |
0 |
8 Months |
50 |
FPHU Study Coordinator |
2020-04-29 |
| PassItOn II: Passive Immunity Trial of Nashville II |
Coronavirus disease 19 infection, Respiratory tract infection |
pathogen reduced SARS-CoV-2 convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanderbilt University Medical Center, US |
|
US |
2020-04-24 |
2021-04-30 |
200738, NCT04362176, PassItOn II |
Phase 3 Clinical |
Not yet recruiting |
0 |
12 Months |
500 |
Amanda J Bistran-Hall, Todd Rice, MD |
2020-04-29 |
| A phase I trial to evaluate AlloRx Stem Cells for the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
AlloRx Stem Cells alone |
|
|
Vitro Diagnostics Inc |
|
US |
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-27 |
| Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients |
Coronavirus disease 19 infection, Dysgeusia, Dysomia |
|
|
|
Centre Hospitalier Universitaire De Nice |
|
France |
2020-03-20 |
2020-05-31 |
20ODONTOCOVID.06, NCT04361565 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
50 |
|
2020-04-29 |
| Acral Cutaneous Thrombotic Vasculopathy and COVID-19 Infection |
Acrocyanosis, Coronavirus disease 19 infection, Necrosis, Purpura, Raynauds disease, Vascular disease |
|
|
|
University Hospital, Montpellier |
Assistance Publique Hopitaux De Marseille, Lyon-Sud Hospital Center, Marseille University Hospital |
France |
2020-04-01 |
2020-10-30 |
NCT04361786, RECHMPL20_0211 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
10 |
Didier BESSIS, PhD, Léo-Paul Secco, Student |
2020-04-29 |
| PRECOVIA: Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital |
Coronavirus disease 19 infection |
SARS-Cov2 testing alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
Roquette Freres |
France |
2020-04-30 |
2020-09-30 |
2020-A00950-39, 2020_34, NCT04362267, PRECOVIA |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
150 |
Annie SOBASZEK, MD, Annie SOBASZEK, MD,PhD |
2020-04-29 |
| CytokCOVID19: Pilot Study on Cytokine Filtration in COVID-19 ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
cytokine adsorption alone, sodium heparin alone, standard intensive care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Clinic of Barcelona |
|
Spain |
2020-04-17 |
2020-07-31 |
CytokCOVID19, HCB/2020/0464, NCT04361526 |
Phase 2 Clinical |
Recruiting |
1 |
3 Months |
40 |
Manuel Castellà, MD PhD |
2020-04-29 |
| A multicenter, randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
shengmai decoction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan 7th Hospital, Wuhan Hospital of Traditional Chinese Medicine, Xiaogan Traditional Chinese Medicine Hospital |
|
China |
2020-04-15 |
2020-07-15 |
ChiCTR2000032205, ChiMCTR2000003235 |
Phase Not Applicable |
Not yet recruiting |
3 |
3 Months |
200 |
Mao Lina, Xia Ping |
2020-04-29 |
| A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period |
Coronavirus disease 19 infection, Viral pneumonia |
Qi-Mai-Fei-Luo-Ping mixture alone, rehabilitation education guidance alone, respiratory training alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hubei province hospital of Traditional Chinese Medicine |
|
China |
2020-04-01 |
2021-03-31 |
ChiCTR2000032165, ChiMCTR2000003230 |
Phase Not Applicable |
Not yet recruiting |
3 |
12 Months |
60 |
Xiao Mingzhong |
2020-04-29 |
| MICROVID: Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-09-30 |
2020-A01042-37, 2020_28, MICROVID, NCT04359706 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
30 |
Saad Nseir, MD,PhD |
2020-04-30 |
| COVID19-SETH: COVID-19 in Liver Transplant Recipients |
Coronavirus disease 19 infection |
|
|
|
Hospital Clinic of Barcelona |
Sociedad Española de Trasplante Hepático |
Spain |
2020-03-01 |
2021-03-31 |
COVID19-SETH, HCB/2020/0384, NCT04361591 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
200 |
Jordi Colmenero, Jordi Colmenero, MD PhD, SETH Scientific Committee |
2020-04-29 |
| Estrogen Patch for COVID-19 Symptoms |
Coronavirus disease 19 infection, Viral pneumonia |
estradiol (transdermal patch, vasomotor symptoms/ osteoporosis), Bayer Schering alone |
Estradiol agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stony Brook University Hospital |
|
US |
2020-04-20 |
2020-11-15 |
NCT04359329, SBU-ESTROGENPATCH-COVID19 |
Phase 2 Clinical |
Recruiting |
0 |
6 Months |
110 |
Alison Stopeck, MD, Andrew Handel, MD, Antonio Gasparis, MD, Christina Preece, Christina Preece, MD, Jie Yang, PhD, Patricia Thompson, Patricia Thompson, PhD, Sharon Nachman, MD |
2020-04-29 |
| A medical records based study for ECMO in the rescue therapy of extremely critical novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
ECMO alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
BaYi Brain Hospital, Children's Hospital of Chongqing Medical University |
|
China |
2020-04-22 |
2020-05-21 |
ChiCTR2000032162 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
80 |
Cao Huiling, Feng Zhichun |
2020-04-29 |
| Study for evolution and clinical outcomes study of novel coronavirus pneumonia (COVID-19) patients: a retrospective, cohort study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Tongji Medical College |
National Natural Science Foundation of China |
China |
2020-02-01 |
2020-06-30 |
ChiCTR2000032161 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
2000 |
Gao Qinglei, Wang Ya |
2020-04-29 |
| CORTICOVIDHUGO: Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Standard of care alone, hydrocortisone hemisuccinate alone, prednisone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Tours |
|
France |
2020-05-31 |
2020-11-30 |
CORTI-COVID-19-HUGO, CORTICOVIDHUGO, DR200136, NCT04359511 |
Phase 3 Clinical |
Not yet recruiting |
12 |
6 Months |
210 |
BAZIN YANN, MD, GOUPIL FRANCOIS, MD, GUY TIPHAINE, MD, JOUNEAU STEPHANE, MD, PhD, LEMMENS BRUNO, MD, LIOGER BERTRAND, MD, LOUIS BERNARD, MD, PhD, MAILLOT FRANCOIS, MD, MARCHAND ADAM Sylvain, MD, PhD, MOREL HUGUES, MD, PECQUERIAUX OLIVIER, MD, POPA Mihai, MD, RABUT Thi- Tuyet Hong, MD, ROY XAVIER, MD, pascal magro, MD, sylvain marchand-adam, MD, PhD |
2020-04-29 |
| Efficacy and safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
ulinastatin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Public Health Clinical Center |
|
China |
2020-04-22 |
2020-12-31 |
ChiCTR2000032135 |
Phase 4 Clinical |
Not yet recruiting |
1 |
8 Months |
50 |
Hongzhou Lu, Yun Ling |
2020-04-30 |
| HBOTCOVID19: Hyperbaric Oxygen Therapy Effect in COVID-19 RCT |
Coronavirus disease 19 infection, Respiratory insufficiency |
hyperbaric oxygen therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assaf-Harofeh Medical Center |
|
|
2020-04-26 |
2020-07-30 |
120-20-ASF, HBOTCOVID19, NCT04358926 |
Phase Not Applicable |
Not yet recruiting |
0 |
3 Months |
30 |
Amir Hadanny, MD, Shai Efrati, MD |
2020-04-30 |
| The effect of pomegranate tea on symptom relief of COVID-19 patients: a double-blind, randomized clinical trial study |
Coronavirus disease 19 infection, Viral pneumonia |
pomegranate tea alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shahrekord University of Medical Sciences and Health Services |
|
Iran |
2020-04-20 |
|
IR.SKUMS.REC.1399.017, IRCT20200416047104N1 |
Phase Not Applicable |
Recruiting |
1 |
|
66 |
Dr. Fereidoun Rahmani, Dr. Mehraban Sadeghi, Dr. Zahra Lorigooini, Dr. Zohreh Abolhassanzadeh, Vahid Reisi-Vanani |
2020-04-29 |
| TX-COVID: Solid Organ Transplant Recipients With Covid-19 French Registry |
Coronavirus disease 19 infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
2020-04-08 |
2021-04-08 |
7766, NCT04360707, TX-COVID |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
300 |
Gabriela GAUTIER, MD, Samira FAFI-KREMER, MD, PhD, Saïd CHAYER, PhD, HDR, Sophie CAILLARD, MD, PhD |
2020-04-29 |
| COVID-DEX: Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients |
Coronavirus disease 19 infection, Pulmonary edema, Respiratory distress syndrome, Respiratory insufficiency |
Variable regimens including dexmedetomidine , propofol, AstraZeneca/Fresenius , remifentanil |
Alpha 2 adrenoceptor agonist, Opioid receptor mu agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Clinic of Barcelona |
|
Spain |
2020-04-15 |
2020-06-30 |
COVID-DEX, NCT04358627, SPEC-M, SPEC-M COVID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
80 |
Pedro L Gambus, PhD MD, Xavier Borrat, PhD MD |
2020-04-29 |
| CIPOLLINI: Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Medical Center Groningen |
|
Netherlands |
2020-06-30 |
2022-06-30 |
CIPOLLINI, CIPOLLINI, NCT04359459 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
150 |
Daan Pouwels, PhD, Dirk-Jan Slebos, MD PhD, Janesh Pillay, MD PhD, Maarten van den Berge, Maarten van den Berge, MD PhD |
2020-04-29 |
| Examination of test accuracy of COVID-19 rapid antibody kit |
Coronavirus disease 19 infection |
rapid antibody kit alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ja Akita Koseiren Omagari Kosei Medical Care Center |
|
Japan |
2020-04-23 |
|
UMIN000040235 |
Phase Not Applicable |
Recruiting |
1 |
|
20 |
Toshiki Horii |
2020-04-29 |
| COCARDE: Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients |
Coronavirus disease 19 infection, Myocardial disease |
transthoracic echocardiography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Toulouse |
|
France |
2020-04-04 |
2020-11-04 |
2020-A00852-37, COCARDE, NCT04358952, RC31/20/0117 |
Phase Not Applicable |
Recruiting |
1 |
7 Months |
50 |
Olivier LAIREZ, PU-PH, Vincent MINVILLE, PU PH, Vincent MINVILLE, PU-PH |
2020-04-29 |
| Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot, Randomized Clinical Trial |
Adult respiratory distress syndrome, Coronavirus disease 19 infection, Viral pneumonia |
dexamethasone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Colorado at Denver and Health Sciences Center |
|
|
2020-05-01 |
2020-12-31 |
20-0811, NCT04360876 |
Phase 2a Clinical |
Not yet recruiting |
0 |
8 Months |
90 |
|
2020-04-29 |
| Database for diagnosis and therapy of COVID-19 infected patients |
Coronavirus disease 19 infection |
data collection alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Institute for Research in Operative Medicine |
|
Germany |
2020-04-26 |
|
75/2020, DRKS00021514 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
150 |
Sarah Schwarz, Tim Mathes |
2020-04-29 |
| Quercetin in COVID-19 |
Coronavirus disease 19 infection |
quercetin alone, routine drug therapy alone |
|
|
Ahvaz University of Medical Sciences |
|
Iran |
2020-04-29 |
|
IR.AJUMS.REC.1399.087, IRCT20200419047128N2 |
Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Ali khodadadi, Mohamad Badavi, َAli Khodadadi |
2020-04-30 |
| Evaluation of the effects of Sitagliptin administration in patients with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including hydroxychloroquine , lopinavir + ritonavir , sitagliptin (Dr. Abidi Pharmaceuticals) |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-05-04 |
|
IR.SBMU.NRITLD.REC.1399.029, IRCT20200420047147N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
84 |
Afshin Zarghi, Ahad Zare, Dr. Atefe Abedini, Farzaneh Dastan |
2020-05-04 |
| Effect of NK cell therapy in COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
allogeneic natural killer cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Middle East Gene Therapy corporation |
|
Iran |
2020-04-27 |
|
IR.TUMS.VCR.REC.1399.069, IRCT20200417047113N1 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
70 |
Minoo Mohraz, Sahar Shojaei |
2020-04-29 |
| Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection |
Coronavirus disease 19 infection |
vaccine BCG alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universidad de Antioquia |
|
Colombia |
2020-04-30 |
2021-11-30 |
NCT04362124, PEC03_2020 |
Phase 3 Clinical |
Not yet recruiting |
1 |
19 Months |
1000 |
Juan C Cataño, MD.MI.ID, Juan C cataño, MD.MI.ID, Liliana Lopez, BSc.MSc |
2020-04-29 |
| Classification of COVID-19 Infection in Posteroanterior Chest X-rays |
Coronavirus disease 19 infection |
DenseNet121 alone, PCX images (chest X-rays) alone, VGG16 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Dascena |
|
US |
2020-04-01 |
2020-04-17 |
04202002, NCT04358536 |
Phase Not Applicable |
Completed |
0 |
|
230 |
|
2020-04-29 |
| Baricitinib Therapy in COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
baricitinib plus lopinavir + ritonavir |
HIV protease inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ospedale Misericordia e Dolce |
|
Italy |
2020-03-16 |
2020-04-07 |
HPRATO-4, NCT04358614 |
Phase 2/Phase 3 Clinical |
Completed |
1 |
|
12 |
Fabrizio Cantini |
2020-04-29 |
| A clinical study of CLBS-119 for repair of COVID-19 induced lung damage in patients with severe SARS-CoV-2 infection that required ventilatory support due to respiratory failure |
Coronavirus disease 19 infection, Lung injury, Respiratory failure |
CLBS-119 alone |
|
|
Caladrius Biosciences Inc |
|
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
|
2020-04-28 |
| Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 |
Coronavirus disease 19 infection |
autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone, Variable regimens including autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences , azithromycin , hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hope Biosciences Inc |
Advanced Diagnostics Healthcare, Hope Biosciences Stem Cell Research Foundation |
US |
2020-05-15 |
2020-10-31 |
ALLOGENEIC TREATMENT COVID-19, NCT04362189 |
Phase 2 Clinical |
Not yet recruiting |
0 |
5 Months |
110 |
Joseph Gathe, MD, FACP, Katherine Ruppert, PhD, Mariann England, Rajiv Thakur, MD, Sherry Diers, RN, Thinh Vo, MD |
2020-04-29 |
| A phase III confirmatory study to evaluate the safety and efficacy of Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection |
Coronavirus disease 19 infection |
repurposed formulation of bucillamine (gout/cystinuria/Wilson disease), Revive Therapeutics alone |
Xanthine oxidase inhibitor |
|
Pharm-Olam International, Revive Therapeutics Ltd |
|
Canada |
|
|
|
Phase 3 Clinical |
Planned |
1 |
|
|
Dr. Kelly McKee, Jr., MD, MPH |
2020-04-30 |
| A clinical trial of Mitotech-19 for the treatment of acute respiratory distress syndrome in patients with COVID-19 infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Mitotech-19 alone |
|
|
Mitotech SA |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-28 |
| RUXCOVID: Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm |
Coronavirus disease 19 infection, Viral pneumonia |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone, standard-of-care alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Novartis AG |
Incyte Corp |
Germany |
2020-04-30 |
2020-06-29 |
2020-001662-11, CINC424J12301, INCB 18424-368, NCT04362137, RUXCOVID |
Phase 3 Clinical |
Recruiting |
1 |
2 Months |
402 |
Medizinischer Infoservice (MCC), Novartis Pharmaceuticals |
2020-04-29 |
| Adaptive, multicenter, randomized, open, comparative clinical trial of the efficacy and safety of the drug favipiravir in patients hospitalized with COVID-19 |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
|
Kromis LLC |
|
Russian Federation |
2020-04-23 |
2020-12-31 |
COVID-FPR-01 |
Phase 3 Clinical |
Status not specified |
17 |
8 Months |
390 |
|
2020-04-25 |
| CORONA: A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 |
Coronavirus disease 19 infection |
BCD-089 alone |
IL-6 receptor antagonist |
|
Biocad Ltd |
|
Russian Federation |
2020-04-22 |
2022-12-30 |
BCD-089-4, CORONA |
Phase 3 Clinical |
Status not specified |
4 |
32 Months |
250 |
|
2020-04-25 |
| A clinical trial of convalescent plasma for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
onvalescent plasma alone |
|
Healthy volunteers accepted |
Viravaxx AG |
|
|
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
600 |
|
2020-04-24 |
| Study of Shreepad Shree Vallabh SSV Formulation to improve immunity in quarantine patients of COVID-19 |
Coronavirus disease 19 infection, Immunization |
SSV Formulation tablet alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
SSV Phytopharmaceuticals |
|
India |
2020-04-27 |
|
CTRI/2020/04/024659, Protocol No. SSV-SF-04/2020 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
30 |
Dr Samadhan Patil, Dr Yogesh Dound |
2020-04-28 |
| RTLS Technology Study |
Coronavirus disease 19 infection |
Real Time Location System alone |
|
|
The Royal Wolverhampton Hospitals Nhs Trust |
Cornell University, La Trobe University |
UK |
2020-01-06 |
2020-12-31 |
2019SUR107, NCT04114110 |
Phase Not Applicable |
No longer recruiting |
1 |
11 Months |
2000 |
|
2020-04-27 |
| CONCOR-1: Convalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness |
Coronavirus disease 19 infection |
Convalescent plasma alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hamilton Health Sciences Corp, Hema-Quebec |
Canadian Blood Services, McMaster University, Universite De Montreal, University of Toronto |
Canada |
2020-04-27 |
2020-12-31 |
CONCOR-1, CONCOR-1, NCT04348656 |
Phase 3 Clinical |
Not yet recruiting |
27 |
8 Months |
1200 |
Andrew Shih, Anne-Sophie Lemay, Arjuna Ponnampalam, Benjamin Rioux-Masse, Brian Berry, Christine Cserti, Danielle Talbot, David Welbourne, Donald M Arnold, MD, Erin B Jamula, MSc., Jacob Pendergrast, Julie Rousseau, Katerina Pavenski, Luigina Mollica, Menaka Pai, Michelle Zeller, Nadine Shehata, Patrice Beauregard, Patricia Pelletier, Shuoyan Ning, Stephen Caplan, Susan Nahirniak, Tony Giulivi, Valerie Arsenault, Vincent Laroche, Yulia Lin, Ziad Solh |
2020-04-30 |
| PRA-001: Plasma Rich Antibodies From Recovered Patients From COVID19 |
Coronavirus disease 19 infection |
Variable regimens including Antibody-Rich Plasma , azithromycin , hydroxychroquine , oseltamivir |
Exo-alpha sialidase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-31 |
FMASU P15/ 2020, NCT04348877, PRA-001 |
Phase 2 Clinical |
Not yet recruiting |
1 |
8 Months |
20 |
Hossam Fahmy, Professor of Faculty of Medicine |
2020-04-27 |
| WAVES: Airway Pressure Release Ventilation for mechanically ventilated patients with COVID-19 in Western Australian Intensive Care Units: an observational study |
Coronavirus disease 19 infection |
Airway pressure release ventilation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sir Charles Gairdner Hospital |
|
Australia |
2020-04-27 |
|
ACTRN12620000474954p, WAVES |
Phase Not Applicable |
Not yet recruiting |
8 |
|
100 |
A/Prof Matthew Anstey |
2020-04-30 |
| COVID RASP: Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM-85 |
Coronavirus disease 19 infection, Respiratory disease |
OM-85 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Queensland |
Australian Government |
Australia |
2020-06-01 |
2020-07-31 |
ACTRN12620000473965p, BV-2020/19, COVID RASP, U1111-1250-2920 |
Phase 3 Clinical |
Not yet recruiting |
3 |
2 Months |
1000 |
Mrs Sharon Brabon, Prof Peter Sly |
2020-04-28 |
| An investigator initiated study to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections |
Bacterial infection, Coronavirus disease 19 infection, Viral pneumonia |
Unyvero system alone |
|
|
Karolinska Institutet |
OpGen Inc |
Sweden |
2020-04-21 |
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
|
2020-04-24 |
| Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial) |
Coronavirus disease 19 infection |
Measles Mumps and Rubella vaccine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Misr University for Science and Technology |
Kasr Alainy School of Medicine |
Egypt |
2020-04-15 |
|
PACTR202004693933092 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
200 |
Ahmed Mukhtar, Mahmoud Nassar, Mostafa Alfishawy |
2020-04-27 |
| COVIPOC: Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial |
Coronavirus disease 19 infection, Respiratory insufficiency |
senicapoc alone |
KCNN potassium channel-4 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Aarhus University |
|
Denmark |
2020-04-14 |
|
0001, 2020-001420-34, COVIPOC |
Phase 2 Clinical |
Recruiting |
1 |
|
|
www.Clinicaltrials.gov |
2020-04-27 |
| A phase I clinical study to assess ABL novel prophylactic COVID-19 vaccine and to analyze biomarker to characterize the immune profile of subjects participating in the study |
Coronavirus disease 19 infection |
ABL novel prophylactic COVID-19 vaccine alone |
|
|
Advanced BioScience Laboratories Inc |
Institut Merieux SA |
|
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-27 |
| Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot placebo-controlled randomized trial |
Coronavirus disease 19 infection |
IHP Detox Tea alone, conventional therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Neimeth International Pharmaceuticals Plc |
|
Nigeria |
2020-05-01 |
|
PACTR202004761408382 |
Phase Not Applicable |
Not yet recruiting |
2 |
|
72 |
Charles Esimone, George Eleje, Jude Duru |
2020-04-29 |
| A diagnostic study IgG and/or IgM antibodies to the SARS-CoV-2 (novel 2019 coronavirus) through ZEUS's lateral flow test |
Coronavirus disease 19 infection |
ZEUS's lateral flow test alone |
|
Healthy volunteers accepted |
Zeus Scientific Inc |
|
China, US |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
|
|
2020-04-24 |
| A medical records based study for 'Guangdong Pneumonia NO.1' in the Treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
Guangdong Pneumonia NO.1 alone, basic treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou Hospital |
|
China |
2020-02-11 |
2020-11-30 |
ChiCTR2000031888, ChiMCTR2000003208 |
Phase Not Applicable |
Recruiting |
3 |
9 Months |
300 |
Liansheng Lin, Luping Lin |
2020-04-27 |
| A phase II clinical study of stem cells to treat hospitalized patients with COVID-19 infection |
Coronavirus disease 19 infection |
stem cells alone |
|
|
Personalized Stem Cells Inc |
|
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-24 |
| A study of Wondfo SARS-CoV-2A point of care test for the diagnosis of COVID-19 |
Coronavirus disease 19 infection |
Wondfo SARS-CoV-2A point of care test alone |
|
|
Guangzhou Wondfo Biotech Co Ltd |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-24 |
| A validation study of Wondfo SARS-CoV-2A point of care test for the diagnosis of COVID-19 |
Coronavirus disease 19 infection |
Wondfo SARS-CoV-2A point of care test alone |
|
|
National Institute of Virology |
Cellmid Ltd, World Health Organization |
India |
|
2020-04-22 |
|
Phase Not Applicable |
Completed |
1 |
|
36 |
|
2020-04-24 |
| A phase IIa, multicenter clinical trial of Cannabidiol-Steroid formulation for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
cannabidiol-steroid alone |
|
|
Stero Biotechs Ltd |
|
|
|
|
|
Phase 2a Clinical |
Planned |
0 |
|
40 |
|
2020-04-25 |
| An IP Protected Cliniacl Trial of Cannabidiol- steroid formulation for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
cannabidiol- steroid alone |
|
|
Stero Biotechs Ltd |
Mor Research Applications Ltd |
Israel |
2020-04-30 |
|
|
Phase Not Applicable |
Planned |
1 |
|
10 |
|
2020-04-25 |
| Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Mútua Terrassa University Hospital |
|
Spain |
2020-04-18 |
|
2020-001536-98, PREPSARS |
Phase 3 Clinical |
Recruiting |
1 |
|
300 |
HOSPITAL UNIVERSITARI MUTUA TERRASSA, INTERNAL MEDICINE DEPARTMENT |
2020-04-27 |
| Study to investigate the safety and effects of vaccines in healthy adults |
Coronavirus disease 19 infection |
BNT-162a1 alone |
COVID19 Spike glycoprotein modulator |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
BioNTech SE |
Pfizer Inc |
Germany |
2020-04-20 |
|
2020-001038-36, BNT162-01, U1111-1249-4220 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
196 |
Clinical Study Management |
2020-04-30 |
| A trial to evaluate BNT-162 for the prevention of COVID-19 infection |
Coronavirus disease 19 infection |
BNT-162a1 alone |
COVID19 Spike glycoprotein modulator |
|
BioNTech SE |
Pfizer Inc |
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-30 |
| CIGB-2020 in contacts and suspects of SARS-CoV-2 infection |
Coronavirus disease 19 infection |
CIGB-2020 alone, conventional treatment alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Center for Genetic Engineering and Biotechnology |
Instituto Pedro Kouri |
Cuba |
2020-03-27 |
2020-06-30 |
CIGB 2020-01, RPCEC00000306 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
3 Months |
80 |
Julia Cuesta Diéguez, Zurina Cinza Estévez |
2020-04-27 |
| PrevenCOVID-19: Study for the prevention of COVID-19 infection in healthcare personnel |
Coronavirus disease 19 infection |
hydroxychloroquine (Dolquine) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla |
|
Spain |
2020-04-19 |
|
2020-001440-26, PrevenCOVID-19, PrevenCOVID-19 |
Phase 3 Clinical |
Recruiting |
1 |
|
184 |
CTU-HUVR, Clinical trial information |
2020-04-27 |
| TAC-COVID19: Outpatient Treatment Of Covid-19 With Early Pulmonary Corticosteroids As An Opportunity To Modify The Course Of The Disease |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , paracetamol , prednisone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hospital San Juan de Dios Burgos |
Hospital Universitario de Burgos |
Spain |
2020-04-19 |
|
2020-001622-64, TAC-COVID19, TAC-COVID19 |
Phase 4 Clinical |
Recruiting |
1 |
|
200 |
María Jesús Coma |
2020-04-28 |
| COVID-Aging: Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , telmisartan |
Angiotensin II receptor antagonist |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
2020-04-24 |
2021-06-01 |
2020-001303-16, 7747, COVID-Aging, NCT04359953 |
Phase 3 Clinical |
Recruiting |
2 |
13 Months |
1600 |
Frédéric BLANC, Frédéric BLANC, MD |
2020-04-29 |
| CAPACoV19: Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation |
Coronavirus disease 19 infection |
data record alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Reims |
|
France |
2020-05-01 |
2022-02-01 |
CAPACoV19, NCT04356378, PO20055 |
Phase Not Applicable |
Not yet recruiting |
1 |
21 Months |
300 |
Francois BOYER, François BOYER |
2020-04-27 |
| Efficacy of Tocilizumab on Patients With COVID-19 |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
Genentech Inc |
US |
2020-04-27 |
2020-08-30 |
2020P001159, NCT04356937 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
300 |
Ana D Fernandes, MA, John H Stone, MD, John H Stone, MD,MPH |
2020-04-27 |
| CORONA-SHIELD: Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19 |
Coronavirus disease 19 infection |
radiation therapy alone, telehealth alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
|
US |
2020-04-14 |
2021-04-30 |
CORONA-SHIELD, NCT04357574, PRO00105266 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
1000 |
Manisha Palta, MD |
2020-04-24 |
| COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 |
Coronavirus disease 19 infection, Respiratory failure |
best supportive care alone, nivolumab alone |
Programmed cell death protein 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Queen Mary Hospital |
The University of Hong Kong |
Hong Kong |
2020-04-14 |
2021-08-31 |
NCT04356508, UW20213 |
Phase 2 Clinical |
Not yet recruiting |
1 |
16 Months |
15 |
Gerry Gin Wai Kwok, MBBS |
2020-04-23 |
| A phase II, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and preliminary efficacy of ATYR-1923 in confirmed COVID-19 positive patients with severe respiratory complications |
Coronavirus disease 19 infection |
ATYR-1923 alone |
Neuropilin 2 inhibitor |
|
aTyr Pharma Inc |
|
US |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
30 |
|
2020-04-23 |
| A Single-blinded, Randomized, Placebo-Controlled, Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic |
Coronavirus disease 19 infection |
azithromycin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
|
Austria |
2020-04-27 |
2020-12-27 |
2020-001327-13, NCT04369365, OnCoVID-19 Trial |
Phase 2 Clinical |
Recruiting |
1 |
8 Months |
200 |
Marika Rosner, Matthias Preusser, MD, Prof. Dr. Matthias Preusser |
2020-05-04 |
| An outpatient study to evaluate the combination of chloroquine with azithromycin for the potential treatment of COVID-19 infection |
Coronavirus disease 19 infection |
azithromycin plus chloroquine, Bayer Inc |
|
|
Bayer Inc, Population Health Research Institute |
|
Canada |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-05-03 |
| A clinical study evaluate the safety and efficacy of combination of chloroquine with azithromycin and interferon beta-1b, to prevent admission to intensive care, mechanical ventilation and/or death to combat COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , chloroquine , interferon beta-1b, Bayer |
Interferon beta ligand |
|
Bayer Inc, Population Health Research Institute |
|
Canada |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-23 |
| MV-COVID19: Measles Vaccine in HCW |
Coronavirus disease 19 infection |
measles, mumps, rubella vaccine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Kasr El Aini Hospital |
|
Egypt |
2020-05-01 |
2020-11-01 |
MV-COVID19, N-20-2020, NCT04357028 |
Phase 3 Clinical |
Not yet recruiting |
2 |
6 Months |
200 |
Abeer Ahmed, MD, Ahmed M Mukhtar, M.D, Doaa Ghaith, MD, Marwa Rashad, MD, Mostafa Alfishawy, MD |
2020-04-24 |
| A pilot study to assess the effect of beta-nicotinamide mononucleotide (NMN) in the prevention/treatment of patients with Covid-19 |
Coronavirus disease 19 infection |
beta-nicotinamide mononucleotide alone |
|
|
Shinkowa Pharmaceutical Co Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-23 |
| Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Sciensano |
Jessa Hospital |
Belgium |
2020-04-30 |
2020-07-30 |
JESSA300, NCT04356586 |
Phase Not Applicable |
Recruiting |
2 |
3 Months |
300 |
Maria Goossens, MD, PhD |
2020-04-24 |
| Feasibility, early intervention, chinese herbal treatment, addition to standard of care, COVID-19 |
Coronavirus disease 19 infection |
Chinese herbal treatment alone, standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sunway TCM Centre |
|
Malaysia |
2020-05-01 |
2020-10-30 |
54625, NMRR-20-759-54625 |
Phase Not Applicable |
Status not specified |
1 |
5 Months |
100 |
Dr LIM REN JYE, Dr Lee Yee Leng |
2020-04-24 |
| PACA: Nebulized Rt-PA for ARDS Due to COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
invasive mechanical ventilation alone, non-invasive ventilation alone, standard of care alone, alteplase plus recombinant tissue-plasminogen activator (nebulized, COVID-19 associated acute respiratory distress syndrome), University college London |
Tissue plasminogen activator stimulator |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University College London |
Royal Free Charity |
UK |
2020-04-22 |
2021-01-14 |
132151, 2020-001640-26, NCT04356833, PACA |
Phase 2 Clinical |
Recruiting |
1 |
8 Months |
24 |
Mark Phillips, Pratima Chowdary |
2020-05-04 |
| SCout: Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections |
Coronavirus disease 19 infection, Viral pneumonia |
CT-imaging alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jena University Hospital |
|
Germany |
2020-04-15 |
2020-04-30 |
IDIR-001-2020, NCT04357938, SCout |
Phase Not Applicable |
No longer recruiting |
1 |
|
145 |
Ulf Teichgräber, Prof. Dr. |
2020-04-23 |
| RISC-19-ICU: The Risk Stratification in COVID-19 Patients in the ICU Registry |
Coronavirus disease 19 infection |
standard of care alone |
|
|
University of Zurich |
|
Switzerland |
2020-03-13 |
2022-03-31 |
KEK-ZH-REQ-2020-00322, NCT04357275, RISC-19-ICU |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
10000 |
Dorothea Heuberger, PhD, Jonathan Montomoli, MD, PhD, Matthias P Hilty, MD, Pedro D Wendel Garcia, MSc, Philippe Guerci, MD, Reto A Schüpbach, MD, Theirry Fumeaux, MD |
2020-04-23 |
| MODIF: Myocardial Infarction Rates Overview During COVID-19 Pandemic In France |
Coronavirus disease 19 infection, Myocardial infarction |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Société Française de Cardiologie |
INSERM |
France |
2020-04-27 |
2020-07-31 |
2020-03, MODIF, NCT04357314 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
80 |
Guillaume BONNET, MD, Guillaume CAYLA, MD, Tessa BERGOT |
2020-04-23 |
| COVIP: Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 |
Coronavirus disease 19 infection, HIV-1 infection, HIV-2 infection |
antiretroviral therapy alone, protease inhibitor therapy alone, usual care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Intercommunal Creteil |
Centre Hospitalier Intercommunal Villeneuve Saint Georges, Service des Urgences |
France |
2020-04-30 |
2020-10-31 |
COVIP, COVIP, NCT04357639 |
Phase Not Applicable |
Not yet recruiting |
5 |
6 Months |
794 |
Alice RAFFETIN, MD, GARRAIT Valérie, MD, Gallien Sebastien, MD, Raffetin Alice, MD, SALMON Dominique, MD, Vignier Nicolas, MD |
2020-04-27 |
| Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease |
Coronavirus disease 19 infection, Viral pneumonia |
azithromycin plus hydroxychloroquine (JWT-629) |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Novartis AG |
|
|
2020-04-30 |
2020-07-21 |
CJWT629A12301, NCT04358081 |
Phase 3 Clinical |
Not yet recruiting |
0 |
2 Months |
444 |
Novartis Pharmaceuticals |
2020-04-30 |
| AVoCaDO: Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation |
Coronavirus disease 19 infection, Hypoxia, Respiratory distress syndrome, Respiratory failure |
ascorbic acid alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hunter Holmes Mcguire Veteran Affairs Medical Center |
Mcguire Research Institute Inc |
US |
2020-04-16 |
2020-08-01 |
AVoCaDO, DAVIS 001, NCT04357782 |
Phase 1/Phase 2 Clinical |
Recruiting |
0 |
3 Months |
20 |
Brian C Davis, MD |
2020-04-23 |
| COVID-19 Among Egyptian Health Care Providers |
Coronavirus disease 19 infection |
online self-administered questionnaire alone |
|
|
Assiut University |
|
Egypt |
2020-04-30 |
2020-05-31 |
COVIDQ, NCT04357431 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
600 |
Ahmed Mohamed Abbas |
2020-04-23 |
| WAVE: Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories |
Coronavirus disease 19 infection |
smartwatch alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Inselspital, Berne |
ETH Zurich |
Switzerland |
2020-05-01 |
2020-07-31 |
NCT04357834, WAVE, WAVE |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
100 |
Aristomenis Extradaktylos, Prof. MD, David D Srivastava, MD, MBA, David Srivastava, MD, MBA |
2020-04-29 |
| COPLASCOV19: Convalescent Plasma For Ill Patients By COVID-19 |
Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia |
convalescent plasma alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto De Seguridad Y Servicios Sociales De Los Trabajadores Del Estado |
Angeles Chihuahua Hospital, GENERAL HOSPITAL OF THE STATE OF SONORA, HOSPITAL CENTRAL NACIONAL PEMEX NORTE, HOSPITAL DE ZONA No.14 IMSS, IMSS General Hospital of Zone 2A "Troncoso", SECRETARIA DE SALUD DEL ESTADO DE SONORA |
Mexico |
2020-05-31 |
2020-12-31 |
COPLASCOV19, NCT04356482, TERAPLASCOV2 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
5 |
7 Months |
90 |
CARLOS BEST, MD, Carlos Martinez-Murillo, MD, Diego Espinoza, MD, FERNANDO PEREZ-JACOBO, MD, LUIS villela, MD, Luis M Villela, MD, Luis Villela, MD,MSc, Melani Otañez, MD |
2020-04-29 |
| Sarilumab treatment in cytokine storm caused by infection with COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
sarilumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Clinica Universidad de Navarra |
|
Spain |
2020-04-16 |
|
2020-001255-40, STRIKE-SARS-CoV2 |
Phase 2 Clinical |
No longer recruiting |
1 |
|
60 |
UCEC |
2020-04-29 |
| Covid-Thelium: Assessment of Endothelial and Hemostatic Changes During Severe SARS-CoV-2 Infection |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Boisguillaume |
|
France |
2020-04-09 |
2020-08-31 |
2020/097/OB, Covid-Thelium, NCT04357847 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
100 |
EBESNIER, emmanuel besnier, MD, thomas clavier, MD, PhD |
2020-04-27 |
| SARICOR: Clinical Trial of Sarilumab in Adults With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
best available treatment alone, sarilumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Maimonides Biomedical Research Institute of Cordoba |
Consejeria de Salud. Junta de Andalucia |
Spain |
2020-04-18 |
2020-07-27 |
2020-001531-27, NCT04357860, SARICOR, SARICOR |
Phase 2 Clinical |
Recruiting |
1 |
3 Months |
120 |
Antonio Luque, José Carlos Garrido Gracia, Julián de la Torre Cisneros, MD, Rafael León López, MD |
2020-04-28 |
| COVID-TGT: Analysis of the Coagulopathy Developed by COVID-19 Infected Patients |
Coronavirus disease 19 infection |
fibrin generation markers assays alone, thrombin generation test assay alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
|
France |
2020-04-30 |
2021-01-31 |
COVID-TGT, NCT04356950, PHRC-I/2020/JCG-01 |
Phase Not Applicable |
Not yet recruiting |
4 |
9 Months |
175 |
Albert Sotto, Anissa Megzari, Antonia Perez Martin, Catherine Lechiche, Charles Cazenave, Claire Roger, Claudine Barbuat, Didier Laureillard, Isabelle Quere, Jean-Christophe Gris, Jean-François Faucher, Jean-Marc Mauboussin, Jean-Yves Lefrant, Kada Klouche, Laurent Muller, Paul Loubet, Saber D Barbar, Vincent Le Moing |
2020-04-30 |